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ABSTRACT
Individuals living in malaria endemic areas acquire immunity against clinical disease through 
repeated encounters with the Plasmodium falciparum parasite during their childhood. As a 
result, the majority o f severe cases of malaria are restricted to younger children. Naturally 
acquired immunity is thought to be partly mediated by antibodies directed at parasite 
derived antigens on the surface of red blood cells infected with mature forms of P. 
falciparum called variant surface antigens (VSA). Of these, P. falciparum erythrocyte 
membrane protein 1 is well characterized and associated with pathology and immune 
evasion. Sera obtained from young children living in endemic areas show limited recognition 
of P/EMP1 unlike immune adult sera that exhibit recognition of a wide range of P/EMP1. It is 
not yet clear whether this wide recognition of PfEMPl by adult immune sera is exclusively a 
product o f variant specific response accumulated over many exposures or whether it 
includes a cross-reactive response that recognizes a diverse set of antigens.
Here, I have used the recombinant DBLa-tag region of P/EMP1 generated from parasites 
isolated from children infected with malaria to show that individuals develop a strong 
variant-specific response to their infecting isolate, accompanied by partly cross-reactive 
response. Based on antigenic and genetic similarities between different DBLa-tag variants, I 
identified potential epitope regions in this study that may account for the cross reactive 
responses. However, these appear to be conformational and predominantly lie towards the 
N-terminal end. Once verified, such regions may form good candidates for inclusion in a 
multi-epitope vaccine construct that affords broad protection against malaria.
2 | P a g e
ACKNOWLEDGEMENTS
I just want to say that I have learned so much in the past 4 years. I have thoroughly enjoyed 
my journey to this PhD and writing this thesis. It has been challenging and it would not have 
been possible if I wasn't surrounded by an excellent scientific community that ensured I had 
all the support and guidance needed. For that, I would like to sincerely like to thank 
colleagues at the Kemri-Wellcome Trust Research Programme who in one way or another 
made this happen.
My deepest gratitude goes out to my supervisory team; Dr. Britta Urban, Dr. Peter Bull and 
Prof. Kevin Marsh for the excellent supervision, for their patience and for holding my hand 
and pointing me in the right direction whenever I was lost (many times!). To Dr. Margaret 
Mackinnon who took me under her wing and selflessly made it her business to teach me all 
matters statistics, I want to say I big thank you. I would also want to thank Prof Derek Smith 
and Dr. Collin Russell for taking time off their busy schedule to meet me, for their invaluable 
advice and for allowing me access to their antigenic cartography software.
I am heavily indebted to my teachers in the lab: Moses Mosobo and Jennifer Musyoki who 
taught me how to culture parasites; Dr. George Warimwe who taught me most of the 
Molecular Biology techniques; Alex Macharia and Dr. Isabella Ochola-Oyier for the DNA 
sequencing lessons and Eva Kimani for the protein expression assay.
I am hugely grateful for the support from the Britta Urban group especially Dr. Evelyn Gitau 
for ensuring we never lacked in reagents. I will forever be indebted to Henry Karanja for the
herculean effort we put in protein expression and for all the discussion we had in the lab.
3 | P a g e
Special gratitude goes to Dr. Sam Kinyanjui and Liz Murabu from the training department for 
your assistance with administrative issues ;to the librarian, Alex Maina, for access with 
publications and to my third party monitor, Dr. Sassy Molyneux for the pastoral care 
throughout this study.
Last, I want to thank my family, especially my loving wife Domtila, for the support and 
understanding during this period.
This work was only possible because of the world class facilities at the KEMRI-Wellcome 
Trust Research Programme and funding from the Wellcome Trust.
4 | P a g e
DEDICATION
Soli Deo Gloria
Contents
ABSTRACT........................................................................................................................................2
ACKNOWLEDGEMENTS....................................................................................................................3
DEDICATION....................................................................................................................................5
LIST OF FIGURES.............................................................................................................................. 9
LIST OF TABLES.............................................................................................................................. 13
LIST OF ABBREVIATIONS................................................................................................................. 14
LIST OF PUBLICATIONS...................................................................................................................16
Chapter 1.......................................................................................................................................17
Literature review........................................................................................................................17
Introduction........................................................................................................................... 18
1.1 Malaria............................................................................................................................ 18
1.2 Lifecycle of P. falciparum..................................................................................................20
1.3 Naturally acquired immunity to malaria............................................................................ 21
1.4 The intra erythrocytic stage.............................................................................................. 25
1.5 A case for strain-transcending immunity........................................................................... 26
1.6 Antibodies on the surface of the infected red cells are targets of naturally acquired 
immunity............................................................................................................................... 28
1.7 Antigens on the surface of the P. falciparum infected red blood cell...................................29
1.8 P/EMP 1 ........................................................................................................................... 31
1.9 P/EMP 1 variants isolated from severe cases are serologically conserved........................... 34
1.10 var genes........................................................................................................................34
1.11 Thesis objectives............................................................................................................ 39
Chapter 2...................................   41
Materials and methods.............................................................................................................. 41
2.1 Study site..........................................................................................................................42
2.2 Ethical approval......................................................................................................  44
2.3 Processing of the blood sample.........................................................................................44
2.4 RNA extraction................................................................................................................. 45
2.5 cDNA synthesis................................................................................................................. 46
2.6 Amplification of the DBL-a tag region.............................  47
2.7 Agarose gel electrophoresis........................................................  47
2.8 Purification of PCR products............................................................................................. 48
6 | P a g e
2.9 Cloning of DBL-a tags........................................................................................................48
2.10 Sequencing.....................................................................................................................49
2.11 Selection of dominant DBL-a tag transcript......................................................................50
2.13 Bacterial cell lysis............................................................................................................ 56
2.14 Purification of recombinant DBL-a tags........................................................................... 57
2.15 ELISA of DBLa-tags with human sera............................................  58
Chapter 3...............................................................................................................................   60
3.1 Introduction..........................................................................................................................61
3.2 Results.....................................   64
3.2.1 The effect of different E. coli strains on expression of DBLa-tags........................................ 64
3.2.2 Induction of protein expression at different time points.................................................66
3.2.3 Reduction in temperature at the time of induction......................................................... 68
3.2.4 Protein refolding by dialysis........................................................................................... 69
3.3 Discussion...................   72
Chapter 4 .......................................................................................................................................75
4.1 Introduction..........................................................................................................................76
4.1.1 The DBL-a tag................................................................................................................ 78
4.2 Methods.............................................................................................................................. 81
4.2.1 Statistical analysis...........................................................................................................81
4.3 Results................................................................................................................................. 86
4.4 Discussion...........................................................................................................................100
Chapter 5.....................................   103
Antigenic Cartography: Quantifying antigenic relationships among variant recombinant antigens 
................................................................................................................................................ 103
5.1 Introduction........................................................................................................................104
5.1.1 Immunological shape space concept............................................................................ 105
5.1.2 Limitations of the numerical taxonomy method........................................................... 108
Serological Networks................................................................................................................ 109
5.2 Method...............................................................................................................................110
5.2.1 Multidimensional Scaling..............................................................................................110
5.2.2 Unfolding analysis........................................................................................................113
5.3 Results............................................................................................................................... 114
5.3.1 Application to ELISA.......................................................... 114
7 | P a g e
5.3.2 Choice of Dimensions...................................................................................................115
5.3.3 Selection of Informative Sera...........................................   116
5.3.4 Adjusting for previous exposure...................................................................................121
5.3.5 Comparing the maps at 4 weeks versus 16 weeks......................................................... 123
5.3.6 Stability of the geometric solutions.............................................................................. 125
5.4 Discussion........................................................................................................................ 127
Chapter 6.....................................................................................................................................135
Comparative quantitative analysis of antigenic and genetic relationships...................................... 135
6.1 Introduction........................................................................................................................136
6.2 Structure of the antigenic map........................................................................................... 140
6.3 Comparison of genetic map to antigenic map......................................................................143
6.4 Loss/gain in response versus antigenic/genetic differences..................................................156
6.4 Discussion...........................................................................................................................159
Chapter 7...............................................................  165
Summary of main points..................................   165
Introduction............................................................   165
7.1 Main findings.......................................................   165
7.2 General Discussion.............................................................   167
7.3 Limitations of the study.......................................................................................................170
7.4 Concluding remarks............................................................................................................ 173
References................................................................................................................................... 175
Appendix..................................................................................................................................... 193
8 | P a g e
LIST OF FIGURES
Fig 1.1 Life cycle of Plasmodium falciparum.................................................................................... 21
Fig 1.2 Classification of DBL-a tag sequences.................................................................................. 37
Fig 2.1 Ethidium bromide stain of 2% agarose gel PCR products from cDNA samples....................... 48
Fig 2.2 Proportion of the dominant DBL-a tags selected for expression for each of the 36 
tags...............................................................................................................................................52
Fig 2.3 A 2% ethidium stained agarose gel showing DBL-a tags amplified with a modified DBLaBR 
reverse primer that had a stop codon included at the 3' end.......................................................... 53
Fig 2.4 Screening of 12 pEXP5-NT/TOPO expression vectors for recombinants in which the DBL-a tags 
were inserted in the right orientation.............................................................................................54
Fig 2.5 Sequences of DBL-a tag transcript inserted into the expression pEXP5-NT/TOPO vector 55
Fig. 2.6 Production of recombinant DBL-a tags using E. coli.......................................................... 56
Fig. 2.7 Purified recombinant DBL-a tag..........................................................................................57
Fig 3.1 Comparison of the soluble (s) and the pellet/insoluble (p) fractions of recombinant DBL-a tag 
proteins......................................................................................................................................... 65
Fig 3.2 Comparison of the soluble (s) and the pellet/insoluble (p) fractions of recombinant DBL-a tag 
proteins expressed in BL21 (DE3) pLysS cells at OD600 of 0.4, 0.6, 0.8,1.0 (A) 1.4,1.6,1.9 and 2.1 
(B)...................................................................................................   67
Fig 3.3 Impact of bacterial culture temperature on protein solubility of expressed protein............68
Fig 4.1 Domain structure of P/EMP1................................................................................................79
9 I P a g e
Fig 4.2 Acquisition of antibodies to 36 distinct DBLa-tag variants with time by 36 children..............88
Fig 4.3 Variation in the mean reactivity of sera to antigens............................................................. 93
Fig 4.4 Variation in the mean immunogenicity of antigens.............................................................. 94
Fig 4.5 Distribution of the raw OD values for each of the serum antibodies tested against the 36 
antigens (A) and for each of the antigens tested against the 36 sera (B) at the time the acute time- 
point..............................................................................................................................................95
Fig 4.6 Distribution of the raw OD values for each of the serum antibodies tested against the 36 
antigens (A) and for each of the antigens tested against the 36 sera (B) at the 2 week-convalescent 
time-point..................................................................................................................................... 96
Fig 4.7 Distribution of the raw OD values for each of the serum antibodies tested against the 36 
antigens (A) and for each of the antigens tested against the 36 sera (B) at the 4 month-convalescent 
time-point..................................................................................................................................... 97
Fig 4.8 Scatter plot of residuals versus fitted values from model 6...................................................98
Fig 4.3 Flistogram showing normal distribution of the residuals from the Model 6........................... 99
Fig 5.1 Relationships between antibodies (A) and antigens (B) as represented by numerical 
taxonomy.....................................................................................................................................107
Fig 5.2 Schematic representation of the algorithm applied in developing antigenic maps...............113
Fig 5.3 Percent stress values (x-axis) plotted against the corresponding number of dimension 
associated with it......................................................................................................................... 116
Fig 5.4 Multipanel plot showing the recognition profile of each serum to the 36 DBLa tags 
tested.......................................................................................................................................... 118
10 | P a g e
Figure 5.5 Antigenic map based on antisera at acute time-point for (A) all sera, (B) informative sera 
only. Procruste's analysis showing the difference between maps (A) and (B) is shown in (C)..........120
Fig 5.6 Antigenic map based on informative anti sera obtained 4 weeks after infection (A) before (B) 
after excluding responses from previous exposures. Procruste's analysis showing the difference 
between maps (A) and (B) is shown before (C) and after (D) adjusting for differences in scale
between the maps....................................................................................................................... 122
Fig 5.7 Antigenic map of the DBLa antigen tags at 16 weeks..........................................................123
Figure 5.8 Procruste's analysis comparing the map drawn at 4 weeks to the map at 16 weeks before 
(A) and after (B) adjusting for differences in scale between the maps........................................... 124
Figure 5.9 Procruste's analysis showing run to run variation of points for the antigenic map at 4 
weeks (A, B, C) and at 16 weeks (C, E, F)...................................................................................... 126
Fig 6.1 Antigenic map of the DBL-a tags colour coded according to the Cys/PolV grouping 
system......................................................................................................................................... 141
Fig 6.2 Antigenic distances between pairs of antigens in the same (blue boxes) versus different 
(green) Cys/PoLV groups..............................................................................................................142
Fig 6.3 Antigenic clusters identified from unsupervised clustering of the pair-wise antigenic distances 
from the antigenic map................................................................................................................143
Fig 6.4 Genetic map of the DBL-a antigen tags colour coded according to the Cys/PolV grouping 
system......................................................................................................................................... 144
Fig 6.5 Genetic distances between pairs of antigens in the same (blue boxes) versus different (green) 
Cys/PoLV groups.......................................................................................................................... 145
11 | P a g e
Fig 6.6 Heatmap of the matrix of the distances obtained from the antigenic map (A, same as Fig 6.3) 
and genetic maps (B and C)..........................................................................................................146
Fig. 6.7 Correlation between the antigenic and genetic distances between DBL-a tags obtained from 
the antigenic and genetic maps respectively................................................................................ 147
Fig. 6.8 Sequence alignment of the expressed 36 DBL-a tag antigens............................................ 149
Fig. 6.9. Correlation between genetic distance and antigenic distances (black line, left y-axis) across 
the entire DBLa-tag region by sliding window analysis.................................................................. 150
Fig 6.10 Correlation (y-axis) between genetic and the antigenic distances among an antigenic cluster 
(black line) by sliding window analysis for each antigenic cluster...................................................153
Fig 6.11 Predicted epitope regions in clusters identified from the antigenic map........................... 155
6.11 Boost/loss in IgG responses to other circulating variants of DBLa-tag the children had not been 
exposed to was measured 4 weeks after infection and regressed against the antigenic distance 
between the DBLa-tags as determined from antigenic cartography.............................................. 157
Fig 6.12 Boost/loss in IgG responses to other circulating variants of DBLa-tag the children had not 
been exposed to was measured 4 weeks after infection and regressed against the antigenic distance 
between the DBLa-tags as determined from antigenic cartography.............................................. 158
12 | P a g e
LIST OF TABLES
Table 2.1 Baseline characteristics of patients at admission.................................................... 43
Table 2.2 Frequencies of dominant DBL-a tag selected for expression........................... 51
Table 3.1 Refolding proteins by dialysis....................................................................................70
Table 3.2 Concentrations of proteins recovered after refolding by dialysis........................... 71
Table 4.1 Overall IgG responses................................................................................................86
Table 4.2 Comparison of Linear mixed models.....................   89
Table 4.3 Multiple linear regression models of immune responses by each time-point of 
serum collection..........................................................................................................................91
Table 4. 4 Multiple linear regression models of immune responses by time of serum 
collection.....................................................................................................................................91
Table 4.5 Multiple linear regression models of immune responses by the differences 
between the acute point of serum collection and subsequent follow up periods..................92
Table 5.1 Hypothetical antigen-antibody affinities................................................................. 107
Table 5.2 Standard deviation of the recognition of each serum to the 36 antigen 
tested........................................................................................................................................ 119
Table 5.2 Guidelines on acceptable stress values proposed by Kruskal 1964b and Clarke 
1993...........................................................................................................................................129
13 | P a g e
LIST OF ABBREVIATIONS
HIV/AIDS Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome
WHO World Health Organization
DDT Dichlorodiphenyltrichloroethane
MHC Major histocompatibility complex
RBCs Red blood cells
SICA Schizont-infected cell agglutination
VSA Variant surface antigens
P/EMP1 Plasmodium falciparum erythrocyte membrane protein 1
RIFINS Repetitive interspersed family proteins
STEVORS Subtelomeric variable open reading frame proteins
SURFINS Surface-associated interspersed family proteins
CD36 Cluster of Differentiation 36
CSA Chondroitin Sulphate A
ICAM-1 Intercellular Cytoadhesion Molecule-1
CR1 Complement Receptor 1
DBL Duffy Binding Like
CIDR Cysteine Rich Interspersed Domain Region
PECAM Platelet endothelial cell adhesion molecule
PoLV Position of limited variability
Cys Cysteine
RNA Ribonucleic acid
DNA Deoxyribonucleic acid
cDNA Complimentary DNA
DEPC Diethylpyrocarbonate
14 | P a g e
TE Tris-EDTA
TBE Tris Borate EDTA
Rpm revolutions per minute
LB Luria-Bertani
PCR Polymerase chain reaction
dNTP Deoxyribonucleotide triphosphate
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis
ELISA Enzyme-linked immunosorbent assay
PBS-T Phosphate buffered saline-Tween
PBS Phosphate buffered saline
KDa Kilodaltons
bp base pairs
ANOVA Analysis of variance
HI Hemagglutination inhibition
MN Microneutralization
OD Optical Density
OPD O-phenylenediamine dihydrochloride
HRP Horse radish peroxidase
LIST OF PUBLICATIONS
Gitau, E. N., Tuju, J., Stevenson, L., Kimani, E., Karanja, H., Marsh, K., Bull, P. C., et al. (2012). 
T-cell responses to the DBLa-tag, a short semi-conserved region of the Plasmodium 
falciparum membrane erythrocyte protein 1. PloS one, 7(1), e30095. 
doi:10.1371/journal.pone.0030095
16 | P a g e
Chapter 1 
Literature review
Introduction
1.1 Malaria
Malaria is a major global health problem that has afflicted humans throughout history. It is a 
disease that is widespread throughout the tropical and subtropical regions of the world 
where it remains a killer of hundreds of thousands even today (World Malaria Report 2011). 
The control of malaria, together with HIV/AIDS and other diseases is crucial to the 
achievement of several of the millennium development goals set by the United Nations by 
2015 (United Nations Millennium Declaration,2000). The past decade has witnessed progress in 
the fight against human malaria. The scaling up of available interventions for the prevention 
and control of the disease has resulted in decreases in the recorded incidence of the disease 
in many endemic regions (World Malaria Report 2011). The WHO malaria report estimates 
that there was a decrease of more than 50% in malaria cases between 2000 and 2010 in 43 
of the 99 countries with on-going malaria transmission. This was accompanied by a 
reduction in malaria mortality of 25% globally and 33% specifically in Africa. These 
interventions include increased use of effective treatment with artemisinin-based 
combination therapies (ACTs), long lasting insecticidal nets, rapid diagnostic tests and 
indoor residual spraying. Improved socio-economic levels may have contributed to this 
decline.
Despite this apparent evidence that the battle is being won, the war is far from over. The 
number of malaria cases and deaths, especially among young children in Africa, remain high. 
In 2010 alone, 216 million cases of malaria were reported worldwide with 81% of these
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occurring in sub Saharan Africa resulting in 655,000 deaths globally. An estimated 596,000 
of these deaths are reported to have occurred in Africa and were mainly restricted to 
children under 5 years of age (World Malaria Report 2011). These statistics, from a disease 
that can be effectively treated when promptly diagnosed, are demoralising. This is further 
compounded by recent reports of emerging resistance of parasites to artemisinin based 
therapies and of vectors to insecticides in several endemic areas (Wongsrichanalai & 
Meshnick 2008; Noedl et al. 2008; Dondorp et al. 2009).
There still remains an urgent need for more investment in vaccine development and drug 
discovery to come up with better methods for malaria control and eventual elimination and 
eradication.
The development and deployment of vaccines has played a big role in the fight against 
infectious agents in the past 6 decades. Vaccination programmes against polio, H. influenza, 
small pox among other diseases have been successful in significantly decreasing the 
incidence of most of these disease to levels close to eradication (Hebert et al. 2012). Despite 
the best effort over the past few decades, there is no licensed effective malaria vaccine. The 
main problem confronting malaria vaccine development has been a poor understanding of 
the targets and mechanism of protection of the naturally acquired immune response.
Malaria is caused by the protozoan parasites from the Plasmodia genus. Members of this 
genus have evolved to form numerous species that affect almost all vertabrates. Of these, 
only five cause disease in human: P. falciparum, P. malariae, P. vivax, P. ovale and P. 
knowlesi. The most virulent of these species is P. falciparum  and is responsible for the 
majority of severe malaria cases and deaths. In the past few years, P. vivax has also been 
recognised as an important public health concern.
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1.2 Lifecycle of P. falciparum
P. falciparum has a complex lifecycle that involves sexual reproduction in the Anopheles 
mosquito and asexual reproduction in the human host with several developmental stages 
that are morphologically and antigenically distinct. Female anopheles mosquitoes inject 
sporozoites into the skin (Reveiewed by Yamauchi et al. 2007) from where they traverse 
cells and enter into the peripheral circulation and find their way to the liver. The sporozoites 
migrate through Kupffer cells and several hepatocytes before finally infecting a hepatocyte 
(Ishino et al. 2004). In the hepatocyte, the sporozoites differentiate asexually to form 
schizonts that rupture to release merozoites into the blood stream and infect red blood cells 
and begin the erythrocytic stage of asexual development. During a 48 hour period, the 
parasites differentiate within the red blood cells from the young ring stage, to mature 
trophozoites and finally to schizonts that rupture to release merozoites that re-infect red 
blood cells to initiate another round of asexual replication ( Reveiwed by Kyes et al. 2001). 
The cyclical fevers that characterize malaria infection are caused by pyrogenic substances 
that are released into circulation when schizonts rapture (Clark et al. 1987; Clark et al. 1981; 
Sherry et al. 1995; Karunaweera et al. 1992). After several rounds of asexual reproduction, a 
few of the merozoites differentiate into male and female gametocytes that are ingested by 
a feeding mosquito to initiate sexual development.
In the midgut, the male and female gametes are released and fuse to form a diploid zygote 
that differentiates to form an ookinete that traverses the gut of the mosquito and further 
differentiates into an oocsyt that undergoes asexual reproduction to produce haploid 
sporozoites. Once they mature, oocsyts rupture to release thousand of sporozoites that
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migrate to the salivary glands from where they are transmitted to humans during a blood 
meal (Sinnis & Coppi 2007).
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Figure 1.1 Life cycle of Plasmodium falciparum. The diagram shows the different stages of development of the 
parasite in the asexual stages, i.e., red blood cells (A) and the liver (B) that take place in the human host, and 
the sexual stages (C) that happen in the mosquito vector.
(Adapted from www.dpd.cdc.gov/dpdx).
1.3 Naturally acquired immunity to malaria
That people become immune to malaria in endemic areas is not in doubt. In areas of high
malaria endemicity, individuals are continuously infected by P. falciparum but only infants,
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young children and malaria-naive visitors suffer from clinical disease; the majority of the 
older children and adults enjoy protection against severe morbidity and mortality. The 
ability of older residents to resist disease is what constitutes naturally acquired immunity 
(Reveiwed by Doolan et al. 2009). It is the beacon that gives malaria vaccinologists hope that 
the development of a malaria vaccine is feasible. Development of strategies that mimic the 
adult like immune status among high-risk infants in malaria endemic regions will greatly 
diminish malaria related morbidity and mortality. A vaccine based on this approach would 
be an attractive option as it would afford children protection from disease and the 
additional benefit of natural boosting from continuous exposure.
1.3.1 Features of naturally acquired immunity
Naturally acquired immunity is acquired after a prolonged period of intense uninterrupted 
exposure to the parasite and at a rate that is determined by the degree of exposure. 
Individuals living in areas with intense transmission develop this protection faster compared 
to their age-matched counterparts in areas with less intense transmission. As a result the 
proportion of people who are susceptible to disease in high intense transmission areas is 
smaller compared to regions where transmission is decreased (Snow et al. 1997).
The continuous intense exposure is required not only for the development but also for the 
maintenance of this immunity. Protection is diminished or lost when individuals move to 
non-malarious areas (Jelinek et al. 2002; Matteelli et al. 1999). This has profound 
implications for interventions that aim to decrease the level of transmission in these settings 
as was discussed by Snow and colleagues (Snow et al. 1997). Interventions that eliminate 
exposure or decrease it to levels that cannot maintain naturally acquired immunity should
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be carefully designed to be highly effective, long-acting or sustainable for a long period and 
have absolute coverage of the endemic areas when implemented. Failure to this will result 
in epidemic malaria as such interventions prevent non-immune individuals from acquiring 
natural immunity and re-introduces susceptibility to severe disease in previously immune 
people.
This was best observed in the malaria epidemic that occurred in the highlands of the 
Madagascar in the 1980s (Reviewed by Mouchet et al. 1997). After a successful period of 
control in the 1950s in which the highlands were rendered malaria-free by DDT spraying and 
free distribution of anti-malarials for chemotherapy, an abandonment of the control efforts 
in the 60's and 70's resulted in rebound malaria infections that caused the deaths of more 
than 40,000 people across all age groups (Reveiwed by Mouchet et al. 1997). This 
observation is of particular importance today as the recent decline in malaria has partly 
been contributed to by vector control programs and widespread distribution of long lasting 
insecticide treated nets that prevent people from developing natural immunity (Lengeler 
2004).
Naturally acquired immunity develops relatively rapidly against severe malaria perhaps after 
only a few episodes of disease during childhood then gradually against mild malaria. 
Sterilizing immunity against infection is maybe never acquired and asymptomatic 
parasitemia is common among clinically immune adults. Older children and adults protected 
from disease in areas with stable transmission will often have asymptomatic parasitemia ( 
Reveiwed by Doolan et al. 2009; Marsh & Kinyanjui 2006.; Baird 1998). These low level
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parasites are thought to mediate protection via a poorly studied mechanism called 
premunition (Sergent & Parrot 1935).
1.3.2 Targets and mechanism of natural acquired immunity
The underlying mechanisms of the acquired protection and the molecular targets remain 
unresolved. It is known, however, that humoral immunity is a key component of this 
protection. This was demonstrated by early experiments in which passive transfer of 
antibodies purified from the sera of malaria immune adults to sick children resulted in 
resolution of both disease and parasitemia (Sabchareon et al. 1991; Edozien et al. 1962; 
Cohen et al. 1961).
The resolution of parasitemia by passively transferred antibodies and the prolonged period 
of exposure characterized by repeated infections for onset of protective immunity when 
taken together point to a cumulative acquisition of antibodies to a diverse repertoire of 
asexual stage antigens. During the asexual stage, the merozoites that invade red cells 
develop into young ring stage trophozoites to the more mature trophozoites and schizonts 
stages as discussed earlier. At each of these stages, the parasite presents the immune 
system with a myriad of antigens. In an area with stable transmission, exposed individuals 
continually make antibody responses to these antigens. Not all of these responses are 
important for protection. Identifying the antigens that are targets of clinical immunity, and 
the mechanism by which it is effected, remains a top priority of malaria immunology. 
Although acquisition of antibodies to antigens expressed by merozoites may play an 
important role in naturally acquired immunity to malaria (Ramasamy et al. 2001; Doolan et 
al. 2009), the scope of this literature review and the studies conducted in this thesis are 
limited to a family of antigens expressed on the mature stages of the parasite.
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1.4 The intra erythrocytic stage
The red blood cells form a safe niche that allows parasites to hide from the surveillance of 
the adaptive immune system during development of the blood asexual stages. Red blood 
cells lack MHC molecules on their surfaces and thus cannot present antigens to the immune 
system (Brown et al. 1979). However, as P. falciparum parasites mature within the red blood 
cells they present what, at face value, appears to be a suicidal development by exporting 
antigens to the surface of the infected red cells. These antigens allow the parasite to 
interact with receptors on endothelial surfaces and sequester away from circulation as one 
of their functions (Reveiwed by Kyes et al. 2001).
The presence of parasite antigens on the surface of infected red blood cells was 
demonstrated by Eaton who pioneered the use of micro agglutination serological assays in 
the late 1930s. In his experiments, Eaton observed that an agglutination reaction occurred 
when red blood cells infected with mature forms of P. knowlesi where mixed with sera 
obtained from rhesus monkeys previously infected with the same parasite. The 
agglutination was not observed when red blood cells infected with young merozoites or sera 
obtained from non immune monkeys were used (Eaton 1938). This indicated that the 
mature forms of the parasites introduced foreign components on the surface of the red cell 
that were recognizable by the immune responses against the P. knowlesi.
In subsequent experiments, it was demonstrated that during chronic P. knowlesi infection in 
rhesus monkeys, the parasite was able to change the antigens inserted on the surface of the 
red cells resulting in a series of immunologically distinct variants within the courses of a 
single infection (Brown & Brown 1965). This change in antigenic phenotype was thought to
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be a mechanism by which the parasite escaped from the antibody response and allowed it 
to maintain chronic infection. This was the earliest demonstration of the concept of 
antigenic variation in a malaria model. This phenomenon was confirmed in a later conclusive 
study that reproduced the same results using clonal lines of P. knowlesi (Barnwell et al. 
1983). The conclusion from these early experiments was that naturally acquired immunity 
was a product of the accumulation of antibodies to these antigens in a variant specific 
manner; a view that is consistent with the long period of continuous exposure required for 
the onset of clinical immunity. Similar observations were made in squirrel monkeys that 
infected with P. falciparum  (Hommel et al. 1982).
The ability to culture P. falciparum paved the way for the development of similar 
agglutination studies in humans. From these studies, it was observed that, as with P. 
knowlesi, agglutination only occurred between red blood cells infected with mature 
trophozoites and immune sera (Sherwood et al. 1985; Marsh et al. 1986); clonal populations 
of P. falciparum in continuous culture undergo changes in the antigenic and adhesive 
phenotype at the red cell surface and that agglutination is largely variant specific (Udeinya 
et al. 1983; Smith et al. 1995). Agglutination studies done using clinical isolates indicate that 
after infection, individuals developed an antibody response that was predominantly isolate- 
specific (Marsh & Howard 1986; Newbold et al. 1992; Bull et al. 1998; Giha et al. 1999; 
Forsyth et al. 1989; Iqbal et al. 1983; Southwell et al. 1989).
1.5 A case for strain-transcending immunity
In their landmark study demonstrating antigenic variation in P. knowlesi (Brown & Brown 
1965), Brown and Brown reported that although the immune responses to the schizont-
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infected cell agglutination (SICA) antigens was acquired largely in a variant specific manner, 
it was accompanied by the development of a strain transcending antibody response; a part 
of their work that is rarely acknowledged. In their experiments, Marsh and Howard, showed 
that isolate-specific antibodies were capable of agglutinating a panel of heterologous P. 
falciparum infected red blood cells (Marsh & Howard 1986). In addition, they also observed 
strain transcending responses, and as with Brown and Brown, this is often overlooked. A 
subsequent study that tested the ability of sera to co-agglutinate pairs of differentially 
stained P. falciparum infected red blood cells observed only single colour agglutinates 
indicating that immune responses were largely variant specific (Newbold et al. 1992). 
Chattopadhay and colleagues exploited the same test in a larger sample of parasite pairs 
against sera obtained from adults who had experienced single monoclonal P. falciparum 
episodes and observed both single- and mixed-color agglutinates indicating both variant- 
specific and strain transcending responses were present (Chattopadhyay et al. 2003). The 
frequencies with which the variant surface antigens are recognized by sera in a population 
vary (Bull et al. 1999). Parasites isolated from severely ill children have variant surface 
antigens that are more frequently recognized by plasma from semi-immune children and 
are preferentially expressed in non-immune host as compared to parasites isolated from 
uncomplicated or asymptomatic infections (Bull et al. 1999; Bull et al. 2000; Nielsen et al. 
2002; Lindenthal et al. 2003). The high frequency of recognition is a common phenotype of 
parasites infecting young (non-immune) children. The differences in these early studies 
could be explained by the choice and number of parasite pairs used in the test as well as 
differences in age and exposure of the host.
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In a different study, Aguiar and colleagues observed that sera collected from different 
geographical regions agglutinated parasites isolated from sick children in Tanzania and 
Gambia, indicating the presence of either identical or cross reactive antigenic variants 
circulating in different places (Aguiar et al. 1992). The acquisition of strain-transcending 
immunity after a single infection has been observed in other studies using different 
methodologies (Elliott et al. 2007). In this study, serum collected from previously malaria 
naive travelers who were diagnosed with malaria after visiting malaria endemic areas was 
used. Heterologous recognition of the antigens on the surface of the infected red cells as 
measured by flow cytometry was observed in 11 of the 14 sera tested.
This broad specificity of immune sera from adults indicates that the antigenic repertoire is 
limited. Although this is mainly a product of multiple specificities to many variants acquired 
after prolonged exposure, there is some level of cross reactive responses generated. The 
contribution of these responses to natural immunity is poorly defined. The studies described 
in this thesis, explore the extent to which such responses are generated against DBL-a tag a 
recombinant segment of one of the main antigens expressed on the surface of the infected 
red blood cells using a subset o f parasites isolated from children admitted to hospital with 
disease.
1.6 Antibodies on the surface of the infected red cells are targets of 
naturally acquired immunity
Antibodies to the variant surface antigens (VSA) introduced at the surface of the red blood 
cells (RBC) by the infecting parasites are thought to be an important component of naturally
acquired immunity. In a study done in the Gambia, Marsh and Howard showed that children
28 | P a g e
develop antibodies to the parasite antigens on the surface of the red cell after exposure 
(Marsh & Howard 1986). A study done in Kenya showed that parasites isolated at the time 
of acute disease are likely to express antigens on the red blood cells that cannot be 
recognized by pre-existing antibodies in children at the time of disease (Bull et al. 1998). In 
this large prospective study, Bull and colleagues obtained sera from children at the 
beginning of the malaria season and followed them up for disease for the next 8 months. 
Parasites obtained from children who fell ill during this period were tested for reactivity by 
the agglutination reaction with homologous sera obtained from the sick children at the 
beginning of the malaria season, at the time of infection as well as to sera obtained from 
community age-matched controls. The homologous sera obtained before the malaria season 
was less likely to recognize the homologous isolate compared to the sera obtained from 
age-matched controls. Taken together, this implies that malaria is caused by parasite 
expressing variants of antigens on the surface of red blood cells to which the host lacks 
antibodies. Further support for this comes from studies done in Sudan that show a 
decreased likelihood of infection with homologous parasites to which individuals have a pre­
existing humoral response (Giha et al. 2000; Dodoo et al. 2001).
1.7 Antigens on the surface of the P. falciparum infected red blood 
cell
A number of antigens have been identified on the surface of the infected red blood cell. 
These include the Plasmodium falciparum  erythrocyte membrane protein (P/EMP1) (Leech 
et al. 1984), subtelomeric variable open reading frame proteins (STEVORS) (Carey et al. 
1994) and surface-associated interspersed family proteins (SURFINS) (Winter et al. 2005).
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The group A subtype of repetitive interspersed family proteins (RIFINS) have also been 
shown to be on the surface of infected red blood cell (Kyes et al. 1999; Kyes et al. 2000; 
Petter et al. 2007) P/EMP1 is the most extensively studied of these and is thought to be the 
major target of the VSA-specific antibodies. All these proteins are encoded by multi-gene 
families and are co-expressed together on the surface of an infected red blood cell making it 
difficult to directly determine the specific role of each family in the development of 
naturally acquired immunity.
Chan and colleagues have recently developed an ingenious strategy that allowed them to 
generate genetically modified P. falciparum parasite lines in which expression of PfEMPl 
was silenced. The genes encoding P/EMP1 are under a mutually exclusive transcription that 
is partly controlled by their promoters. In this study, a drug selectable marker under the 
control of a promoter from a gene encoding native P/EMP1 was transfected into parasites. 
When the parasites were grown under drug pressure, expression of the marker allowed the 
transfectants to grow and silenced endogenous P/EMP1 transcription. Using 2 parasite lines 
they observed significant reduction in the recognition of red cells infected with PfEMPl- 
silenced parasites line by sera obtained from immune adults (Chan et al. 2012). In addition, 
the PfEMPl-silenced parasites showed significant decreased opsonic phagocytosis and 
binding to host receptors in vitro. All together, these data point to a role of PfEMPl in 
cytoadhesion and as the major target of naturally acquired antibodies that target the 
surface of infected red blood cells. There has been increased interest in the non-PfEMPl 
surface antigens in the recent past and early reports implicating RIFINs and STEVORs in the 
development of acquired immunity. It is possible that the parasite lines used by Chan and 
colleagues in their investigations were expressing poor immunogenic forms o f the non-
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PfEMPl surface antigens and this would exaggerate the role of PfEMPl in humoral 
immunity. More extensive studies that include many infected red blood cells expressing 
different variants of these antigens are required before a conclusive argument can be made.
1.8 P/EMP 1
PfEMP 1 is a family of high molecular weight polymorphic proteins of parasite origin that are 
inserted on the surface of P. falciparum infected red blood cells at the mature stages where 
they mediate adhesion to host receptors on endothelial cells (Leech et al. 1984; Baruch et 
al. 1995; Smith et al. 1995; Su et al. 1995). This sequesters the parasite away from 
circulation and as a result, only erythrocytes infected with very young P. falciparum 
trophozoites (ring stages) circulate in the peripheral blood, but nearly all infected red blood 
cells containing mature trophozoites and schizonts are sequestered in the capillary vessels 
of different organs. This is thought to be a mechanism by which parasites avoid splenic 
clearance. This is supported by the observation that infection of individuals with no spleen 
results in the circulation of the mature forms of the parasites that are usually sequestered 
(Bach et al. 2005; Bachmann et al. 2009; Demar et al. 2004; Looareesuwan et al. 1993). 
Repeated passage of adherent parasites in splenectomized monkeys and in mice resulted in 
a phenotype in which parasites no longer expressed variant surface antigens which this was 
restored when the parasites were used to infect animals that had a spleen (Barnwell et al. 
1982; Barnwell et al. 1983; Handunnetti et al. 1987).
The adherence of infected red blood cells to host tissues and to other cells is thought to be 
the major factor that makes P. falciparum more virulent than other human malaria 
parasites. The cytoadherent properties of infected red blood cells arise mainly from the
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introduction of P/EMP 1 at the erythrocyte surface. P/EMP 1 can bind to a diverse range of 
host receptors that include CD36 (Baruch et al. 1997), Intercellular Cytoadhesion Molecule-1 
(ICAM-1) (Berendt et al. 1989), Chondroitin Sulphate A (CSA) (Rogerson et al. 1995) and 
Complement Receptor 1(CR1) (Rowe et al. 1997).
Most of these receptors exhibit heterogeneity in phenotype and levels of expression in 
different organs while PfEMPl variants differ in their affinity to these receptors. This results 
in the accumulation of parasites expressing certain variants in specific organs. This is partly 
responsible for the different clinical manifestation of the disease. Adhesion to ICAM-1, a 
receptor enriched on brain endothelial surfaces, has been associated with cerebral malaria 
(Fernandez-Reyes et al. 1997; Turner et al. 1994; Newbold et al. 1997)whereas rosetting 
(Udomsangpetch et al. 1989), a phenotype where infected red blood cells bind non infected 
red blood cells, is associated with severe anaemia and generally severe disease 
(MacPherson et al. 1985; Rowe et al. 1995; Carlson et al. 1990). By contrast, parasites from 
children with mild disease tend to bind better to CD36 (Newbold et al. 1997; Rogerson et al. 
1999; Ochola et al. 2011).
The association between the adhesion phenotype of particular PfEMPl variants and disease 
is best exemplified by parasites causing placental malaria. The clinical immunity developed 
against disease by women living in malaria endemic areas is suddenly breached by parasites 
during their early pregnancies (McGregor 1984). This arises because the development of the 
placenta presents a novel ecological niche that sequesters parasites away from circulation. 
Parasites bind to CSA and hyaluronic acid expressed on the placenta in a process mediated 
by PfEMPl (Fried & Duffy 1996; Beeson et al. 2000). Studies have identified var2csa as the
specific PfEMPl responsible for this phenotype (Salanti et al. 2003) and it forms a promising
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vaccine candidate against placental malaria. In addition to sequestration, P/EMP 1 mediates 
antigenic variation as described earlier. It is therefore conceivable that in the absence of 
negative selection by immune responses, availability of particular receptors or polymorphic 
variants of receptors may favor the binding of particular PfEMPl variants. As a result, 
parasites expressing such variants can evade immune clearance in the spleen and will 
dominate that infection.
Malaria parasites are adapted to invade and propagate within the red blood cells. As a 
result, human genetic polymorphisms in red blood cell components critical for the optimal 
survival of parasites will modify risk of developing malaria. Hemoglobin, found within the 
red blood cells, is the main oxygen carrier in the body. Genetic resistance to malaria has 
been demonstrated for polymorphisms that affect the structures of the human B-globin 
gene, i.e., heterozygous hemoglobin S (sickle cell trait, HbAS) (Allison 1954), homozygous 
hemoglobin C (HbCC) (Agarwal et al. 2000) and haemoglobin E (HbE) (Flatz et al. 1965). In 
addition, the inability to express optimum levels of the globin chains (a & p-thalassaemias) 
(Flint et al. 1986; Yenchitsomanus et al. 1986; Willcox et al. 1983) as well as deficiencies in 
glucose-6-phospate (ALLISON & CLYDE 1961) and pyruvate kinase dehydrogenases (Durand 
& Coetzer 2008) have been implicated in providing innate resistance to disease. Other 
human genetic conditions that affect the risk of disease include the South-East Asia 
ovalocytosis (Castelino et al. 1981) and Duffy antigen/chemokine receptor (Miller et al. 
1976). The uneven distribution of these traits in malaria endemic area is thought to be the 
result of evolutionary selection pressure from malaria.
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1.9 P/EMP1 variants isolated from severe cases are serologically 
conserved
There is increasing evidence that the expression of P/EMP1 in non-immune hosts is not 
random. Although more work needs to be done in epidemiological settings, limited data 
from lab isolates selected with sera from severe cases support the hypothesis that parasites 
infecting non-immune hosts tend to express a restricted sub-group of these antigens that 
are also implicated in causing severe malaria (Staalsoe et al. 2003; Jensen et al. 2004). This 
suggests that parasites isolated from severe malaria express a sub-group of PfEMPl that 
have a survival advantage over parasites isolated from mild malaria cases in the non- 
immune host. This advantage however may come at the expense of epitope diversity as 
immunity to severe, non-cerebral malaria develops much quicker compared to immunity to 
mild malaria (Gupta et al. 1999). In addition, parasites isolated from severe malaria cases 
express PfEMPl variants which are more frequently recognized by immune sera than those 
expressed by parasites isolated from uncomplicated (Bull et al. 2000; Nielsen et al. 2002). 
This high frequency of recognition is a common phenotype of parasites infecting young 
(non-immune) children (Bull et al. 2000; Nielsen et al. 2002). The high frequency of 
recognition may be due to restricted epitope diversity brought about by functional 
constraints as exemplified by parasites causing pregnancy associated malaria (Fried et al. 
1998).
1.10 var genes
PfEMPl molecules are encoded by a multi-gene family called the var genes (Su et al. 1995; 
Baruch et al. 1995; Smith et al. 1995). Each parasite contains between 50-60 copies of these
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genes in their genome (Gardner et al. 2002). The majority of these genes are found in 
subtelomeric regions of the chromosomes where they cluster together with genes encoding 
members of the r if  and stevor gene families. With a few exceptions, members of this multi­
gene family exhibit extreme polymorphism both within and between genomes resulting in 
almost unlimited numbers in a parasite population (Barry et al. 2007).
In order to maintain chronic infection, the parasites maintain a tight control in the 
expression of var genes in an immune environment. At any point, the parasites expresses 
only one var gene while the rest are silenced in what is termed mutual exclusive expression 
(Chen, V Fernandez, et al. 1998; Scherf et al. 1998; Kyes et al. 2000) although expression of 
two different PfEMPl on infected erythrocytes has been described (Joergensen et al. 2010). 
This ensures the parasite does not expose its entire repertoire of variant antigens all at once 
to the immune system. However, recent work shows that this does not prevent this from 
happening at the population level (Warimwe et al. 2013). Expression appears to be 
regulated at the transcription level in an epigenetically controlled process that involves 
promoter-promoter interactions. Each var gene has a 5'-upstream promoter that is 
transcribed to produce mRNA that is translated into protein and an intronic promoter that is 
transcribed to produce "sterile" mRNAs that do not form protein. Mutually exclusive 
expression requires the pairing of the 5'-upstream and the intronic promoters and removing 
the latter results in constitutive transcription of the gene controlled by the 5'-upstream. In 
addition, reversible acetylation and methylation of histones and sub-nuclear localization are 
known to shift the genes on and off between transciptionally active states (Tonkin et al. 
2009; Duraisingh et al. 2005).
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All var genes have the same basic structure consisting of two exons separated by an intron. 
The first exon encodes the extracellular portion that is divided into distinct domains (N- 
terminal sequence, Duffy Binding Like domains (DBL) and Cysteine Rich Interspersed Domain 
Regions (CIDR)). The second exon encodes the intercellular and relatively conserved acidic 
terminal sequence (Gardner et al. 2002; Smith et al. 2000). The DBL domains have been 
classified into 5 major homology groups based on sequence alignment i.e. DBLa, (3, y, 6, and 
s. Similarly, the CIDR domains are classified into 3 main classes i.e. CIDRa, p and y (Smith et 
al. 2000; Rask et al. 2010). Binding of PfEMPl to particular host receptors has been mapped 
to specific PfEMPl domains: DBLa has been associated with binding to heparin sulfate (HS) 
(Chen, Barragan, et al. 1998), blood group A antigen and complement receptor 1 (CR1) 
(Rowe et al. 1997), DBLp with binding to ICAM-1 (Smith et al. 2000), DBL8 with binding to 
PECAM-1 on platelets whereas binding of CD36 has been associated with CIDRa domains 
(Baruch et al. 1997).
In addition to sequence polymorphisms, P/EMP1 members vary in the number and 
composition of DBL and CIDR domains. In spite of this conserved pairing of certain domains 
is observed across multiple genomes (Rask et al. 2010). In particular, the overall structural 
organization of the N-terminal half o f most P/EMP1 molecules studied so far is relatively 
conserved (Chen et al. 2000). It is made up of the N-terminal sequence, DBLa and CIDRa 
domains together forming a conserved head structure. Despite considerable sequence 
heterogeneity, the DBLa domain is the most conserved domain within and between parasite 
isolates. It contains short stretches of conserved sequence that have been used to design 
universal primers with which DBLa tags from field and lab isolates can be sampled (Taylor et
al. 2000). Bull et al have exploited distinct sequence features within these tags to classify
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these DBLa tag sequences into 6 groups. This classification is based on short blocks of
sequences showing limited variability (PoLV) and the number of Cysteine residues (Cys) (Bull 
et al. 2007).
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distinct sequence identifier
MFKS-LRED-KAIT-2-PTYL-114 
LFLG-VREY-NAIT-2-PTNL-109 
LYGG-LRED-KAMT-2-PTNL-122 
LYLG-LRED-KALT-4-PTYF-132 
LYLG-IREY-KALT-4-PTNF-114 
LYLS-LREY-KAIT-6-PTYF-135
Fig 1.2 Classification of DBLa tag sequences. The classification system relies on the number of Cysteine 
residues and the four positions of limited variability marked PoLV 1-4. The PoLVs are located in the sequences 
using anchor points a, b , c and d. The 6 sequences are representative of the 6 DBLa tag sequence groups and 
indicated the PoLV motifs associated with each group. Figure adapted from (Bull et al. 2007)
The PoLV/Cys classifications groups have been shown to independently associate with immune 
status of the patient, disease syndromes as well as parasite phenotype. A small study by Bull and 
colleagues involving 12 parasites showed that parasites isolated from children with poor 
agglutinating antibody responses were likelier to express Cys2 DBL-a tags with MFK motif at PoLVl 
(Bull et al. 2005) . In addition, this group reported an association between PoLV group 2 sequence 
tags and the rosetting phenotype. In a separate study done in Mali, Kyriacou and colleagues 
observed that parasites isolated from children with cerebral malaria predominantly expressed cys2 
DBL-a tags (Kyriacou et al. 2006). A recent study by Warimwe and colleagues sampled 14,516 DBL-a 
tags from 217 clinical isolates from Kenyan children observed an association between cys2 DBL-a 
tags with severe malaria anemia and impaired consciousness (Warimwe et al. 2009).
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Other investigators have grouped var genes in the 3D7 genome into 3 major groups (A, B and C) and 
two intermediate groups (B/A and B/C) that represent transitions between the three major groups. 
This classification considers the chromosomal location, the direction of transcription, domain 
architecture of the encoded proteins and sequence similarity in non-coding promoter regions 
(Gardner et al. 2002; Voss et al. 2000). DBLa-tags isolated from group A type var genes are 
predominantly of the cys2 type described earlier (Bull et al. 2007).
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1.11 Thesis objectives
As described above, clinical immunity to malaria is a function of antibody responses to a 
wide range of different variants of PfEMPl as well as other polymorphic parasite antigens. 
While this protection is acquired largely in a variant specific manner, it may be accompanied 
by responses that are partly cross reactive. This thesis aims to look at the extent of variant- 
specific and cross-reactive antibody responses against different DBL-a tag fragments from 
P/EMP1 variants.
Aims:
1) To improve the recombinant expression of PTEMPl peptides in E  coli
The expression of plasmodial proteins in £  coli is a trial and error process characterized 
by tailor made conditions that are optimal for the particular protein of interest. In this 
work, I wanted to express variant forms of the DBLa tag region from PfEMPl isolated 
from parasites obtained from clinical isolates. I tested various £  coli cell lines 
supplemented with solubility enhancing characteristics as well as different bacterial 
culture conditions that aim to improve protein expression.
2) To determine the degree to which cross-reactive responses are generated 
between variants of DBL-a tags isolated from clinical isolates
P. falciparum displays immense variability in the immunologically important antigen 
P/EMP1. This molecule varies between clonal parasite populations as well as in a single 
isogenic clone over time. This allows it to escape humoral responses. While the antibody
response generated after infection will react strongest to the expressed PfEMPl variant
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of the infecting parasite isolate, there is evidence that shows appreciable serological 
recognition of other variants that the host was not exposed to. The role of such 
heterologous responses against P/EMP1 antigen family is poorly defined. Using DBLa tag 
antigen as a model antigen, I wanted to identify variants of PfEMPl that would cross 
react with each other and quantify the "antigenic distance" between them. I used ELISA 
to estimate the serological distances and refined the serological relationships by 
antigenic cartography.
3) To screen for potential epitope regions within the DBL-a tags gene targeted 
by the cross reactive responses 
Antibodies that recognize multiple PfEMPl variants can protect the host from multiple 
P. falciparum serotypes. Vaccines against antigenically variable targets are typically 
designed to provide such broad spectrum protection. However, the targets of such cross 
reactive responses are poorly defined for PfEMPl. In this PhD, I carried out an integrated 
fine-grain analysis genetic and antigenic data to identify potential regions in the DBLa 
tag antigen that may be targets of cross reactive responses.
40 | P a g e
Chapter 2 
Materials and methods
2.1 Study site
The samples used in this study were obtained from children attending the Kilifi District 
Hospital, located approximately 60km to the North of coastal town of Mombasa in Kenya. It 
is the main hospital for Kilifi district and a serves population of about 680,000 that is mainly 
rural (Central Bureau of Statistics-Kenya, 2007). Malaria is endemic with peaks in 
transmission between May-August and December-January (Snow et al., 1993). This follows 
the two rainy seasons that occur from April to June and October-November. A recent 
reduction in malaria transmission in this area has resulted in a decrease in malaria related 
hospital admissions from 18.43 per 1000 children in 2003 to 3.43 per 1000 in 2007 (O'Meara 
et al. 2008).
Study Cohort
Children attending the Kilifi District Hospital with acute malaria and their parents were 
invited to take part in the study, and after providing informed consent, a 3 ml venous blood 
sample was collected on admission. Clinical malaria was defined as microscopic determined 
parasitemia of greater than 2500 parasite per pL with fever. All children and their parents 
were invited to attend follow-up appointments 4 weeks and 16 weeks after discharge. At 
these appointments, children were examined by a clinical officer and a 3 ml blood samples 
was taken for full white blood cell count, microscopy for parasites and storage of plasma 
and PBMCs.
Samples used in this study were selected from a biobank of stored samples from children 
attending Kilifi District Hospital with acute malaria collected between 2006 and 2009.
Criteria for selection of samples were a full set of stored PBMCs and plasma from all time
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points and RBCs and parasite RNA from admission samples. Among the children represented 
in this study, four suffered from severe respiratory distress (deep breathing), three from 
cerebral malaria (Blantyre coma score <3) and six from impaired consciousness (Blantyre 
coma score <5). There was an overlap of these symptoms in some of the patients with 
altogether nine children suffering from one or more symptoms of severe malaria. None of 
the children died. Baseline characteristics of the patients recruited in this study are given in 
table 2.1.
Table 2.1. The baseline characteristics of the patients at admission.
Patient Age at
admission
(m onths)
Parasites/m l Hem oglobin Blantyre 
com m a score
Severe
respiratory
distress
6387 6.93 137280 6.4 5 0
6398 46.23 190080 10.2 5 0
6408 8.97 125120 7.2 5 0
6429 58.77 247520 7.2 5 0
6430 52.9 148240 11.8 5 0
6433 60.63 73980 8.9 5 0
6485 29.73 218880 9.7 5 0
6964 47.97 134720 8.2 5 0
7045 21.23 38586 7 3 0
7069 24 927080 11.5 5 0
7084 28.8 56242 10.3 5 0
7116 37.17 155100 6.5 5 1
7134 128.2 74502 8.4 5 0
7157 40.47 803400 9.4 5 1
7160 44.97 231804 7.9 5 0
7183 4.1 67160 9.5 1 0
7198 10.6 63000 11.9 5 0
7204 34 257304 8.6 5 0
7249 53.6 719440 8.3 3 1
7250 46.07 294060 9.4 2 0
7323 32.9 430000 11.1 5 0
7337 84.63 147376 8.7 5 0
7391 23.37 98659 9.6 5 0
7410 9.8 10958.5 9.2 5 0
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7506 70.67 87208 7.6 5 0
7530 63.6 1696800 9.8 5 0
7630 86.7 263900 10.1 5 0
7781 32.23 126210 8.9 5 0
7799 42.17 369720 6 5 1
7860 77.9 204870 7.1 5 0
7864 45.73 966520 7.9 1 0
8204 27.33 202080 11.1 4 0
8344 18.1 100100 8.9 5 0
8349 74.53 386640 10 0
8383 71.63 263840 7.6 5 0
8472 16.77 22792 7.3 5 0
8477 50.57 200200 7.4 5 0
8482 56 156480 9.1 5 0
8585 29.83 166820 10.7 5 0
8618 38.37 22064 10.3 5 0
8706 43.77 326400 9.4 5 0
2.2 Ethical approval
The study was approved by the Kenyan National Ethics Review Committee (protocol no. 
1131) and the Oxford Tropical Research Ethics Committee (protocol no. 30-06)
2.3 Processing of the blood sample
At all time points, 3 ml of blood was collected in heparinised polypropylene tubes (Falcon) 
and spun at 2000rpm for 5 minutes to separate plasma from blood cells. The plasma was 
collected and stored at -80°C till further use. The blood cells were then resuspended in 5mls 
of RPMI 1640 medium (Gibco) supplemented with 25jag/ml D-glucose(Gibco), Im M  L- 
glutamine (Gibco) and 25pg/ml gentamicin (Gibco) and carefully layered onto an equal 
volume of Lymphoprep (Axis-shield) and spun at 1800rpm for 20 minutes w ith the slowest 
deceleration settings to separate peripheral blood mononuclear cells from other cells. 
PBMCs were frozen in fetal calf serum/10% DMSO in liquid nitrogen. The remaining cells
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were washed twice in 5mls of RPMI 1640 medium (Gibco) then layered onto Plasmion 
(Bellon) at 37°C for 15 minutes in order to separate granulocytes from the red blood cells 
(RBCs). At the acute time-point, the infected red blood cells were then washed twice in 5mls 
of RPMI 1640 medium (Gibco) after which lOOjil packed cells were resuspended in 1ml of 
Trizol and stored at -80°C for RNA isolation as described below.
2.4 RNA extraction
To extract RNA, 200(il of Chloroform (Sigma-Aldrich) was added to thawed samples of 
llOOfil Trizol lysates. The lysates previously stores at -80°C, contained 100p,l packed cell 
volume of infected red blood cells. The samples were shaken vigorously and allowed to 
stand for 3 minutes before they were spun at 4200rpm for 35 minutes at 4°C in a microfuge 
to separate the RNA rich aqueous layer from the protein rich organic layer. To maximize the 
yield of the aqueous layer, the samples were allowed to stand for 2 minutes in the sample 
rack after centrifugation. 500p,l of the upper aqueous layer was then harvested taking care 
not to disturb the lower organic layer and transferred into fresh tubes to which 2pJ of 
Glycoblue dye (Ambion) had previously been added.
The RNA was then precipitated with an equal volume of isopropanol (Sigma-Aldrich) for 2 
hours at 4°C then spun at 13000rpm for 30 minutes. The supernatant was discarded while 
the pellet was washed once with 500|il o f ice-cold 75% ethanol by gentle inversion and 
collected by a gentle spin at the bottom the tube after the alcohol was carefully poured out. 
Any residual alcohol was aspirated using a pipette and the pellet was air dried for 5 minutes. 
To re-suspend the RNA, 20jal of RNAsecure (Invitrogen) was added to the pellet and
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incubated at 60°C for 10 minutes then mixed gently with a pipette. The RNA samples were 
stored at -80°C awaiting cDNA synthesis (Bull et al. 2005).
2.5 cDNA synthesis
2|il of the isolated parasite RNA sample was retrieved and transferred into 0.6ml test tubes 
for cDNA synthesis. To digest any contaminating DNA, the sample was treated with ljul of 
DNAsel (Ambion) in total reaction volume of 30jal that had 3pJ DNAsel buffer and 24pJ of 
RNAse free DEPC water and incubated at 30°C for 20 minutes. To prevent DNAsel from 
affecting downstream processes, 3jnl o f DNAse inactivation reagent was added and 
incubated for 2 minutes at room temperature after which the mix was spun at 10,000rpm 
for 2 minutes to pellet the inactivation slurry.
For each sample, two 8jil aliquots of the DNAse digested total RNA sample were then 
transferred into 0.2ml strip tubes. 1 \i\ of Random hexamers and lpJ of dNTPs were added 
to the samples before they were incubated in a thermocycler at 65°C for 5 minutes to 
denature the RNA followed by 4°C for 1 minute for the hexamers to anneal. A cDNA 
synthesis mix that had 2\i\ of 10X reverse transcriptase buffer,4|il of 25mM MgC^, 2\i\ of 
0.1M dithiothreital and ljal of RNAseOUT (40U/|al) (all Invitrogen) was added to all tubes. 
For each sample, l f i l  of superscript III transciptase (200U/|il, Invitrogen) was then added to 
one tube and a l j i l  of DEPC water (Ambion) added to the second tube to form the negative 
control sample. The samples were then incubated in a thermocycler under the following 
conditions: 25°C for lOminutes, 42°C for 50 minutes, 10°C for 10 minutes and 4°C for 
minute for cDNA synthesis. The RNA was then digested from the cDNA:RNA hybrid using
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0.25(J.I of RNase H at 37°C for 20 minutes. The cDNA was stored at 4°C till required (Bull et 
al. 2005).
2.6 Amplification of the DBL-a tag region
DBL-a tags were amplified from cDNA by PCR using the universal degenerate DBLaAF' (5- 
G CACG (A/ C) AGTTT (C*/T)G C-3') and DBLaBR (5'-GCCCATTC(G/C)TCGAACCA- 
3 ') described by Bull et al 2005 in a 25jj,I reaction volume containing 2.5fil o f 10X PCR buffer, 
3mM MgCl2, l - 25mM of each primer and 2 units of Amplitaq Gold polymerase enzyme 
(Applied Biosystems) in a thermocycler under the following conditions: initial denaturation 
at 95°C for 5 min followed by 35 cycles of denaturation at 94°C for 30 seconds followed by 
annealing at 42°C for 30 seconds and extension at 42°C for 45 seconds. A final incubation at 
65°C was added at the end of the last cycle.
2.7 Agarose gel electrophoresis
2g of agarose (Promega) was boiled in 0.5x TBE buffer then pour into a gel chamber (Biorad) 
and allowed to set. 5fd o f PCR products were mixed with l j i l  o f the 6x DNA loading buffer 
(30% glycerol, a tip o f spatula bromphenol blue and xylene cyanol, 70% TE) and loaded onto 
a gel. Gel electrophoresis was run at constant 90V for 90 minutes after which the gel was 
dipped in a staining buffer (0.5X TBE, 0.125|xg/ml ethidium bromide) for 30 minutes and 
visualized under ultra-violet light.
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Fig 2.1 Ethidium bromide stain Of 2% agarose gel PCR products from  cDNA samples (RT+) w ith  the ir 
corresponding negative control reaction run w ithou t the reverse transcriptase. There was no genomic DNA 
contam ination during preparation in all o f the cDNA samples generated.
2.8 Purification of PCR products
700pJ of Sephacryl S-400 matrix (Amersham Biosciences) was added into empty microspin 
columns (Amersham Biosciences) and spun at 2800rpm for 2 minutes to pack the column. 
The matrix was then equilibrated twice w ith 200jrl of IX TE buffer and spun at 2800rpm for 
1 minute each time. The PCR products were then loaded into the pre-equilibrated columns 
and spun at 2800rpm for 2 minutes to collect the purified PCR products.
2.9 Cloning of DBL-a tags
2 jliI of the purified PCR product was ligated to pCR 2.1 TOPO cloning vector (Invitrogen) in a 
6pl reaction containing lp l salt solution (1.2M NaCI,0.06M MgC^), 0.5 jil o f the vector and 
2.5pJ o f water. The reaction was incubated at room temperature for 5 minutes to allow for 
ligation to occur. 2|il o f the cloning reaction was gently mixed with 25pJ of One Shot TOPIO 
competent E. coli cells (Invitrogen) and incubated on ice for 30 minutes. The cells were then 
rapidly transferred to a preheated water bath at 42°C for 30 seconds before being 
transferred back to ice for 3 minutes. 250pil of pre-warmed SOC medium was then added to 
the cells and incubated in a shaking incubator at 200rpm and 37°C for 1 hour. 20|il o f the
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transformation reaction was then plated on pre-warmed selective LB agar plates containing 
50jag/ml ampicillin (Sigma-Aldrich) and cultured overnight at 37°C in an incubator.
For each sample, 10-20 single bacterial colonies were randomly picked from each plate 
using sterile toothpicks and grown overnight in 5ml of LB broth (Invitrogen) containing 
lOOjig/ml ampicillin in a shaking incubator at 200rpm and 37°C. Plamids were extracted 
from 1.5ml of the overnight bacterial culture using the Perfect prep plasmid purification 
(mini) kit (Promega) according to manufacturer's instructions.
2.10 Sequencing
Subsequently, plasmids from the 10-20 colonies were sequenced to determine the 
dominant DBL-a tag transcript. The sequencing reaction was prepared in Micro Amp 96 well 
optical reaction plates (Applied Biosystems) using the BIG DYE terminator v3.1 cycle 
sequencing kit (Applied Biosystems) as follows: 0.25p,l of the Big Dye reaction mix, 1.75|il of 
Big Dye terminator v l . l ,  v3.1 5X sequencing buffer(Applied Biosystems), 0.5p,M M13 
forward primerfS'-GTAAAACGACGGCCAG-S') and 75ng of template in a IOjliI reaction. The 
reaction mix was taken through cycle PCR in a thermocycler under the following conditions: 
initial denaturation at 96°C for 5 min followed by 25 cycles of denaturation at 96°C for 10 
seconds followed by annealing at 42°C for 5 seconds and extension at 60°C for 4 minutes.
The cycle PCR products were precipitated by adding 50jal o f a precipitation solution (made 
by mixing 33\i\ of 3M sodium acetate, 62.5jil of 95% ethanol and 24.2|il water) into each 
reaction and incubating on ice for 35 minutes. The plates were spun at 4000rpm for 30 
minutes at 4°C in a biofuge and the supernatant discarded by inverting the plate over a pad
of tissue. The PCR products were then washed twice with 150jliI of 70% ice-cold ethanol and
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spun at 4000rpm for lOminutes at 4°C each time. The plate was left to air dry for 30 minutes 
at room temperature before lOpI of Hi-Di Formamide was added to each well. The plate 
was heated at 96°C for 3 minutes in a thermocyler to resuspend the PCR products and then 
place on ice for 5 minutes to cool. Capillary electrophoresis and detection of the cycle PCR 
products was carried out in a 3130XL sequencer machine (Applied Biosytem) with a 50cm 
capillary.
The sequences were then classified according to the Cysteine/PoLV grouping system 
described by Bull and colleagues (Bull et al. 2007) using a Perl script developed by this 
group. This classification assigns the tags one of six groups based on the number of 
cysteines and sequence motifs (Fig 1.2)
2.11 Selection of dominant DBL-a tag transcript
The sequences were aligned by clustal in Bioedit using the defaults settings after the vector 
sequences had been cleaved off. The sequence that was most abundant among the 10-20 
sequenced was selected for expression (Table 2.2 and Fig. 2.2).
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Table 2.2 Frequencies of dominant DBL-a tag selected for expression
Tag Number
of
identical
DBLa-tag
sequences
Total number of 
DBLa-tags 
sequenced
Proportion
6387 7 12 0.58
6408 8 18 0.44
6429 4 10 0.40
6430 14 20 0.70
i 6433 8 19 0.42
6485 3 15 0.20
6964 13 20 0.65
7045 4 9 0.44
7069 5 9 0.56
7116 6 16 0.38
f 7134 4 15 0.27
7157 5 10 0.50
f 7160 4 10 0.40
7183 5 17 0.29
| 7198 4 10 0.4
7204 5 18 0.28
1 7249 6 12 0.5
7250 5 13 0.38
i 7323 3 12 0.25
7337 11 21 0.52
7391 11 17 0.65
7410 6 14 0.43
; 7506 5 10 0.5
7530 5 11 0.45
1 7630 3 14 0.21
7781 4 13 0.31
1 7799 6 15 0.4
7864 9 14 0.64
1 8204 4 17 0.24
8349 5 10 0.5
1 8344 5 10 0.5
8383 7 15 0.47
i 8477 5 14 0.36
8482 6 11 0.55
8585 5 14 0.36
8706 5 13 0.38
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Fig 2.2. Proportion o f the dom inant DBL-a tags selected fo r expression fo r each o f the 36 tags (A), and the 
distribution o f the frequencies o f the selected sequences and the to ta l number o f clones selected for 
sequencing (B).
It was isolated from the cloning plasmid using the the DBLaAF' p rim er and a modified 
DBLaBR primer containing a 3 -stop codon (5'-TTAGCCCATTC(G/C)TCGAACCA-3') 
under the following PCR conditions: initial denaturation at 95C for 5 min followed by 35 
cycles of denaturation at 94°C for 30 seconds followed by annealing at 42°C for 30 seconds 
and extension at 65°C for 30 seconds. A final incubation at 65°C was added at the end of the 
last cycle. The PCR reaction contained 2.5pl of 10X reaction buffer, 3mM MgCh, 0.8mM 
dNTP mix,0.4pM of each primer and 2 units of Amplitaq Gold polymerase enzyme (Applied 
Biosystems) in a 25pl reaction. The amplified products were separated by agarose gel 
electrophoresis as previously described.
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Fig 2.3 A 2% ethidium stained agarose gel showing DBL-a tags amplified with a modified DBLaBR reverse 
primer that had a stop codon included at the 3' end.
The amplified DBL-a tag was excised from the gel, weighed and purified using the 
Perfectprep Gel Cleanup kit (Eppendorf) according to manufacturer's protocol.
2.12 Protein Expression
The dominant transcript was cloned as earlier described into the expression vector pEXP5- 
NT/TOPO (Invitrogen) that contains an N- terminal histidine tag for purification. The cloned 
fragments are then transformed into One Shot TOP10 competent E. coli cells (Invitrogen) as 
earlier described and grown overnight in selective LB Agar plates containing lOOpg/ml 
ampicillin (Sigma-Aldrich).
From each LB agar plate, 8 single bacterial colonies were randomly picked using sterile 
toothpicks and grown overnight in 5ml of LB broth (Invitrogen) containing lOOpg/ml 
ampicillin in a shaking incubator at 200rpm and 37C.
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The colonies were then screened by PCR for inserts with the correct orientation by PCR 
using the T7 forward primer and the DBLaBR primer. As templates, crude plasmid 
preparations were made by diluting lOfil of the overnight bacterial culture with sterile 
water and boiling for 5 minutes. 5jal of the crude plasmid sample was used as template in a 
that reaction contained 2.5pJ of 10X NH4+ reaction buffer, 3mM MgCh, 0.8mM dNTP 
mix,0.4|iM of each primer and 2 units of Taq polymerase enzyme (Bioline) in a 25|il reaction 
. After an initial denaturation (5 min 94°C) the PCR cycle was as follows: 30 seconds 
annealing at 42°C, 30 seconds elongation at 65°C and 45 seconds melting at 94°C, 35 cycles.
500bp
400bJ>
300b|p
200b[p
lOOb'p
500bp
400bp
300bp
200bp
XOObp
Fig 2.4 Screening of 12 pEXP5-NT/TOPO expression vectors for recombinants in which the DBL-a tags were 
inserted in the right orientation. Lanes 1,2,3,4,5,6,7,8,10 and 12 had the inserts in the correct orientation while 
lanes 8 and 11 had the insert in the wrong orientation.
Plasmids were extracted from the overnight bacterial culture that had a PCR product of the 
desired orientation using the Perfect prep plasmid purification (mini) kit (Promega) 
according to manufacturer's instructions. Subsequently, the plasmids were sequenced as 
earlier described to confirm that the insert was in the correct orientation and of the proper 
reading frame for protein translation.
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10 20 30 40 50 60 70 80 90
1 MSGSHHHHHHGSSGEiJLYFQSLARSFADI GDIVR KDLFLG-— HKQRKKELEKRLVEMFK IQ --------------------------------------GHHSKLRIL
1 MS GSHHHHHHGS S GENLYF Q SLARSFAD I  GDIVRGKDLFLG HKQRKKELEKRLVEMFKHIQ--------------------------------------GHHSKLRTL
1 MS GSHHHHHHGS S GEHLYF Q SLARSFAD I GD IVR KDMFRS IE------------KIE LRKLFKKIHDLHKSKIiJD------------------------ YDRDGP--
1 MSGSHHHHHHGSSGE LYFQ SLARSFAD I  D IIR  RDMFLGlffiETDKE KVKLEK LKfilFKKIYEELREEGKKRK AKPKH GRAQIEARYKKDEED
1 MSGSHKHKHHGSSGEHLYFQSLAR5FADIGDIIRGKDLYLDHE PGKQHLEERLEIMFQHIQYMT------------------------------- E L K IP — -
1 MS GSHHHHHHGS S GEHLYF Q SLAR SFAD I  GD I IR  KDLYL GHG D YKVKL S HI LRAIFKKI YE ILHDKVKEI ----------------------- YKGDE—
1 MSGSHHHHHHGSSGEHLYFQSLARSFADIGDIVR RDLYRGMD KEKD RKOLKK LKIIFEHIRK------------------------------------EUKSKLSTL
Stop codon
110 120 130 140 150 160 170 180 1
 I  I  I  I  I  I  I  I  I  I  I  I  I  I  I  I  It
73 HVREYffffAL RD jVffKAI TCDADTGHAYFRTTCSDSHRSGTFSQAKDKCRCKDKK—  KMTDQVPTYFDWPnYLRtfFDEtfAX
73 HVREYffffAL RD yVffKAITCDADT GltAYFRTTCSDSHRSGTFSQAKDKCRCKDKK— GKHTDQVPTYFDYVPQYLRffFDEffAX
75 YKLREAWffKA RDyVffKAITCHAPYKSRYFIQSEM------- TQLFSHRQCGHGEHE------------- VLTIfLDYVPyYLRffFDEffAX
101 YKLREDffff FA ;RD sVffKALTCSADGSEEYFIQSESH-------KKLFSNSKCGHDEiH?------------- VLTHLDYVPi]YLRHFDEffAX
73 PKVREYffffAL RD VffKAITCHA KDDAYFRHSSGG-------EYKFTSGYCGRHEGK------------- VPTHLDYVPQHLRffFDEffAX
79 YKLRDDffffHAHRDDVffYAITCHAPYKAflYFMHSEDH------- TLLFS1YKCGHEESR------------- VLTIOYVPQYLRHFDEffAX
77 EQIREYffffYA RAIWYAITCHAGSG-KYFRPTCIDEQGG— AQM-KCRCTK---------QPAD QVP T YFDYVP I) YLRHFDEffAX
Fig 2.5 Sequences o f DBL-a tag transcript inserted into the expression pEXP5-NT/TOPO vector tha t introduces 
a histidine tag at the N term inal end. The stop codon introduced at the C term inal end is indicated by X in the 
alignment. The sequences were aligned by clustal in Bioedit using the default settings.
The purified plasmids were transformed into BL21 (DE3) pLysS E.coli cells (Invitrogen) as 
described earlier and cultured overnight in 5ml LB broth containing lOOjag/ml ampicillin and 
34|rg/ml chloramphenical (both Sigma-Aldrich). The 5ml overnight cultures o f the 
recombinant BL21 (DE3) pLysS E.coli cells were diluted 1:10 with fresh 50ml LB Broth 
bacterial culture medium containing the antibiotics ampicillin (100|rg/m) and 
chloramphenical (34|ag/ml) and incubated in a shaking incubator at 37°C. The growth of 
bacteria was periodically monitored by OD at 600 nm and was induced to express protein at 
O D 60o of 0.4 with a final concentration o f Im M  IPTG. 1 ml of the bacterial culture was 
sampled as the un-induced control just before adding IPTG. After 6 hours, 1 ml o f the 
bacterial was similarly sampled as the induced control for comparison. The remainder of
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the culture was harvested by centrifugation at 12,000 rpm for 20 minutes and stored at - 
20°C until further use.
The un-induced and induced samples were spun at 13,000rpm and the supernatants 
discarded. 50jul of Laemmli sample buffer (Biorad) supplemented with p-mercaptoethanol 
was added to the pellets and boiled and then analysed by sodium dodecyl sulphate 
electrophoresis-polyacrylamide gel electrophoresis SDS-PAGE (described below).
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Fig. 2.6 Production of recombinant DBL-a tags using E. coli lOpI of bacterial pellet from paired IPTG induced 
and uninduced sample were run on a 12% SDS-Polyacrylamide gel and stained with Coomassie blue stain. 
Molecular mass standards are shown outside the panel.
2.13 Bacterial cell lysis
The bacterial pellet was lysed in 2.5ml Bugbuster lysis solution (Novagen) supplemented 
with O.lpJ benzonase nuclease (250U/ml,Novagen) and incubated at 4°C for 20 minutes 
with gentle rotation. The benzonase nuclease reduces viscosity due to chromosomal DNA 
released by cell lysis. The suspension was spun at 12000 rpm for 30 minutes at 4°C in a 
biofuge. The supernatant was aspirated and the pellet was washed in IX PBS and
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resuspended in 2.5ml of urea buffer (8M Urea, 200mM NaCI, lOmM Tris, pH 7.8). 20jil of 
both the supernatant and the resuspended pellet were mixed with 20pil of Laemmli sample 
buffer (Biorad) supplemented with p-mercaptoethanol, boiled for 5 minutes then analysed 
bySDS-PAGE.
2.14 Purification of recombinant DBL-a tags
1 ml of Probond resin was packed in a tube by spinning at lOOOrpm for 5 minutes at 4°C. 
The resin was washed twice with 10ml of water then equilibrated twice with 10ml 
denaturing binding buffer (8M urea, 20mM NaP04, 500mM NaCI, pH 7.8). At each of these 
steps, the resin was rotated gently for 2 minutes then spun at lOOOrpm for 5 minutes at 4°C 
in a biofuge. The resuspended pellet was diluted with the denaturing binding buffer in a 
ratio of 1:3 and mixed with the pre-equilibrated resin. The resin was gently rotated at 4°C 
for 30 minutes to allow the recombinant proteins to bind. The resin was spun at lOOOrpm 
for 5 minutes at 4°C before being washed 5 times with 5ml of wash buffer (8M urea, 20mM 
NaP04, 500mM NaCI, pH 6.0). The proteins were eluted from the beads with low pH elution 
buffer (8M urea, 20mM NaP04, 500mM NaCI, pH 4.0). 20ul of the flowthrough, washes and 
elutes were mixed with 20pJ of Laemmli sample buffer (Biorad) supplemented with p- 
mercaptoethanol, boiled for 5 minutes then analysed by SDS-PAGE. The quantity of the 
recombinant proteins was measured by the BCA assay according to manufacturer's 
instructions.
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Fig. 2.7 Purified recombinant DBL-a tag. Lane 1 contains the flow through; the protein purification resin was 
washed 5 times, lanes 2-7. The proteins were eluted 3 times in Urea buffer, pH 4, lanes 8-10.
2.15 ELISA of DBLa-tags with human sera
Maxisorb 96 well ELISA plates (Nunc) were coated over night at 4°C with lpg/m l 
recombinant protein in lx  PBS. Plates were washed three times in an ELISA washer and 
blocked for 2 hours at room temperature with lOOul 3% BSA in PBS 0.01% tween 20 (PBS-T). 
Then, plates were washed again and incubated with human sera diluted 1:200 in 1% non-fat 
milk powder in PBS-T. After incubation for 2 hours at room temperature, the plates were 
washed twice in the ELISA washer and then incubated with the secondary antibody (mouse 
anti-human IgG alkaline phosphatase labeled (1:5000) in 1% non-fat milk powder in PBS-T 
for one hour at room temperature. After washing, the plate was developed with OPD and 
measured in an ELISA reader at 490nm.
Non-immune sera were obtained from European donors with no history of malaria or travel 
to malaria endemic areas were used as negative control samples. For each antigen, 
background absorbance against 10 non-immune sera was subtracted from each value. In
addition, each antigen was tested against a pool of hyper immune sera obtained from
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clinically immune adults living in a malaria endemic area. All samples were run in duplicates 
and a mean for each sample was calculated.
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Chapter 3
Recombinant expression of DBL-a tag from clinical isolates
Expression of recombinant proteins is commonly used to generate antigens for 
immunological characterization and vaccine production. Plasmodial proteins are typically 
difficult to express in heterologous systems. Differences in protein translational mechanisms 
coupled with a characteristic high AT rich genome and frequent Lysine and Arginine repeats 
make expression of plasmodium proteins in E. coli particularly difficult. The lack of a 
universal method applicable to the expression of plasmodial protein means that each 
protein is handled on a case by case basis. In this study, I tested different E. coli cell lines 
and various bacterial growth conditions that favour soluble protein expression of variants of 
the DBL-a tag isolated from parasites obtained from children diagnosed with malaria. These 
methods, though successful for other plasmodial proteins, did not result in improved 
solubility of the expressed protein. In all cases, the expressed product was in a precipitated 
insoluble form. The proteins were recovered by denaturing them in urea and gradually 
renaturing them by dialysis in a process that was sensitive to pH and glycerol. The 
recombinant variants of DBLa tags were then used as molecular tools to quantify cross­
reactive antibody responses and antigenic relationships between them.
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3.1 Introduction
Immunological, structural or functional characterization of proteins requires that they are 
first expressed in large quantities as purified recombinant forms in their native 
conformation. This is commonly achieved using heterologous expression systems that 
include bacteria, yeast, insect cells, mammalian cells and recently cell-free expression 
systems. The E coli expression system is the most attractive and widely used because it is a 
cheap method that produces high protein yields in short time using simple laboratory 
equipment. This system, though attractive, typically results in poor quality proteins that are 
improperly folded often forming inclusion bodies and lacking in post-translational 
modifications (Carrio & Villaverde 2002). These limitations are primarily due to differences 
in features of the translational machinery between E. coli and the organism from which the 
recombinant gene to be expressed is sourced. These include differences in codon usage and 
bias, abundance of certain amino acids and tRNAs, GC content among other factors (Sayers 
et al. 1995; Rogers 1996).
Plasmodium proteins are difficult to express in heterologous systems, particularly in E coli. 
This is thought to be due to various reasons: a high AT-rich genome (80%) of Plasmodium 
compared to E coli (50%), codon bias that is different from E coli, proteins rich in arginine 
and lysine residues as well as high molecular weights of many plasmodial proteins (Gardner 
et al. 2002; Schneider et al. 2005; Sayers et al. 1995; Saul & Battistutta 1988; Singer & 
Hickey 2000). Heterologous expression of plasmodial proteins in E coli is typically 
characterised by failure of expression or in the expression of precipitated forms of the 
protein that aggregate to form inclusion bodies (Mehlin et al. 2006; Aguiar et al. 2004;
Vedadi et al. 2007). This was highlighted by an extensive study carried out by Mehlin et al in
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which 1000 open reading frames from a sequenced genome of a P. falciparum strain were 
cloned for expression in E. coli. The authors were able to successfully express only 337 as 
recombinant proteins. Only 63 of the expressed proteins were in soluble form, the rest 
formed inclusion bodies. In that study, proteins that either had higher molecular weight, 
high isoelectric point or distant homology to E. coli proteins, were less well expressed in E. 
coli. In addition, among the 337 that were successfully expressed, the soluble ones were 
likely to have higher isoelectric points. More importantly, the authors observed that there 
was no universal applicable method for the expression of plasmodial proteins. In a similar 
study, up to 30% of 1008 genes obtained from four apicomplexan parasites were 
successfully expressed in soluble recombinant form using a strain of bacteria supplemented 
with additional tRNA. Of the 1008 genes, 400 were obtained from P. falciparum  (Vedadi et 
al. 2007).
Over production of proteins in E. coli exerts immense metabolic stress beyond what the 
endogenous translational mechanism in E. coli can cope with. Strategies that supplement 
the deficiencies in the endogenous translational mechanism or those that lower the rate of 
translational process have resulted in improved solubility of expressed products. The 
extreme AT rich genome results in a codon bias that is different from E. coli. The codons 
AGA and AGG that encode arginine, are particularly rare in E. coii but are over-represented 
in P. falciparum (Sayers et al. 1995). During translation, the limited numbers of tRNAs in the 
host cell are unable to cope with the demands of codons that are over represented in the 
host cell resulting in unwanted substitutions, translational stalling and termination 
(Schneider et al. 2005). The accumulation of such truncated misfolded protein contributes 
to inclusion body formation. Two different strategies have been used to overcome codon
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bias in the expression of P. falciparum proteins in E coli, i.e., the supplementing the 
translational machinery with additional copies of raretRNAs (Baca & Hoi 2000; Rogers 1996) 
or harmonizing the codons of the target genes to suit the codon usage in E.coli (codon 
optimisation) (Yadava & Ockenhouse 2003; Zhou et al. 2004; Angov et al. 2008; Yazdani et 
al. 2006). Alternative conditions that lower the growth rate of bacteria have also been used 
to enhance soluble expression in bacteria (Graslund et al. 2008; Flick et al. 2004). Flick and 
colleagues were able to dramatically improve solubility of recombinant P/EMP1 domains 
expressed in E.coli by delaying the induction of expression to the lag phase where bacterial 
growth is slow. The slowing down of metabolic processes is thought to allow the protein 
translational mechanism time to properly fold the expressed proteins. Growing bacterial at 
low temperatures and use of weak promoters to reduce the metabolic stress on E coli have 
been proposed as attractive alternatives. Despite the availability of all these strategies, 
expression of soluble protein remains a trial and error process as there is no universal 
method applicable to P. falciparum antigens. Conditions have to be optimized on a case by 
case basis.
Initial attempts at expressing the DBL-a tags as recombinant antigens resulted in formation 
of inclusion bodies. I tested several of the above strategies with an aim of developing a 
method best suited for the expression of most DBLa-tags in soluble form.
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3.2 Results
3.2.1 The effect of different E. coli strains on expression of DBLa- 
tags
Four strains of E. coli were tested for expression of soluble DBL-a tag antigens: the 
BL21(DE3)pLysS that contains a plasmid that limits the basal expression of the target gene; 
BL21trxB(DE3)pLysS that is supplemented with the thioredoxin to enhance disulphide bond 
formation; the origami(DE3)pLysS strain that is supplemented by the thioredoxin and 
glutathione reductase genes to greatly enhance disulphide bond formation and the BL21 
(DE3) CodonPlus-RIL strain that is supplemented with rare tRNAs to allow for expression of 
genes with rare codons. The BL21(DE3)pLysS was used as a comparator for better 
expression.
Briefly, 50ml LB Broth bacterial culture medium containing the antibiotics ampicillin the 
appropriate antibiotic were inoculated with 5ml overnight culture of either BL21 (DE3) 
pLysS, BL21trxB(DE3)pLysS, BL21 (DE3) CodonPlus-RIL or origami(DE3)pLysS E.coli cells 
transformed with recombinant pEXP5-NT/TOPO with a DBL-a tag fragment. The cultures 
were incubated at 37°C and induced with a final concentration of Im M  IPTG when OD6oo 
was 0.4. Four hours later the bacteria were harvested by centrifugation at 12,000rpm for 
20minutes. The bacterial pellet was lysed in Bugbuster lysis solution supplemented with 
benzonase nuclease. The insoluble proteins were separated by centrifugation at 12000rpm 
for 30minutes. The pellet was washed in PBS and resuspended in Urea buffer (8M Urea, 
200mM NaCI, lOmM Tris, pH 7.8). lOul of the supernatant (soluble) and resuspended pellet
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(insoluble) fractions were run on a 12% SDS poly acrylamide gel and stained with Coomassie
blue dye.
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Fig 3.1 Comparison of the soluble (s) and the pellet/insoluble (p) fractions of recombinant DBL-a tag proteins 
expressed in: BL21 (DE3) pLysS lanes 1 and 2; BL21trxB(DE3)pLysS lanes 3 and 4; BL21 (DE3) CodonPlus-RIL 
lanes 5 and 6; origami(DE3)pLysS E.coli cells lanes 7 and 8. The proteins were analysed by 12% SDS PAGE and 
stained by coomassie blue dye.
P/EMP1 proteins are particularly rich in Cysteine residues that are probably play a role in 
folding the proteins and maintaining their structure. I envisaged that the use of host strains 
optimized to enhance disulphide bond formation would enhance proper folding of the DBL- 
a tags hence improve their solubility. Expression in BL21trxB(DE3)pLysS and 
origami(DE3)pLysS E.coli strains resulted in no improvement as compared to the BL21(DE3) 
Fig 3.1 lanes 1-6.
While there was decreased yields obtained with the origami (DE3)pLysS E.coli cells, the 
quality of the expressed product was not improved in all the cells tested. The BL21 (DE3) 
CodonPlus-RIL E. coli strain is supplemented with extra copies of E. coli argU, ileY, and leuW
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tRNAs that are overrepresented in AT rich genomes. This however did not enhance the 
solubility of the DBL-a tags tested (Fig 3.1, lanes 7 and 8).
3.2.2 Induction of protein expression at different time points
In order to establish whether late induction of protein expression would improve solubility 
of the expressed proteins, 50 ml of BL21 (DE3) pLysS E. coli cells transformed with 
recombinant pEXP5-NT/TOPO-DBLa plasmid were cultured at 37°C and induced with a final 
concentration of Im M  IPTG when OD6oo was 0.4, 0.6, 0.8,1.0,1.4,1.6,1.9 and 2.1. The 
cultures were allowed to grow for 4 hours to allow for protein expression before they were 
harvested by centrifugation and processed as previously described.
By inducing expression in the latter stages of bacterial growth, Flick and colleagues observed 
an increase in the ratio of the amount o f recombinant proteins in the soluble as compared 
to the insoluble fraction for each of the time points (Flick et al. 2004). While there was a 
gradual decrease in the amount of the proteins in the insoluble fraction with each delayed 
induction, it was not accompanied by a corresponding increase in the amount of soluble 
protein (Figs. 3.2 A and B). The decrease growth rates were thus not helpful in enhancing 
bacterial growth.
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Fig 3.2 Comparison of the soluble (s) and the pellet/insoluble (p) fractions of recombinant DBL-a tag proteins 
expressed in BL21 (DE3) pLysS cells at OD60o of 0.4, 0.6, 0.8,1.0 (A) 1.4,1.6,1.9 and 2.1 (B). The proteins were 
analysed by 12% SDS PAGE and stained by coomassie blue dye.
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3.2.3 Reduction in temperature at the time of induction
It has been reported that incubation of bacterial culture at low temperatures after induction 
greatly improves the solubility of the final product. To check for the effect of temperature 
on solubility, 50 ml of BL21 (DE3) pLysS E.coli cells transformed with recombinant pEXP5- 
NT/TOPO-DBL-a plasmid were cultured at 37°C and induced with a final concentration of 
Im M  IPTG when OD60o was 0.4 .The cultures were subsequently cultured at 20°C for 4 hours 
to allow for protein expression before they were harvested by centrifugation and processed 
as described earlier.
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Fig 3.3 Impact of bacterial culture temperature on protein solubility of expressed protein. Comparison of the 
soluble (s) and the pellet/insoluble (p) fractions of recombinant DBL-a tag proteins expressed in BL21 (DE3) 
pLysS cells cultured at 20°C for four hours after induction.
Consistent with the results obtained by late induction, slowing bacterial growth by lowering 
culture conditions did not improve the solubility of the expressed product (Fig 3.3).
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3.2.4 Protein refolding by dialysis
As it was not possible to express soluble protein through any of strategies listed above, I 
explored strategies to recover the protein from inclusion bodies. 50ml of bacterial culture 
was processed as described earlier to obtain the insoluble protein fraction. The insoluble 
fraction was washed in PBS and resuspended in Urea buffer (8M Urea, 200mM NaCI, lOmM 
Tris, pH 7.8) then mixed with 0.5ml Ni-TA agarose beads and purified as described in chapter
2. The proteins were eluted from the beads with low pH elution buffer (8M Urea, 200mM 
NaCI, lOmM Tris, pH 4.0). This was then subjected to four different dialysis strategies (table 
3.1).
1). Direct dialysis. 1ml of the purified protein was placed in dialysis tube and dialyzed 
against 2L of refolding buffer (200mM NaCI, lOmM Tris, pH 7.4) in a beaker at 4°C overnight.
2). Gradual dialysis with direct pH change. Similar to 1 but starting with the refolding buffer 
with denaturing conditions and at pH 7.4, (6M Urea, 200mM NaCI, lOmM Tris, pH 7.4). The 
urea in refolding buffer was diluted 1:2 using a diluent buffer, (200mM NaCI, lOmM Tris, pH 
7.4) every two hours for 24 hours to a final concentration of 0M Urea as described in 
chapter 2.
3). Gradual dialysis + gradual pH change. Similar to 1 but starting with the refolding buffer 
with denaturing conditions and at pH 4.5, (6M Urea, 200mM NaCI, lOmM Tris, pH 4.5). The 
refolding buffer was diluted as in 2) allowing for gradual change in both urea concentration 
in the buffer as well as pH.
4). Similar to 3) but with addition of 10% glycerol to the refolding and diluent buffers.
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10 DBLa tags were tested in each experiment and precipitates were removed from the 
solution by centrifugation at 13,000rpm for 10 mins. Quantity of the recombinant peptides 
was measured by the BCA assay as described in chapter 2 and is shown in table 3.2.
Table 3.1 Refolding proteins by dialysis
Experiment Recovery
(No of proteins recovered)
11. Direct dialysis
i ■
0/10
L .. . ........ ..... ........................ ........., ... -.... ... . ...
2. Gradual dialysis + direct pH change 4/10....................................... .
\ 3. Gradual dialysis + gradual pH change 8/10
4. Gradual dialysis + gradual pH change + 10% glycerol 10/10
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Table 3.2 Concentrations of proteins recovered after refolding by dialysis.
DBL-a tag Molecular weight, Da Isoelectric point Concentration, pg/ml
I 6429 17137.24 9.32 300
6387 17908.98 8.32 348
6398 18259.24 7 216
6408 16789.76 8.87 279
\ 6430 19342.1 6.55 326
6433 18572.89 8.83 255
i 6485 19240.14 8.29 213 !
6964 18316.28 7.7 212
7045 17674.57 6.22 180 i
7069 17180.08 8.5 190
[ 7084 17796.69 7.14 531
7116 19028.13 8.61 212
j 7134 18321.29 7.08 213 1
7157 17687.69 9.14 199
1 7160 18306.16 6.75 123 i
7183 17468.4 5.95 216
j 7198 20152.38 7.76 270
7204 18303.29 7.73 263
I 7249 18651.71 8.86 456
7250 17700.44 6.23 115.1
i 7323 20068.31 6.66 266 i
7337 16884.95 6.75 169
1 7391 19118.29 8.27 180
7410 18446.52 6.5 267
7506 19480.38 6.16 244 i
7530 16724.49 6.59 311
7630 18779.96 8.72 324 :
7781 19277.33 8.6 236
7799 19150.16 8.97 409
7860 18537.55 7.12 244
7864 17581.67 7.83 378
8204 19035.11 6.54 243
8344 18547.79 7.16 235
8349 18498.42 6.3 193
8383 17130.28 9.06 195
8472 18578.53 7.74 347
8477 17056.11 9 245
8482 19184.06 7.04 360
8585 18451.35 6.7 178
8618 17955.87 8.64 240
f  8706 19453.21 8.2 279
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3.3 Discussion
Characterization of the immunological or biochemical properties is best done on properly 
folded proteins. Soluble expression of a recombinant protein is typically a good indicator 
that it properly folded into its native structure. However, heterologous expression of 
eukaryotic proteins, particularly P. falciparum, results frequently in the formation of 
inclusion bodies (Vedadi et al. 2007; Mehlin et al. 2006). The process by which these 
inclusion bodies form is not known but is linked to over production of the heterologous 
target in the host (Carrio & Villaverde 2002). Almost invariably, expression of proteins in E. 
coli is targeted in producing as much of the protein as is possible. Overproduction of 
heterologous proteins is thought to overwhelm the protein translational machinery in E. coli 
resulting in truncated and/or misfolded forms of the protein that aggregate to form 
inclusion bodies. Successful strategies used to improve soluble expression of recombinant 
expression of plasmodial proteins in £  coli have either supplemented the £  coli 
translational machinery with the features it requires for expression or slowed the 
translation process so as not to overwhelm the translational machinery. These include co­
expression with molecular chaperons and solubility enhancing fusion partners, codon 
harmonization, use of host strain supplemented with tRNAs that are abundant P. 
falciparum, use of weak promoters and lower bacteria culture temperatures (Flick et al. 
2004; Stephens et al. 2011; Zhou et al. 2004; Yazdani et al. 2006).
The successes of these strategies vary from one recombinant protein to another. This study 
proposed to express different variants of the DBL-a tag in £  coli for antigenic
characterisation. As expected, the expressed product formed inclusion bodies that
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precluded further antigenic characterisation. In order to improve solubility, I tested several 
established strategies that have been proven effective for plasmodial proteins.
Use of plasmids that encode rare tRNAs found in P. falciparum has been shown to improve 
expression in E.coli (Zhou et al. 2004; Baca & Hoi 2000). Four different strains of E. coli with 
differing genetic backgrounds were used to optimize expression: the BL21(DE3)pLysS strain; 
the BL21trxB(DE3)pLysS and origami(DE3)pLysS strain that enhance disulphide bond 
formation and the BL21 (DE3) CodonPlus-RIL strain that is supplemented with rare tRNAs to 
allow for expression of genes from AT rich genomes. In all the strains, the recombinant tag 
was expressed as an inclusion body.
Slowing down the synthesis of proteins is thought to allow the protein translational 
machinery ample time to fold newly synthesized protein into proper structures and thus 
improving solubility. Indeed, expression of plasmodial protein at the lag phase and growing 
bacteria at low temperatures where growth is slow have independently been shown to 
yields of soluble protein (Flick et al. 2004). Attempts to slow down bacterial growth by these 
methods did not improve the solubility of the expressed proteins.
Formation of inclusion bodies by bacteria is a reversible process (Villaverde & Carrio 2003; 
Carrio & Villaverde 2001). Soluble functional proteins can also be recovered from inclusion 
bodies via dialysis. Refolding by dialysis has been used to recover functional P. falciparum 
dihydrofolate reductase (Sirawaraporn et al. 1993) and falcipain-2 (Kumar et al. 2007) 
proteins from inclusion bodies. Protein refolding is a complicated procedure that requires 
extensive optimization to produce functional proteins (Vallejo & Rinas 2004). Different 
dialysis strategies of refolding DB-La tags were tested. A dialysis process that allowed for
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both the gradual change in pH and the concentration of the urea allowed us to increase the 
number of proteins recovered from 4/10 to 8/10. Addition of 10% glycerol, allowed us to 
recover all the proteins that were tested. Glycerol reduces non-specific interactions 
between proteins.
For this study, a total of 39 recombinant DBL-a tags were expressed. All without exception 
formed inclusion bodies. However, it was possible to recover all the expressed proteins from 
inclusion bodies by refolding using dialysis. The strategy developed here, allows for efficient 
recovery of aggregated proteins of highly polymorphic nature from inclusion bodies. 
Refolding of plasmodial protein by dialysis, though under-utilized, provides an attractive 
option that offers the possibility of tremendously improving the recovery of plasmodial 
proteins and accelerate their characterization.
74 | P a g e
Chapter 4 
Characterization of homologous and heterologous antibody 
responses to DBL-a tags isolated from clinical isolates
Humoral immune responses to the DBLa domain region have largely been studied using 
parasite material from adapted lab isolates. In most cases, this involves heterologous 
antigen-antibody pair measurements. In this chapter, I describe the pattern of acquisition of 
both homologous and heterologous immune responses to the DBL-a tags in the field. In 
addition, as a preamble to the next chapter that describes antigenic relationships, I wanted 
to explore the variability in the mean recognition of the antigens by the sera and the 
variability mean immunogenicity of the antigens. I report an increase in the homologous 
antibody response to the DBL-a tags that fits with the previously described "hole-in-the- 
repertoire" hypothesis in which individuals get infected by parasites to which they lack 
antibodies to.
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4.1 Introduction
The surface of red blood cells infected with P. falciparum contains antigens of parasite origin 
that are highly immunogenic. Unlike other malaria antigens that require several rounds of 
exposure before generation of antibodies, a single infection is enough to generate 
appreciable amounts of antibody (Elliott et al. 2007). Acquisition of antibodies to these 
antigens on the erythrocyte surface has been associated with protection against malaria 
(Bull et al. 1998; Mackintosh et al. 2008b). There are several families of these surface 
proteins containing multiple copies in a family per haploid genome with extensive 
polymorphism between members, a possible indication that they are all under immune 
selection. The presence at the surface on the infected erythrocyte has been confirmed by 
surface staining for PfEMPl, RIFINs and STEVORs (Petter et al. 2007; Blythe et al. 2008). 
Similarly, recombinant antigens of PfEMPl, RIFINs and STEVORs are subject to recognition 
by naturally acquired antibodies (Abdel-Latif et al. 2002; Mackintosh et al. 2008a; Schreiber 
et al. 2008). However, current opinion and data support the view that most of this response 
is directed at P/EMP1 molecules, though the role of non-P/EMPl antigens in natural 
immunity remains poorly defined. In a recent study Chan and colleagues developed 
genetically modified parasites that allowed them to silence the expression of PfEMPl 
without affecting the expression of the other variant gene families (Chan et al. 2012). Using 
2 different strains of P. falciparum they were able to demonstrate that a loss in P/EMP1 
expression was accompanied by a concomitant loss in recognition of the surface red blood 
cells infected by the mature forms of this parasite. While this supports the role of PfEMPl as 
the dominant variant surface antigen, there is need for more extensive studies that include 
different variants of these proteins. A poorly immunogenic non-PfEMPl variant antigen
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paired with a highly reactive PfEMPl antigen could potentially exaggerate the role of 
PfEMPl.
So far, antibody responses to P/EMP-1 have been studied using red blood cells infected with 
trophozoites from lab isolates or field isolates as a target. The method measures the 
collective response to all variant antigens and is limited by the volume of the sample 
obtained when studying clinical isolates and by the inability to distinguish the target 
epitopes being recognised.
Cloning and expression of antigens as recombinant forms has been used extensively to 
generate a renewable source of purified proteins for immunological assays and, ultimately, 
development of vaccines. A number of laboratories have expressed recombinant domains 
from sequenced laboratory isolates and used those for the analysis of antibody responses to 
PfEMPl by ELISA. In particular, several studies have used recombinant DBLa domains from 
the 3D7 P. falciparum  isolate to show that it is a target of naturally acquired antibodies and 
that they are acquired at a rate that is determined by the degree of exposure (Cham et al., 
2010; Joergensen et al., 2007; Mackintosh et al., 2008a). In two separate studies, it was 
observed that the order by which antibodies to the domains is acquired is non-random. 
Children acquire immunity to DBL domains isolated from group A or B/A PfEMPl type 
antigens much earlier compared to group B and C P/EMP1 (Cham et al. 2010; Cham et al. 
2009). This is consistent with published reports that showed the association between the 
expression of group A or B/A PfEMPl P/EMP1 and severe disease in young children 
(Warimwe et al. 2009; Jensen et al. 2004). In a separate finding, Barry and colleagues 
showed that children acquire antibodies to group 2 DBL-a tags much earlier compared to
the other Cys/PoLV groups (Barry et al. 2011). In their work, Joergensen and colleagues
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observed limited cross-reactivity among DBL domains isolated from a single parasite 
genome but did not observe the ordered acquisition of antibodies with respect to the A, 
B/A, B, B/C and C types of P/EMP1 (Joergensen et al. 2006).
The major drawback of these studies is that most of them are limited to analysing responses 
to DBLa region within a single sequenced genome. Extensive polymorphism among 
members of the var gene family has limited the expression of recombinant P/EMP1 proteins 
from clinical isolates. A small tag region within the DBLa domain is accessible in most 
parasites and has been used to characterise the properties of these genes from clinical 
isolates.
4.1.1 The DBL-a tag
The N-terminal end of most sequenced P/EMP1 members share a common N terminal head 
structure composed of the N-terminal sequence, DBLa and CIDR (NTS-DBLa-CIDRa) 
domains (Smith et al. 2000; Gardner et al. 2002). A recent study analyzing P/EMP1 members 
from seven genomes found this domain structure present in up to 95% of all the P/EMP1 
analysed (n=311) (Rask et al. 2010). The DBLa domain is relatively conserved and has short 
islands of homology have allowed for the design of degenerate primers that allows this 
region to be sampled from most parasite genomes.
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Fig 4.1 Domain structure of P/EMP1. The extracellular end of PfEMPl molecules is made up of variable 
numbers of Duffy biding like (DBL) and Cysteine Inter-domain Rich (CIDR) domains in differing permutations. 
The N-terminal end of most member has a semi-conserved head structure within with is a DBLa domain. The 
DBLa tag is a small region within this domain that is accessible by primers in most P/EMP1 isoforms.
The region within the DBLa domain amplified by these primers is termed the DBL-a tag and 
is approximately 350bp long. It is due to this that this is the region of PfEMPl that has been 
most studied from most clinical isolates. I isolated and expressed this region from 36 
isolates and used them as a model antigen to measure immune responses to PfEMPl 
isolated from sick children.
While P/EMP1 plays a crucial role in host immune evasion, it is to date unclear why this 
P/EMP1 repertoire is so big and what differences might exist in terms of cross-reactivity 
between the different P/EMP1 proteins. In this work I wanted to test how recombinant 
expressed DBLa domains of P/EMP1 from parasites of acutely ill children are recognized by 
their corresponding homologous sera and by heterologous sera obtained from children 
infected by other isolates within the same population. I hypothesize that the gains/losses of 
responses to heterologous antigens after infection is determined by the degree of antigen 
similarity between any two variant antigens.
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To test my hypothesis I have chosen a sero-epidemiological approach and assessed antibody 
titres in plasma from 36 children admitted to hospital with acute malaria. Antibody titres 
were assessed against 36 different recombinant expressed DBL-a tags from P/EMP1 derived 
from this same group of children. Recognition of the DBL-a tags was tested against plasma 
obtained at three time points; the time the child presented to hospital (Acute), 4 weeks post 
treatment (C2) and four months post treatment (C3).
Unlike influenza or respiratory syncitial viruses in which disease is caused by a single 
dominant antigenic variant that changes with seasonality, individuals living in malaria 
endemic areas are continuously exposed to multiple strains of P. falciparum. The number 
and type of variants that people are exposed to is expected to vary from individual to 
individual. This, coupled with the heterogeneity in the antigenicity of the variants, generates 
variability between serum donors in their total PfEMPl specific IgG responses. By testing 
which DBL-a tags were recognized by these children at three different time points, I was 
able to study the variability of the individual mean antibody reactivity to the DBL-a tags and 
the variability in the individual mean antigenicity of the DBL-a tags and its dynamics through 
time.
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4.2 Methods
4.2.1 Statistical analysis
Multiple linear regression was used to explore factors that influence variation in the 
responses measured against the tags. Multiple linear regression is a statistical tool that 
looks at linear relationships between one variable and other related variables. It measures 
how changes in one variable, the dependent variable, are affected when changes occur in 
other variables (independent variables) that share a relationship which is linear with the 
dependent variable. In the work described here, these models were used to describe factors 
that influence variability in the measure of antibody responses (O.D.) against recombinant 
DBLa tags.
The extent to which a change in the dependent variable is influenced by a change in any of 
the independent variables is given by the regression coefficient, p. It estimates the amount 
of change in the dependent variable when the independent variable changes by one unit. 
The larger the regression coefficient, the more a change in the independent variable 
influences the dependent variable. A p-value is attached to each regression coefficient, p 
that gives the probability of observing an influence of the independent variable on the 
dependent variable where none exists. Low p-values therefore suggest that the influence is 
real.
In most cases, a single independent variable explains only part of the variation in the 
dependent variable. To better describe the variation observed in a dependent variable it is 
necessary to include other variables in the model that also explain variation of the 
independent variable in the model. In a regression model with more than one variable, the
81 | P a g e
p coefficient describes the influence of changes in the independent variable on the 
dependent variable after correcting for the influence of all other independent variables in 
the model.
In the case at hand, there were repeated measures of immune responses taken over a short 
period of time for the same individual and this potentially violates the assumption that 
measures of the dependent variable are independent and uncorrelated. This was taken into 
account by fitting linear mixed effect models that included a random variable effect for each 
child.
The total amount of variation in the dependent variable that is explained by the 
independent variables in a regression model is quantified by the R2 value. As explained 
above, when more independent variables are added to the regression model, more 
variation in the dependent variable is explained, i.e., adding more independent variables 
increases the R2 value. Some of this increase could be due to chance: this is corrected by an 
adjusted R2 value (R2adj) is computed that takes into account the number of independent 
variables in the model and the number of observations in the sample.
The models were built by stepwise addition of individual independent variables and 
assessment of their contribution to the variation explained. If adding the variable 
contributed significantly to the model then it was retained; otherwise it was dropped. This 
method ensured that the model ended up with the smallest possible set of independent 
variables included. The stepwise addition of independent variables in a model results in an 
additional increase of the variance being explained (R2 change). At each step, an ANOVA was 
carried out to compare two models, Model 1(M1) and Model 2 (M2) by an F-test, where M l
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is a nested model of M2 with the difference that M2 contains an additional independent 
variable whose effect on the overall model is being tested. The ANOVA test determines 
whether the increase in variance explained as a result of adding an independent variable is 
statistically significant.
4.2.1.1 Assumptions of the models
1. There is a linear relationship between the dependent variable and each of the 
independent variables.
2. The residuals follow a normal distribution
3. There is zero correlation between the dependent variables
4. There is homoscedasticity, i.e., the variance of the residuals remains approximately 
the same across levels of the independent variable in the regression.
To explore this variability, I built the following multiple linear regression models using 
antibody responses (logioOD) as the dependent variable and various explanatory variables 
as described below.
Model 1, explanatory variable: Time of sampling
This is a simple linear regression model that has time as its only explanatory 
variable. In this analysis, I explored whether antibody responses to the DBL-a 
tags vary over time points.
Model 2, explanatory variables: time, antigens
In this model I explored the effect of antigenic differences on the antibody
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responses having controlled for the effects of variation over time. I proposed 
that the 36 DBL-a tags I tested are antigenically different and therefore should 
show some level of differential recognition by human sera. For this and 
subsequent models, the categorical explanatory variable antigen was dummy 
coded for use in linear regression.
Model 3, explanatory variables: time, antibodies
In this model I explored the effect differences between individual sera having 
controlled for the effects of variation over time. Individuals are exposed to 
different variant antigens and as a result respond differently to the DBL-a tags. 
For this and subsequent models, the categorical explanatory variable antibody 
was dummy coded for use in linear regression.
Model 4, explanatory variables: time, antigens, antibodies
In this model I explored the effect of antibody differences on the antibody 
response having controlled for the effects of variation over time and antigenic 
differences. Similarly, we explore the effect of antigenic differences having 
controlled for variation overtime and antibody differences.
Model 5, explanatory variables: time, antigens, antibodies, homologous-heterologous 
response
In this model I explored whether there are differences in homologous versus 
heterologous responses having controlled for variation over time, antigenic 
differences and antibody differences.
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Model 6, explanatory variables: time, antigens, antibodies, interaction between antigens 
and antibodies
In this model I checked for interactions between antibody and antigens i.e. 
investigates whether there are particular antibody-antigen pair responses that 
are either high or low compared to the average for the antigen and antibody 
involved.
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4.3 Results
In the case at hand, I employ linear regression models to explore variability in the 
antigenicity of the proteins as well as variability between serum donors in their total IgG 
directed at PfEMPl and adjust for these in order to profile homologous-heterologous 
responses over time. Table 4.1 shows the amount of variance explained by each of the 
models (R2Adj) and the P values obtained from the ANOVA comparing nested models as 
described above. I built the model stepwise from individual independent variables and 
compared the contribution of the added variable to the overall fit of the model by carrying 
out ANOVA test comparing the model containing the independent variable to a nested 
model lacking the independent variable. This analysis tells us whether the additional 
variance explained by adding the additional independent variable is statistically significant 
i.e. whether the change in R2Adj is statistically significant.
Table 4.1. Overall IgG responses
Model Radj ANOVA P value
; i 0.0114
2 0.0975 Model 1-Model 2
(To test the effect of adding antigen to a model 
containing time)
0.004
3 0.2733 Model 1-Model 3
(To test the effect of adding antibody differences 
to a model containing time)
< 0.0001
4 0.3650 Model 4-Model 2
(To test the effect of adding antibody differences 
to a model containing antigen differences)
Model 4-Model 3
(To test the effect of adding antigen differences to 
a model containing antibody differences)
< 0.0001 
< 0.0001 1
5 0.3648 Model 5-Model 4
(To test for differences in homologous and 
heterologous responses)
0.4189
6 0.4579 Model 6-Model 5
(To test the effect of antibody antigen interactions)
<0.0001
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From this analysis, there was significant variability between serum donors in their mean IgG 
directed at the DBL-a tags tested as well as variability in the mean antigenicity of the 
proteins indicating the heterogeneity of exposure and of the antigenic properties. After 
controlling for antigen and antibody differences, I analyzed the difference between the 
overall homologous and heterologous responses and observed that it was not statistically 
significant. However, there was a significant interaction between the two groups with time. 
At the time of infection, the heterologous response was high and declined significantly over 
the 16 week period while the homologous response was low at the acute time-point but 
gradually increased during the follow-up period (Fig 4.2).
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Heterologous
Homologous
Timepoint
Fig 4.2 Acquisition o f antibodies to 36 distinct DBLa-tag variants w ith  tim e by 36 children. At the tim e o f 
infection children had higher levels o f antibodies to other circulating variants (Heterologous, red) as compared 
to the variant they were infected w ith (Homologous, blue). A fter infection, the children developed antibodies 
to  the ir infecting variant.
I tested to see if there were interactions between the antigen and antibody using model 6. 
This allowed me to determine whether there are particular antibody-antigen pairs that have 
responses that are either high or low compared to the average response. From this analysis, 
I observed significant interactions between antigens and antibodies (Table 4.1). The dataset 
used in this analysis excluded immune responses directed at the homologous DBL-a tag and 
as such the antigen-antibody interactions observed involved heterologous antibody-antigen 
pairs. Such interactions signal gain or losses in heterologous IgG responses between specific 
antigen-antibody pairs after infection.
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Many statistical tests assume that measurements or observations are independent. In the 
case at hand, linear regression models are built on the assumption that the OD 
measurements within and between individuals are independent or unrelated. In this study, 
repeated measures of OD were taken from the same individuals at 3 different time-points. 
Such repeated measures tend to be correlated. Linear regression treats data obtained from 
the 3 time points as independent, artificially increasing the sample size and decreasing the P 
value. This predisposes the analysis to type 1 error, i.e., observing effects as being significant 
when they are not. Analysing these data without accounting for the within person variability 
is analogous to using a 2 sample t-test where a paired t-test is required. In order to account 
for this dependency in the data set, I used linear mixed effects models in which the 
individuals were fitted as random variables. Even after correcting for within-individual 
correlations, the variations in mean DBLa specific antibodies in sera and the variability of 
the antigenicity remain significant. In the linear mixed effect models, the antigen-antibody 
interactions also remained significant (Table 4.2).
Table 4.2. Comparison of Linear mixed models
Linear mixed model P values corrected for repeated
ANOVA measures
Model 3-Model 4 <.0001
Model 4-Model 5 0.0366
Model 5-Model 6 <.0001
In addition, I carried out regression analysis of the antibody responses using datasets for 
each time point separately (Table 4.3 and 4.4). Although this reduces the sample size, it
eliminates the dependency inherent in the dataset with all time points together. From this
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analysis, there was a statistically significant variation in the mean reactivity of the sera 
against the 36 antigens tested at all the time points (Fig. 4.3) Similarly, I observed significant 
variations in the mean antigenicity of the antigens against the 36 sera tested (Fig. 4.4). This 
indicates that these individuals have exposures to different sets of antigens and that the 
DBL-a tags have different antigenic properties from one variant to another. After correcting 
for these sources of variation, I observed a significant difference between the mean 
homologous and heterologous IgG responses to the tags at acute and 4 week time-points 
but not at the 16 weeks. This is consistent with the observations seen with the combined 
analysis of all the time points in which the homologous response is low at the acute time 
point and increase to levels comparable to the heterologous response by the 16 week time- 
point. The distribution of the raw ELISA OD values for each of the antigens and antibodies at 
each of the acute, C2 and C3 time-points is shown presented in Figures 4.5, 4.6 and 4.7 
respectively.
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Table 4.3. Multiple linear regression models of immune responses by each time-point of
serum collection.
Model Explanatory Variables
r Model 7 Antigens
Model 8 Antibodies
Model 9 Antigens, Antibodies
Model 10 Antigens, Antibodies, Homologous-Heterologous response
Table 4. 4. Multiple linear regression models of immune responses by time of serum 
collection.
Radj ANOVA P value
Acute
Model 7 0.1441
Model 8 0.1226
Model 9 0.2858 Model 9- Model 7 <.0001
Model 9- Model 8 <.0001
Model 10
i..........  .............
0.3578 Model 10- Model 9 <.0001
\ 4 weeks, C2
Model 7 0.1023
[ Model 8 0.4658
Model 9 0.6087 Model 9- Model 7 <.0001
i Model 9- Model 8 <.0001
Model 10 0.6196 Model 10- Model 9 0.01090
16 weeks, C4
Model 7 0.1087
Model 8 0.4683
Model 9 0.6182 Model 9- Model 7 <.0001
Model 9- Model 8 <.0001
Model 10 0.6167 Model 10- Model 9 0.624
In order to exclude the effects of prior infections, I also analyzed the difference between the 
antibody measures at the acute sampling time and those from the two follow up periods 
(Table 4.5). There was significant variation in both the mean reactivity of the sera and the
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mean antigenicity of the tags observed at 4 and 16 weeks after infection. This indicates 
heterogeneity in the parasites that infected these children even after correcting for past 
infections. However, there was a significant difference between the heterologous and 
homologous response at 4 weeks but not at 16 weeks.
Table 4.5. Multiple linear regression models of immune responses by the differences 
between the acute point of serum collection and subsequent follow up periods.
Radj ANOVA P value
r 4wks - Acute
Model 7 0.119
; Model 8 0.3865
Model 9 0.5417 Model 9- Model 7 <.0001
[ - - - - - -  - Model 9- Model 8 <.0001
Model 10 0.5533 Model 10- Model 9 0.01444
16wks - Acute
Model 7 0.1871
Model 8 0.02171
Model 9 0.2238 Model 9- Model 7 0.0482
Model 9- Model 8 <.0001
Model 10 0.2939 Model 10- Model 9 <.0001
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Figure 4.3 Variation in the mean reactivity of sera to antigens. The bar plot shows the mean response o f the 
each child to  the DBLa tag antigens at Acute (A), C2 (B) and C3 (C). 7249 serum volume was insufficient fo r C3 
tim epoint
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Figure 4.4 Variation in the mean immunogenicity of antigens. The immune response to  each o f the 36 DBLa 
tags measured against 36 sera was measured by ELISA. The bar plot shows the mean recognition o f the each 
antigen at Acute (A), C2 (B) and C3 (C).
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Figure 4.5 Distribution of the raw OD values for each of the serum antibodies tested against the 36 antigens (A)
and for each of the antigens tested against the 36 sera (B) at the time the acute time-point.
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Figure 4.6 Distribution of the raw OD values for each of the serum antibodies tested against the 36 antigens (A)
and for each of the antigens tested against the 36 sera (B) at the 2 week-convalescent time-point.
96 | P a g e
A4
3
-L .
2
1
J .  J-
0
to  co o o
MiSociies
B
O
4
T  O
3
-JL.
2
1
0
i- D t  V g  co h. w  u t coN C O Q O P j i n v i n a t o v K o n o o ' s r o o c o K o  o  o  o
Antigens
Figure 4.7 Distribution of the raw OD values for each of the serum antibodies tested against the 36 antigens (A)
and for each of the antigens tested against the 36 sera (B) at the 4 month-convalescent time-point.
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To test the assumptions of the models, a scatterplot of the residuals versus the fitted values 
was plotted. The distribution of the residuals remains fairly even for most of the fitted 
values in all the models. This indicates that the data meets the homoscedasticity assumption 
as shown for model 6 in figure 4.8. In addition, most of the residuals cluster around the zero 
line, indicating that the assumption of normality is justified. The histogram plot of the 
residuals shows normal distribution of the data (Figure 4.9). It is important to note that the 
dependent variable (O.D. values) were log transformed in all the models to achieve a normal 
distribution.
Fitted values
Figure 4.8 Scatter plot of residuals versus fitted values from model 6.
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Figure 4.9 Histogram showing normal distribution of the residuals from the Model 6.
4.4 Discussion
In summary, I observed significant contribution to the variation of the immune response by 
both antigenic and antibody differences in all the models irrespective of whether the model 
was fitted to the collective responses at all time points (Table 4.1) or whether it was fitted to 
the immune reactivity measured at each time point separately (Tables 4.4) and this 
remained significant even after correcting for repeated measures (Table 4.2). This indicated 
that there is differential recognition of the DBL-a tags by IgG at all the time points.
In the model testing the interactions between homologous-heterologous responses with 
time, the levels of heterologous responses to the tags declined over time while the 
homologous responses increased over the follow up period in a pattern congruent with the 
"hole in the repertoire theory", i.e., a patient is infected by parasites expressing variants of 
the antigens to which the host has limited recognition as evidenced by the low recognition 
of the DBL-a tags at the time the child presented to hospital with the infection. The 
immunity to such variants is generated after infection as shown by the increased recognition 
of the DBL-a tags at subsequent follow up period. Bull and colleagues used a large 
prospective study to show that children falling ill with disease were more susceptible to 
infection with parasites to which they lack agglutinating antibodies than parasites to which 
they had antibodies (Bull et al. 1998). Taken from this perspective, the results presented 
here indicate that the DBL-a tag region could potentially be part of the epitopes targeted by 
the protective antibodies or has epitopes associated with the protective sites within the 
P/EMP1 molecules. A recent case-control study analysing sex and age-matched children 
admitted to hospital with severe malaria and uncomplicated malaria found an association
100 | P a g e
between IgG responses to the DBLa and reduced parasite density. In the same study, severe 
malaria was associated with low IgG responses to DBLa (Rovira-Vallbona et al. 2012). In 
three separate studies using animal models, vaccine formulations based on the DBLa 
domain were effective in preventing infection with P. falciparum. Taken together, this points 
to a role for DBLa as a target of protective immune responses.
The immune responses to PfEMPl are largely variant specific. However, I observed 
insignificant difference between homologous and heterologous responses (as measured by 
model 5) for the collective IgG responses (Table2) and this was true even after controlling 
for repeated measures (Table 3). When the analysis was run on the immune reactivity 
measured at each time point separately, significant differences were only observed 
between homologous and heterologous responses at 4 weeks post treatment, C2 (table
4.4). The increase in immune reactivity was more in the homologous responses indicating 
the responses were largely variant specific. Of interest is the increase in heterologous 
responses following a single episode of malaria. This point to the possible existence of a 
level of cross reactivity between different DBLa tags.
Most of the studies done on immune responses to recombinant DBLa are effectively 
measuring cross-reactive responses. In all these studies, the recombinant antigens are 
obtained from lab isolates to which the subjects from which the sera is obtained have 
probably not been exposed to (Joergensen et al. 2007; Joergensen et al. 2006; Mackintosh 
et al. 2008b; Cham et al. 2009; Rovira-Vallbona et al. 2012). The immune recognition 
observed in these studies points to the presence of strain transcending immunity. 
Immunisation with DBLa, has been shown to generate protective cross reactive immune
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responses in an in vivo model of malaria (Moll et al. 2007; Ahuja et al. 2006).
Cross-reactive responses can only be generated by one antigen against another if they 
shared B cell epitopes and this would often be reflected at the genetic level by sequences 
similarity for linear or conformational epitopes and at the serological level by the pattern of 
responses. Two or more similar DBL-a tags will have a similar pattern of responses when 
tested against several immune sera. The heterologous antigen-antibody interactions is of 
particular interest and points at antigen-antibody specificity among heterologous pairs. This 
can be probed by further analysis of whether there are similarities /dissimilarities among 
the antigens with high/low heterologous interactions with the homologous antigen. This 
involves a combined analysis of the genetic and serologic properties of these DBL-a tags by 
antigenic cartography. Therefore, combining the genetic and serological data will allow us to 
refine the search for such epitopes.
Chapter 5
Antigenic Cartography: Quantifying antigenic relationships among 
variant recombinant antigens
Cross reactive responses against variant antigens of the same protein family within a 
parasite species provide empirical evidence of the presence of shared epitopes between 
variants. Analysis of such responses can yield important information about the antigenic 
structure of the parasite population. This information is important for vaccine design and 
immuno-surveillance in a post vaccine era. In influenza, for example, viruses are organized 
into distinct immunological clusters and vaccines are designed and continuously revised to 
be cluster specific. In this chapter, I utilized antigenic cartography - the tools used in the 
immunological analysis of cross reactive responses between influenza variants - to measure 
and visualize antigenic distances between variants of DBL-a tags from clinical isolates.
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5.1 Introduction
The humoral immune system theoretically has the capacity to distinguish between an 
extremely large pool of antigens. In practice, it is common for different antigens to appear 
the same from the perspective of the immune system. In such cases, an antibody responses 
raised against one antigen fails to discriminate between the two different antigens. The 
ability of the antibodies to discriminate between antigens is a function of the antigenic 
similarity or differences between antigens.
There is no direct measure of antigenic similarity/differences between antigens. Antigenic 
distance is measured indirectly using common laboratory assays that include agglutination 
Inhibition (HI), microneutralization (MN), and Enzyme-linked immunosorbent assay (ELISA) 
(Smith et al. 2004). These assays rely on the ability of antibodies to distinguish between 
closely related molecules. Classical analysis presented immunological distance 
measurements from such assays in table format. In such a format, and especially for large 
antigen datasets, it is characteristic to have a lot of noise in the data and interpretation can 
be very challenging. Antigenic cartography is a recently developed computational tool that, 
similar to geographical cartography, draws maps based on the immunological distance 
measurements from assays that allows for visualization and quantification of distances 
between antigenic variants.
Antigenic cartography relies on the exquisite molecular specificity of antibodies for their 
ligands. The degree to which an antibody response specific to one antigen recognizes 
another antigen is dependent on the degree of similarity between the two antigens. Hence
104 | P a g e
two antigens that are both highly recognized by a particular antibody are antigenically 
similar and vice versa. A high assay reading on two antigens as measured by a particular 
antibody is therefore taken to indicate a close antigenic relationship.
The ability to distinguish between many closely related antigens is greatly enhanced when 
several antibodies with different specificities are tested against the antigens. In addition, it 
enhances the resolution of antigenic relationships and allows for a combined analysis of 
antigenic and genetic data where these are available.
When I analyzed antibody responses to the DBLa tag identified in clinical parasite isolates, 
significant gains and losses in heterologous antibody responses were observed as described 
in the previous chapter. The work discussed here describes the development of antigenic 
maps that explore these antigen-antibody interactions.
5.1.1 Immunological shape space concept
" Shape space" formalism was proposed by Perelson and Oster in 1979 as a theoretical 
concept in which antigen-antibody binding is represented in an abstract space of a given 
dimension (Perelson & Oster 1979). Antigens and antibodies are represented as points by 
coordinate vectors in this space and the distances between antigens and antibodies is 
related to their binding affinities. In their model, Perelson and Oster made the assumption 
that affinity measurements for the interactions between antibodies and antigens are related 
to the distances describing them in the shape space by a monotonic function. High 
experimental affinities are represented by small distances in shape space and vice versa. 
While they grossly estimated the "immunological space" to be of low dimensions, they had
no means of deriving the actual coordinates of the antigens and antibodies in that space.
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Given experimental data that measure the affinity between N antigens and M antibodies, 
the challenge is to derive the dimensions of the immunological space and the N+M 
coordinates describing the antigens and antibodies such that the distances between the 
antigens and antibodies in the shape space is monotonically related to the experimental 
data. Early approaches exploited techniques used in numerical taxonomy to represent 
antigenic relationships from an NxM panel in a multidimensional space whose dimensions 
were defined by M (Beyer & Masurel 1985; Dudman & Belbin 1988; Sneath & Sokal 1962). 
To illustrate this, take an NxM panel in which N antigens (in the rows) are tested against M 
sera (in the columns). Each row in this panel forms a vector that describes the coordinate of 
the respective antigen in an M dimensional space. Similarly, the columns contain vectors 
that describe the position of the antibodies in an N dimensional space. The antigen-antigen 
and antibody-antibody distances can then be deduced using the Euclidean method.
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Table 5.1 Hypothetical antigen-antibody affinities.
Antibodies
A B
X 0.5 2
VJ
QJ
W) Y 1.5 2.5+->
C< Z 2 1
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0 0.5 1.0 1,5 2.0 2.5 3
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0.5 1.00.0 1.5 2.0 2.5 3.0
Fig 5.1. Relationships between antibodies (A) and antigens (B) as represented by numerical taxonomy. The co­
ordinates for the antibodies are obtained directly from the experimental readings in the columns i.e. A (0.5, 
1.5, 2) and B (2, 2.5, 1). Similarly, the co-ordinates describing the antigens are obtained from the rows i.e. X 
(0.5,2), Y (1.5,2.5) and Z (2, 1). Antigen-antibody affinities cannot be assessed because the antibodies are 
defined by a 3 dimensional space while antigens are defined by a 2 dimensional space.
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5.1.2 Limitations of the numerical taxonomy method
In cases where antigens are tested against more than three antibodies, the configuration of 
the antigens is represented in hyperspace and is not immediately tractable to the human 
eye. In addition, the panel based approach defines coordinates either for the antigens (in M 
dimensional space) or for the antibodies (in N dimensional space) but not for both 
simultaneously (Fig 5.1). The antigens and antibodies cannot therefore be represented in 
the same space. Hence antigen-antibody distances cannot be deduced. Moreover, the 
distance obtained from this method is an aggregate of multiple measurements and does not 
correspond to the individual antibody-antigen distances in the experimental data. Lastly, 
Lapedes and Farber demonstrated that the dimensions defined by the width/length of the 
panel may not be the true underlying shape space that best describes the experimental data 
resulting in inaccurately projected similarities (Lapedes & Farber 2001).
Lapedes and Farber exploited ordinal multidimensional scaling (MDS), a technique 
developed in mathematical psychology that allowed them to define the true underlying 
dimensions of the shape space and position the antigens and antibodies in the same space 
such that antigen-antibody as well as antigen-antigen and antibody-antibody distances 
could be recovered. MDS are a set of algorithms that reconstruct the relative coordinates of 
points in shape space given only the experimental distances.
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Serological Networks
Antigenic relationships between variant surface antigens have previously been described by 
a network approach (Buckee et al. 2009). This method adapts mathematical formulas used 
to describe relationships in human social networks to describe the population structure of 
the variant antigens by analyzing heterologous responses between P. falciparum  parasite 
isolates obtained from clinical isolates as measured by an agglutination assay. In this 
method, the patient (antibody) and the parasite (antigen) are represented as one 
point/node in a space of pre-defined dimensions. The positioning of the points/nodes in this 
space is arbitrary and does not reflect any quantitative measure between the patient- 
antibody pairs. Instead, heterologous recognition between patient-parasite pairs are 
represented as a directed edge between the respective node pairs such that an edge 
directed away from a node represents recognition of the parasite while an edge pointing 
away from a node represents an agglutinating heterologous response from the patient. This 
method can help to easily identify which parasites or antigens are related, but cannot 
quantify the magnitude of these relationships. It reduces the quantitative data obtained 
from serological experiments into a binary measurement of whether or not parasite-patient 
(antigen-antibody) pairs have any sort of heterologous relations. Dichotomizing data in this 
way throws away data that would be helpful in distinguishing the degree of relationships 
among objects, parasites or antigens that share a relationship. The obvious advantage that 
antigenic cartography has over the network approach is that it provides a quantitative 
measure of the antibody-antigen, antigen-antigen and antibody-antibody relationships 
whereas the network approach is largely qualitative.
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5.2 Method
5.2.1 Multidimensional Scaling
Antigenic cartography relies on multidimensional scaling which is an exploratory statistical
technique that demonstrates relationship (distances or similarities) among objects by 
projecting the relationships in a low dimensional space such that there is a linear correlation 
between the measured/observed relationships among the objects and the relationships 
among the objects as projected in geometric space. Distance in the multidimensional space 
is summarized by the Minkowski distance model below
pij=measured distance between objects i and j
n= number of dimensions
Xj|<=the position of point i on dimension k
xjk=the position of point j on dimension k
r=user defined parameter that defines distance model; where
5. r= l, City-block distance model
6. r=2, Euclidean distance
Multidimensional scaling methods are used to project antigen-antibody relationships in 
geometric space such that distances between antigen-antibody pairs in that space match as
7 r  r n
V i j  =
Lfc=l
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close as possible the antibody-antigen pair distances as measured by an immunological 
assay, e.g. the hemagglutination inhibition. In a typical experiment, multiple antigens are 
tested against multiple sera such that positions of the antigen and antibody points on the 
map are determined by multiple measurements. This improves the resolution and precision 
at which these data can be interpreted and minimizes noise and allows for the constructions 
of accurate maps even where some antigen-antibody pair readings are incomplete. In 
addition, by drawing the antigen-antibody positions in low dimensional space, it allows for 
the visualization and quantification of the antigen-antigen distances. In brief, the following 
steps are taken to generate an antigenic map.
i. Generate a matrix of pair wise antibody-antigen distances measurements 
from an immunological assay, (Djj matrix), consisting of N number of rows 
(antigens) and M number of columns (antibodies).
ii. Choose an appropriate space of r dimensions.
iii. Draw an initial configuration in which points are allocated arbitrary 
coordinates in the r dimensional space
iv. The pair wise distances between antibody-antigen points are obtained from 
the initial projected configuration to make Pu matrix using a Euclidean 
distance model.
v. Compare the Dy matrix to the Pg matrix by linear regression. The goodness of 
fit of the regression is computed by the least squares method in which the 
sum of square differences between the measured distances (Djj matrix) and 
the projected distances (Py matrix). The goodness of fit measure is called the 
stress value and is calculated by the stress formula below.
I l l  | P a g e
Stress = y  \Dtl - pu
i j
The stress value indicates the degree of correspondence between the measured 
values and the projected distances on the map
vi. Points in the projected configuration are then moved in the ordination space 
in a direction that minimizes stress the most. This is achieved with using 
multiple random starting points using the conjugate gradient optimization 
method (Ziegel et al. 1987).
vii. Steps iv-vi is repeated until the minimum stress value solution is obtained.
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Find direction of 
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I
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Compute distances, Pij
Compare w ith  data, Dij
Calculate goodness-of-fit 
Stress( | Djj-Pjj |2)
No
Exit
Fig 5.2 Schematic representation of the algorithm applied in developing antigenic maps.
5.2.2 Unfolding analysis
In a typical scenario, only the antigen-antibody distances are available from the 
experimental data. The antigen-antigen and antibody-antibody pair wise distances are only
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unraveled after projecting the antigen-antibody distances in the same multidimensional 
space. This is referred to as the "unfolding problem" in MDS.
5.3 Results
5.3.1 Application to ELISA
Antigenic cartography has mainly been applied to study antigenic relationships among 
influenza viruses. Antibody reactivity in influenza is measured by the hemagglutinin 
inhibition assay using two-fold serial dilution with titre values ranging from <10 to >10,240 
(Hirst 1943). A large inhibition of agglutination by sera induced by one strain against 
another strain indicates a small antigenic distance between them. In this work, antibody 
recognition was measured using ELISA, an immunological assay that measures the reactivity 
between a reference antibody and a test antigen by optical density (O.D.) measurements of 
a colorimetric reaction. Similarly, a high OD reading indicates that there is close similarity 
between the test antigen and the antigen against which the reference antibody was 
generated. Low OD values indicate distant relationships.
In order to apply the methods developed for influenza, the antigenic cartography maps 
were obtained by transforming the ELISA O.D. readings to equivalent titre dilution values 
suited to the hemagglutinin inhibition (HI) titres obtained from HI assay used by WHO and 
national influenza centers to quantify seroreactivity of influenza virus isolates (Ampofo et al. 
2012; Smith et al. 2004). Briefly, the lowest OD reading was subtracted from the highest for 
each antigen tested to obtain the range which was subsequently divided by 11 to form 
categories of OD that correspond to the 11 HI titre dilution levels. The transformed OD 
readings were used develop antigenic maps through ACMACS-web program at
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https://acmacs-web.antigenic-cartography.org/acmacs-web that employs metric 
multidimensional scaling in drawing its map. Metric multidimensional scaling is a parametric 
method that draws its maps in an Euclidean space.
In addition, an implementation of the ACMACS-web program in the R statistical software 
was also used. It included the modifications on metric multidimensional scaling described by 
Smith DJ and colleagues (Smith et al. 2004) in which the antigen-antibody pair wise 
immunological distances in the Djj matrix are obtained transformed as below to normalize 
them.
a) The experimental distances (Hy) were normalized to the maximum HI values
Dy =br log2 (Hij)
b]= the log2 of the maximum transformed ELISA titre measurement for antibody j  
Hij= Transformed ELISA titre between antigen / and antibody j
5.3.2 Choice of Dimensions
The goodness of fit of an antigenic map to measured distances is greatly influenced by the 
number of dimensions in the ordination space. Ideally, the map should have no or low stress 
values in dimensional space that is tractable to the human eye (i.e. dimension < 3). Maps 
that have acceptable stress values at dimensions higher than three cannot be visualized by 
the human eye and are difficult to interpret. On the other hand, maps projected on low 
dimensional space but with high stress values are highly distorted and are a 
misrepresentation of the original data.
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In order to determine the choice of dimensions for the antigenic maps described here, I 
plotted a scree diagram (Fig 5.3) by projecting the stress as a percentage in different 
numbers of dimensions and choosing the dimension that has the best balance between the 
interpretability of the data and stress value. The stress value of the maps in a 2 dimensional 
space was 8.3 % which was acceptably low and comparable with published data.
S c r e e  p l o t
N um ber o f dimensions
Fig 5.3 Percent stress values (x-axis) plotted against the corresponding number of dimension associated with it
From henceforth, therefore, all the maps were drawn in a 2 dimensional Euclidean space.
5.3.3 Selection of Informative Sera
Antigenic cartography relies on the ability of antibodies to discriminate between antigens. 
Sera that react highly or poorly with most antigens are poor molecular tools for 
discriminating antigens and have to be dropped from the analysis before drawing the 
antigenic maps. In addition, it is important to select sera with high diversity of reactivity
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with the antigens in order to enhance the resolution of the maps. To address both these 
issues, only sera with a high standard deviation for recognition of antigens were included in 
the analysis. A standard deviation cut-off of 0.86 was used to select the sera (Table 5.3). This 
cut-off was selected based on the inspection of pattern of responses of individual sera (Fig
5.4). Dropping poorly discriminative sera from the construction of the map resulted in 
minimal movement of the positions of the antigens within the map (Fig.5.5 a,b,c). Despite 
this minimal change, subsequent maps were developed using informative sera.
To compare the changes in configuration of the points in the two maps, I used Procrustes 
analysis. This is a statistical tool that compares the geometry of two or more shapes in order 
to establish whether they are similar. It superimposes two configurations taking into 
account rotation, translation and reflection transformation to optimally align them to be as 
similar as possible.
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Sera 8383 8472
SD 0.8806 0.9446
Sera 7530 7630
SD 1.00465 0.73189
Sera 7198 7204
SD 0.9285 0.83236
Sera 7045 7069
SD 1.02038 0.78614
Sera 6387 6398
SD 0.82722 0.74538
8477 8482 8585
0.9587 0.9083 0.21203
7642 7799 7864
0.77927 0.80174 0.89719
7249 7250 7323
1.08394 0.8512 0.68680
7084 7116 7134
0.90829 0.91362 0.92654
6408 6429 6430
0.88393 0.73720 0.81898
8618 8706
1.0280 0.2591
8204 8344 8349
0.8487 0.3015 0.8347
7391 7410 7506
0.90815 0.77654 0.84775
7157 7160 7183
0.8791 0.88379 0.8134
6433 6485 6964
0.81563 0.81730 0.86202
Table 5.2 Standard deviation of the recognition of each serum to the 36 antigen tested. An arbitrary cut off of 
0.86 was set in order to select the most informative set of sera for antigenic cartography analysis. The sera 
that were dropped from this analysis are highlighted in yellow.
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5.3.4 Adjusting for previous exposure
The sera used to discriminate the antigens were obtained from children living in a malaria 
endemic area. It is reasonable to presume that these children have had previous encounters 
with the parasite and will therefore contain in their sera antibody responses to variants of 
PfEMPl from previous exposure(s). In such a scenario, it will be difficult to distinguish broad 
reactivity to multiple antigens observed as a result of the current infection in question from 
reactivity resulting from multiple antibody specificities to several antigens obtained past 
exposures. The ELISA OD readings at the acute time point give an indication of any long lived 
responses present in the sera from past exposure as well as early responses arising from the 
current infection. In order to filter out the effect of past exposure, the OD readings at acute 
time point were subtracted from those at the convalescent time points to obtain the immune 
responses that were as a result of the current infection under investigation. Antigenic maps 
were then developed maps on these values (Figs 5.6b and 5.7). This had the effect of shrinking 
the maps (Figs 5.6c and 5.8). This was because the average antibody titres had been reduced by 
subtracting previous titres. However, when this scaling effect was taken into account it was 
noted that some antigens moved to new positions resulting in a new pattern of orientation for 
the antigens. This shift of antigen positions was mostly among antigens defined by large 
antigenic distances whereas close antigenic relationships were maintained. As a result there 
was good correlation between inter point distances between antigens close to each other the 
two maps. For example, the antigenic relationship is maintained within the following 3 sets 
antigens in the two maps but not between them, i.e, (6964, 7157, 7506, 7160), (6430, 6433,
121 | P a g e
6408) and (7630, 7183, 8706). This analysis showed that responses from past exposure can 
confound the observed antigenic relationships especially between sets of antigens and it is 
important to exclude such responses before drawing antigenic maps.
CM
Dimension 1
CM
Dimension 1
rvi
Dimension 1
<N
Dimension 1
Fig 5.6 Antigenic map based on informative anti sera obtained 4 weeks after infection (A) before (B) after 
excluding responses from previous exposures. Procruste's analysis showing the difference between maps (A) and 
(B) is shown before (C) and after (D) adjusting for differences in scale between the maps. The points show the 
position of the map containing sera without previous exposure and the arrows point to their respective point in 
the map that includes responses due to previous exposure. The dotted lines indicated the orientation of the map 
drawn without previous exposure and solid lines in the map indicate the degree of rotation on the map with 
previous exposure taken to fit the two maps
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5.3.5 Comparing the maps at 4 weeks versus 16 weeks
The apparent antigenic relationships between antigens change over time as the heterologous 
responses wane over time. There is a rearrangement of relative positions between points on 
the map at 16 weeks and as a result the overall pattern is altered when compared to the maps 
at 4 weeks. These movements included sets of antigens that shared close and distant relations. 
This is consistent with the temporal changes in heterologous response described in chapter 4. 
Due to this, the positions of the points in the immunological space are poorly constrained by 
the data at 16 weeks results and have alternative solutions that vary greatly from run to run.
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Fig 5.7 Antigenic map of the DBLa antigen tags at 16 weeks. In order to exclude the effects of previous exposure, 
the immune response at acute was deducted from that at week 16.
B
Dimension 1
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Figure 5.8 Procruste's analysis comparing the map drawn at 4 weeks to the map at 16 weeks before (A) and after 
(B) adjusting for differences in scale between the maps. The points show the position of the map at 4 weeks and 
the arrows point to their respective position at 16 weeks. The dotted line shows the orientation of the maps at 4 
weeks and solid lines in the map indicate the degree of rotation on the maps at 16 weeks taken to fit the two 
maps.
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5.3.6 Stability of the geometric solutions
The relative positions of the antigens and antibodies are constrained to specific coordinate 
positions within the immunological shape space depending on the amount of information 
contained within the sera. Highly informative sera restrict these positions to specific regions 
and result in a unique solution that varies only slightly from run to run. The only observed 
variations involve rotation, reflection or translation of the overall configuration while 
maintaining the relative distances between points. In contrast, solutions derived from low 
reactive sera are unstable. The positions of the antigens and antibodies are less constrained 
and vary greatly from run to run. To establish the rigidity of the antigenic configurations 
presented here, each data set was run though the antigenic cartography algorithm 10 times 
and the pair wise correlation between the points compared. For each dataset, the mean from 
the 20 pair-wise correlation permutations possible was computed. The average run to run 
correlation of the distances between points on the maps at 4 and 16 week convalescent time 
points was 0.95 and 0.80 respectively. Caution should be applied in interpreting maps that vary 
from run to run. Such variation could be restricted to a few egregious points or distributed 
evenly among all points.
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5.4 Discussion
The immunological shape space is a powerful concept that allows us to quantitatively 
project, in silico, how the humoral immune system processes information about antigens it 
encounters. In a naive individual, this immunological space is devoid of immunological 
responses and hence there are no restrictions to antigens. Pathogens expressing any 
antigen variant can survive in this space. However, with each infection or vaccination, 
individuals develop immune responses that close the gaps occupied by antigens in this 
space. The degree to which an antibody is effective against an antigen is determined by 
their antigenic distance. By projecting antigens and antibodies in the same space, it is 
possible to determine the antibody-antigenic and antigenic-antigenic distances and 
determine the degree to which cross reactive responses are generated between antigens.
This method has been used to describe antigenic relationships in several antigenically
variable viruses including human and animal influenza viruses, enteroviruses, lysaviruses
and flavivirus (Smith et al. 2004; De Jong et al. 2007; Huang et al. 2009; Mansfield et al.
2011; Ducatez et al. 2011; Horton et al. 2010). The WHO relies on antigenic cartography to
monitor antigenic changes in the circulating influenza viruses in order to decide on whether
to update vaccines for the next season (Ampofo et al. 2012; Fouchier & Smith 2010). The
malaria parasite lends itself to analysis by antigenic cartography; its immunological targets
exhibit variation between and in some targets within parasite genomes. The shape-space of
the malaria parasite and how the immune system covers it is probably complex. The
parasite has several morphologically distinct developmental stages with multiple stage
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specific antigens that exhibit great antigenic diversity. Defining the shape space parameters 
for individual antigens associated with protection provides a simpler alternative. The work 
presented in this chapter set out to determine the shape space characteristics of DBLo tag 
antigens.
Given experimental data, the computational task in antigenic cartography involves not only 
determining the coordinate points in shape space of antibodies and antigens that fit the 
data but also the dimensionality. Using qualitative arguments, Perelson and Oster estimated 
the dimensions of shape space describing antigen-antibody binding to be low, (N=5-10) 
(Perelson & Oster 1979). This was confirmed by Lapedes and Farber who exploited MDS to 
infer the dimension of shape space using a series of experimental HI data sets (Lapedes & 
Farber 2001). In determining the dimensionality of experimental data, maps are usually 
constructed in different numbers of dimension, say from 1 to 10, and the goodness of fit 
value analyzed for each dimension. The true underlying dimensions of the experimental 
data will be given by the minimum dimension in which coordinates of antigens and 
antibodies do not yield stress. For HI data, this was shown to between 4-5 dimensions 
(Lapedes & Farber 2001). For the work presented in this chapter, the zero stress solution 
was observed in 6 dimensions consistent with the estimations of Perelson and Oster. Such 
dimensions although low, are not tractable to the human eye; in most studies a 
compromise is made between the stress and the ease of interpretability. A certain amount 
of stress that does not distort the configuration too much is tolerable. There is no absolute 
cut off for acceptable stress levels. This is analyzed on case by case basis as stress increases
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with increase in the size of the datasets even for the same underlying data structure and 
maybe evenly distributed across all points or restricted to a few egregious points. Kruskal 
and Clarke have proposed several "rules of thumb" to act as guidelines for evaluating stress 
(Kruskal J.B. 1964b; CLarke K. R. 1993).
Table 5.2 Guidelines on acceptable stress values proposed by Kruskal 1964b and Clarke 1993
% Stress Kruskal's guidelines
1 2.5 Excellent
5 Good
! 10 Fair
20 Poor
[ Clarke's guidelines
<5 An excellent representation with no prospect
of misinterpretation.
! 5-10 A good ordination with no risk of drawing false : 
inferences
10-20 Can still correspond to a usable picture, 
although values at the upper end suggest a 
potential mislead. Too much details should
not be placed on details of the plot
; >20 ............ Likely to yield a plot that is relatively ]
%\ dangerous to interpret. By the time stress is j
I 35-40 the samples are placed essentially at
1 random, with little relational to the original
I distances
The antigenic map at 4 weeks yielded stress values of 0.21 for the one-dimensional solution, 
0.08 for the two-dimensional solution and 0.05 for the three dimensional solution. The two 
dimensional solution was selected as the best solution for ease of interpretability.
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This method relies on the information about the antigens that is contained within the 
antibody response/reactivity. Sera that have similar experimental reactivity to antigens they 
are tested against have little informational content about the differences between antigens. 
Sera that are highly reactive will have similar readings for all antigens and will end up close 
to each other on the shape space. Such sera offer little information that allows the 
determination of distances between antigens. On the other hand, maps drawn using sera 
with low OD or titre values to most of the antigens will fall into random positions every time 
the map is drawn. The position of the antigens in shape space is not constrained by the 
poorly reactive sera. In order to develop robust antigenic maps, I included only informative 
sera in my analysis. In this analysis, I used a cut off of 0.86 to exclude sera that reacted 
poorly with most antigens as well as sera that reacted highly with most antigens. The 
exclusion of these sera did not alter the geometric orientation of the maps consistent with 
the view that they contain little information. This also indicated that the sera used in the 
analysis contained enough information to constrain the location of the antigens and 
antibodies to specific coordinates in shape space.
Antigenic cartography has been used to study relationships between antigens in various 
pathogens. In all of these studies, the sera used to discriminate the antigens were raised in. 
animals after a single infection (Smith et al. 2004; Horton et al. 2010). These are 
monospecific polyclonal sera i.e. it is a mixed population of antibodies that bind to different 
epitopes within a single antigen with varying binding affinities. Antigenic cartography 
represents the overall reactivity of these multiple specificities as a single point on the map.
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This becomes challenging however for polyclonal polyspecific sera, i.e., sera that contains 
mixed population of antibodies that bind multiple antigens that have variable multiple 
epitopes within them. Antigenic cartography assumes that each antibody represents a 
single binding affinity to an antigen. Representing several sera with binding affinities to 
multiple antigens as a single point will inaccurately project the relationships between 
antigens. To illustrate this, consider sera obtained from individuals vaccinated with the 
leading malaria vaccine, RTS,S , a conjugate vaccine that contains both P. falciparum and 
hepatitis B virus antigens (Cohen et al. 2010). Such sera when experimentally tested will 
react strongly with the two organisms. When projected in shape space, this would show an 
erroneous antigenically relationship between P. falciparum and the hepatitis B virus. 
Similarly, the sera used in this study were obtained from children likely to contain antibody 
specificities to multiple antigens. The antigenic relationships observed maybe influenced by 
pre-existing antibody specificities acquired from exposure to previous infections. Exclusion 
of antibody responses acquired before the infection under investigation resulted in the 
movement of some antigens from specific regions of the shape space. These antigens 
appear to have been anchored at these positions by responses from past exposure or by 
responses generated very early in the immune responses. Within a single monoclonal 
infection, P. falciparum parasites can express more than one P/EMP1 isoform resulting in 
sera with multiple specificities. For this study, antigens were expressed and sera obtained 
from individuals from whom we identified the dominant P/EMP1 isoform. The degree to 
which a DBL-a tag was dominant varied widely among the parasite isolates (10-85%) (Gitau 
et al. 2012). A thorough investigation of the antigenic relationships between PfEMPl
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antigens will require variant specific sera obtained from naive animals or individuals (i.e. 
first infection).
Chapter 4 describes temporal changes in the levels of homologous and heterologous 
responses over a 16 week period after infection. The decrease in heterologous response 
results in sera that have lower reactivity to the antigens at 16 weeks as compared to 4 
weeks after infection. Such sera, because of low informational content, do not constrain the 
position of the antigens to specific coordinates within the immunological shape space. As a 
result, there was run to run variation in the relative position of the antigens in maps drawn 
using sera at 16 weeks. In contrast, the geometry of antigenic relationships of the maps 4 
weeks after infection is resistant to such changes. My favored interpretation is that that the 
configuration of antigens observed at 4 weeks is maintained by short-lived cross reactive 
responses that are lost by 16 weeks. Recker and colleagues have developed mathematical 
models that implicate short lived cross reactive responses in maintaining chronic infection 
by orchestrating antigenic variation (Recker et al. 2004). In this hypothesis, short lived cross 
reactive responses to minor epitopes prevent the emergence of new P/EMP1 variants while 
a dominant long lasting and variant specific response prevents the infecting variant from 
persisting for long. By combining antigenic cartography with sequence data, it may be 
possible to identify regions within the gene that underlie such cross reactive responses. 
Such regions, once identified, potentially form good components of a multi-epitope vaccine. 
This is investigated in more detail in chapter 6.
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So far, I have assumed that the experimental data available are a measure of the distance 
between antigen-antibody pairs. The ordination method that assumes linear relationship 
between the experimental data and the distances projected in shape space is called metric 
MDS. It is possible however to recover an accurate reconstruction of the configuration of 
the points using only the rank order of the experimental data (Kruskal J.B. 1964b; Kruskal 
J.B. 1964a). The numerical values of the experimental data are only used to sort the values 
in rank order. Given enough data, the set of ordinal relations across and along the panel 
generates adequate variation on the distances between points in the space such that the 
solution from the derived simultaneous inequalities divides the immunological shape space 
into small regions to which the points are restricted. This form of ordination is called the 
ordinal or non-metric MDS.
Although ordinal MDS is non-parametric, it results in metric space from which accurate 
antigen-antibody, antigen-antigen and antibody-antibody distances can be obtained 
(Lapedes & Farber 2001). The advantage of this method is that no assumptions are made 
about the nature of the monotonic relationship between distances from the experimental 
data and the shape space distances. The nature of this relationship can be recovered using 
the ordinal MDS. When applied to hemagglutinin inhibition (HI) titres, the relationship 
between the experimental data and the shape space distances was found to be linear 
allowing Smith and colleagues to develop modify the algorithm originally described by 
Lapedes and Farber from ordinal to metric MDS which is computationally less intensive. This
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becomes important especially where there is experimental data of low precision for which 
only ordinal relationship may have significance.
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Chapter 6 
Comparative quantitative analysis of antigenic and genetic 
relationships
The antigenic phenotype of any organism is largely determined by the genotype. In this 
chapter, I carried out an antigenic phenotype-genotype analysis in order to define regions in 
the genes encoding the DBL-a tags that best explain the serological patterns obtained by 
antigenic cartography. Genetic maps based on pair-wise distances obtained from sequence 
alignment of the DBL-a tags were compared to the antigenic map by a sliding window approach 
to identify regions in the genes that best fit the antigenic maps. The regions identified in this 
study exhibited considerable diversity even among members of a serologically distinct cluster 
indicating that they may be members of a conformational epitope. It also highlights the pitfall 
of inferring serological diversity from primary sequence data.
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6.1 Introduction
In order to avoid clearance in the spleen, P. falciparum introduces antigens on the surface 
of the infected red cell that allows it to bind to the host's endothelial surfaces and 
sequester away from peripheral circulation in blood. While this may be an effective way to 
evade clearance in the spleen, it renders the parasite-infected red cells susceptible to 
humoral responses. To evade the latter, P. falciparum employs antigenic variation, a 
mechanism by which the parasite alters the antigens at the surface of the infected red 
blood cells. The metabolic cost of this to the parasite is expected to be high. The immune 
system is exposed to what appears to be an unlimited number of antigen/parasite variants 
and has to rise to the occasion by creating immune responses that recognise each and every 
variant. Given the extreme antigenic diversity within a parasite population that the immune 
system must experience in order to protect individuals from disease, how specific should 
the antibody responses be?
Although immunity to variant surface antigens is acquired mainly in a variant specific
manner, it is accompanied by the generation of partly protective heterologous responses to
parasites to which the host has not been exposed (Elliott et al. 2007). There are several
lines of evidence to support this in both human and animal models: after a single episode of
malaria in previously immunologically naive hosts, 5 out of 14 individuals, developed
antibody responses that recognized variant surface antigens to which the host had not been
exposed (Elliott et al. 2007). This has also been demonstrated in animal models: gibbons
challenged with P. falciparum developed immune responses against heterologous parasites
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(Cadigan & Chaicumpa 1969; Cadigan et al. 1969). Infection of Aotus monkeys previously 
exposed to a single variant of a homologous strain P. falciparum with antigenic distinct 
variants of the same strain yielded partial cross protection (Siddiqui et al. 1978). In humans, 
patients being treated for syphilis by infection with the malaria parasite developed 
immunity to malaria after relatively few infections (Reveiwed by Doolan et al. 2009). In the 
natural setting, the intuitive conclusion that anti disease immunity is acquired after 
relatively few infections compared to extreme diversity of variant surface antigens within a 
parasite population points to an accumulation of cross-reactive responses. Adult malaria- 
naive immigrants developed immune responses to malaria rapidly when exposed suddenly 
to malaria in an endemic zone (Baird et al. 1991; Baird et al. 1993). In a similar study, the 
threshold for acquiring anti-disease immunity was set at 4 infections within a two-year 
period (Baird et al. 2003). Collectively, these underscore the importance of cross-reactive 
responses.
The adaptive arm of the immune system has, in theory, receptors that can bind and 
discriminate between an extremely large repertoire of diverse antigens (Pancer & Cooper 
2006). Naive B cells have broad specificity that allows them to bind closely related antigens. 
However, after affinity maturation, mature B cells arise that can discriminate between 
closely related antigens. Having bound their cognate antigens, receptors on naive B cells 
undergo a process of affinity maturation in which several rounds of somatic hyper­
mutations followed by a selection of the best binders results in enhanced specificity of 
antibodies to their ligands. In theory, this should allow the immune system to generate
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antibodies with high specificity for every antigen encountered. In practice, however, failure 
of the adaptive response to discriminate between different antigen/parasite variants is 
common. In that case, from the perspective of the immune system, two or more different 
but closely related antigens would appear the same. In such a scenario, just one infection 
would protect the host from parasite variants to which the host has not been exposed.
Generation of antibodies that recognize antigens on parasites strains (or species) that are 
different from the original strain that initiated the antibody response provides an 
accelerated and efficient way in which the immune system can cover extreme antigenic 
diversity. Such cross-reactive responses could arise as a result of a limitation imposed on 
the affinity maturation process such that the B cells have inadequate interaction with their 
cognate antigens to form specific high-affinity discriminatory antibodies during the first 
infection. Alternatively, the generation of cross-reactive responses could be driven by 
shared or similar antigens/epitopes between parasite strains or species.
Antibodies recognizing antigens other than those that initiated the first response are often
observed in nature. The binding specificity of such antibodies is expected to be a function of
the "antigenic distance" between any two antigens. There is no direct measure of antigenic
similarity: these measurements are usually obtained indirectly using quantitative
immunological assays that exploit the exquisite specificity of antibodies for their ligands, for
example, the hemagglutination inhibition assay for the influenza virus (Hirst 1943). In this
assay, the degree to which antiserum raised against one strain of influenza inhibits the
agglutination of red blood cells by another influenza strain is taken as a measure of
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antigenic similarity. A large inhibition infers small antigenic distance between the strains 
and vice versa. Antigens that are poorly discriminated by the humoral immune system will 
have very small distances between them. Representing such distances in low dimensional 
space allows for identification of antigenically related parasite strains/species and the 
development of cross-reactive antibody responses where these are generated as a result of 
antigenic similarity (Lapedes & Farber 2001; Smith et al. 2004). Furthermore, when 
combined with genetic similarity at the sequence level, the precise position of linear 
antibody epitopes driving such cross-reactive responses can, in principle, be found. In the 
work that follows I test the hypotheses that:
• antigenic distance and genetic distance are correlated.
• gain/loss in responses after infection is a function of the antigenic and/or 
genetic distance between variant antigens.
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6.2 Structure of the antigenic map
For subsequent analysis, the antigenic map derived in chapter 5 from sera at 4 week 
convalescence period was used. This map was constructed using informative sera and removing 
effects of previous exposure by subtracting the ELISA OD readings at the acute time point from 
those at the 4 week convalescent time-point. From the immune system's point of view, 
antigens within a close cluster are perceived as being similar. In the antigenic map (Fig 6.1), it 
was observed that rather than being scattered across the antigenic space, there were small 
DBL-a tag antigenic clusters with some antigens pairs appearing almost antigenically identical, 
e.g. 7204 and 7045.
Antigens within a cluster are perceived to be similar by the immune system mainly because at 
the molecular level there are common epitopes shared between them. Such epitopes could 
either be linear and are much easier to decipher from sequence data and/or conformational 
that are much more difficult to decipher. Despite considerable sequence heterogeneity among 
PfEMPl variants, the DBL-a domain is the most conserved domain within and between parasite 
isolates (Smith et al. 2000; Rask et al. 2010). It contains short stretches of conserved sequence 
that have been used to design universal primers with which DBL-a tags from both field and 
laboratory isolates can be sampled. Bull et al have exploited distinct sequence features within 
these tags to classify these DBL-a tag sequences into 6 groups (the Cys/PoLV grouping) (Bull et 
al. 2007; Bull et al. 2005). This classification is based on short blocks of sequences showing 
limited variability (PoLV) and the number of Cysteine residues (Cys).
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Fig 6.1 Antigenic map of the DBL-a tags colour coded according to the Cys/PolV grouping system. The map was 
derived from recognition of the antigens by a subset of the sera that showed great variability in recognizing the 
tags obtained from the convalescent children at week 4. In order to exclude the effects of previous exposure, the 
immune response at acute time point was deducted from that at week 4.
To investigate whether antigens cluster according to the Cys/PoLV grouping, the DBL-a tag 
sequences were classified as previously described and the map was color coded according to 
the genetic groupings. Comparison of the antigenic clusters to the Cys/PoLV grouping yielded 
no discernible clustering (Fig 6.1). To examine the degree of clustering in a more quantitative 
manner, the distances between all possible pairs of antigens were calculated and grouped 
according to whether the pair included antigens from the same versus different Cys/PoLV 
grouping (Fig 6.2). This showed that the antigenic distances within Cys/PoLV groups had a 
spread of values that were not different from the pair-wise distances between members of a 
particular Cys/PolV group or members of other different groups (Fig 6.2). It is thus apparent
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that the antigenic similarity is poorly explained by the Cys/PolV groups and indicates that the 
epitope regions lie beyond the PoLV region.
Antigenic distance by Cys4/PoLV grouping
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Fig 6.2 Antigenic distances between pairs of antigens in the same (blue boxes) versus different (green) Cys/PoLV 
groups. The interquartile range of the pair-wise antigenic distances is indicated by the length of the boxes while 
the median is shown by the vertical line through the box. The whiskers indicate the range of the distances 
excluding the outliers (indicated by points below and/or above the whiskers). The red dotted line indicates the 
mean antigenic distance for all tags.
To further examine clustering of antigenically similar DBLa-tags, unsupervised hierarchical 
cluster analysis of the pair-wise antigenic distance matrix from the antigenic map was carried 
out. This identified 6 main clusters at the antigen level as shown in the heat map in Fig 6.3. This 
result further indicates that the immune system recognises some groups of antigens as more 
similar than others and supports the clustering observed in the antigenic map (Fig 6.1).
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Fig 6.3 Antigenic clusters identified from unsupervised clustering of the pair-wise antigenic distances from the 
antigenic map. The rows/columns are labelled with the antigen name followed by the Cys/PoLV group type. The 
braces on the right vertical axis and the dendograms indicate the antigenic clusters identified.
6.3 Comparison of genetic map to antigenic map
In order to compare the relationship between the protein sequence and antigenic similarity of 
the DBL-a tags, genetic maps based on protein sequence alignment of the DBL-a tag sequences 
were constructed. To draw the genetic map, all the 36 sequences were aligned across the 
whole length of the DBL-a tag region (Fig 6.8) and the pair-wise identity scores between the
sequences were computed by the p-distance method. This method counts the number of 
amino acid differences at each site and expresses them as a proportion of all the sites analysed. 
Sites with missing data or alignment gaps were not included in this computation.
The genetic map was constructed using the same method and settings used for constructing 
the antigenic map. The resulting genetic map (Fig. 6.4) showed the DBL-a tags clustering 
according to the Cys/PoLV groups with more similarity within groups than between groups (Fig
6.5).
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Fig 6.4 Genetic map of the DBL-a antigen tags colour coded according to the Cys/PolV grouping system. The map is 
a projection of the pair-wise identity scores of the DBL-a tag sequences.
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Fig 6.5 Genetic distances between pairs of antigens in the same (blue boxes) versus different (green) Cys/PoLV 
groups. The interquartile range of the pair-wise genetic distances is indicated by the length of the boxes while the 
median is shown by the vertical line through the box. The whiskers indicate the range of the distances excluding 
the outliers (indicated by points below and/or above the whiskers). The red dotted line indicates the mean 
antigenic distance for all tags.
As for the antigenic map, the genetic pair-wise distance matrix from the genetic map was used 
to construct a heat map. The heat map was ordered to follow the arrangement of antigens on 
the heat map that derived antigenic clusters by unsupervised cluster analysis (Fig 6.3). There 
was no correspondence between the clusters identified on the antigenic and the genetic map 
(Figs 6.6 A and B). Flowever, as expected, the points in the genetic map clustered according to 
the Cys/PoLV grouping (Fig 6.6 C).
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Fig 6.6 Heatmap of the matrix of the distances obtained from the antigenic map (A, same as Fig 6.3 ) and genetic 
maps (B and C). The Heatmap in (B) was arranged to have the same order of antigens as those in heatmap A, and 
for comparison, unsupervised ordering of antigens is shown in heatmap C.
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To further compare the genetic map and antigenic maps, the pair-wise antigenic distances were 
obtained from the antigenic map (Fig 6.1) and regressed against the corresponding pair-wise 
genetic distances from (Fig 6.4). No overall relationship between the antigenic distance and the 
genetic distance was observed when analysed across all antigen and genetic groups
(Fig 6.7).
1 -----------------1-----------------1-----------------1-----------------r
0.0 0.5 1.0 1.5 2.0
Genetic distance
Fig. 6.7 Correlation between the antigenic and genetic distances between DBL-a tags obtained from the antigenic 
and genetic maps respectively. The line is the linear regression line for all pair-wise antigenic distances and genetic 
distances excluding homologous pairs.
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Overall, the genetic clusters formed were different from the ones formed by the overall 
antigenic map and this was reflected in a poor correlation between distances on the overall 
genetic map and those on the antigenic map (Fig 6.7). This is not surprising because the pair­
wise genetic distance between sequences used in this comparison contained both epitope and 
non-epitope regions. The inclusion of non-epitope regions in the analysis could dilute any 
potential correlation between genetic distance and antigenic similarity for a linear epitope for 
the antigenic clusters. In other words, that antigenic distance may be defined by just a small 
immunogenic region of the tag.
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To determine whether there is a correlation between antigenic and genetic pair-wise distances 
driven by sub-regions of the DBL-a tag, a series of genetic maps based on small regions of the 
DBL-a tag were generated and compared to the antigenic map. Genetic maps were obtained 
from the alignment using a sliding window approach with a window length of 14 amino acids 
and an offset of 1 amino acid between each window. For each window, the distances from the 
genetic map were compared to those from the antigenic map and their correlation coefficient 
was plotted against the window location (Fig 6.9). It was found that there were correlation 
peaks adjacent to PoLVl and between PoLV2 and PoLV3. This potentially identifies epitope 
regions.
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Fig. 6.9. Correlation between genetic distance and antigenic distances (black line, left y-axis) across the entire 
DBLa-tag region by sliding window analysis. The correlation based on the entire tag region is shown by the blue 
dotted line. The red plot indicates the amino acid identity score at each point (right, y-axis). The location of 
Positions of Limited Variability (PoIVs) are in the alignment are indicated by the shaded blue bars.
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The analysis showed that the regions with the highest correlations were located in protein 
regions with greater sequence variability (troughs in red line, Fig 6.9). This may indicate that 
such regions are undergoing diversifying immune selection. However, the sliding window 
analysis yielded little or no improvement on the correlation between genetic and antigenic 
distance using genetic windows compared with genetic distances based on the whole length of 
the DBLa-tag. By contrast, peaks with high correlation values could potentially identify epitope 
regions specific to each antigenic cluster. To determine this, the sliding window analysis was 
repeated on sub-groups of sequences falling within the antigenic clusters defined in Fig 6.4. This 
allowed for further refinement of potential regions within the sequences. For all the antigenic 
clusters, there was greater correlation between the genetic and antigenic distances at each 
window tested. As before, the regions with the highest correlation occurred within regions with 
high sequence variability. The high correlation observed at these regions signifies congruence 
between the relative positions of points of the antigens in the antigenic and genetic maps. That 
these regions show polymorphisms indicates that the relationships between the antigens are 
maintained in part by structural features that are similar within an antigenic cluster despite the 
considerable diversity at the sequence level. Such regions are likely to be components of 
conformational epitopes.
Smith and colleagues identified 10 hyper-variable blocks (l-X) of sequences that are 
interspersed between 10 homology blocks (A-J) among the DBL domains in PfEMPl protein
family (Smith et al. 2000). The DBL-a tag stretches from homology blocks D to H and
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encompasses hyper-variable blocks V-VIII. In all the clusters, the regions with the highest peak 
in correlation were located towards the N terminal end of the DBL-a tag. For antigen clusters 2, 
3, 4 and 6, this region occurred in homology block E (Fig 6.11. B, C, D, E) indicating that this 
region is potentially immunogenic across different clusters (Fig 6.10. B, C, D, E).
In the antigenic cluster 1 and 5 (Fig 6.10. A, F) the potential epitope region with the greatest 
correlation between the genetic and antigenic data occurs in homology block F (Fig 6.11 A, F). 
This region also exhibits high correlations in the antigenic clusters 2 and 6. This region is 
relatively conserved and contains two of the four conserved anchor points as well as PoLV2 that 
is used in the Cys/PoLV classification system (Bull et al. 2007). Due to relatively limited diversity 
in homology block F, the potential epitope regions identified from this region might be linear 
epitopes. Using synthetic peptides, Blomvqvist and colleagues have recently shown that this 
region of the DBL-a tag induces antibody responses that are cross-reactive and that recognize 
the surface of red blood cells infected with mature P. falciparum parasites (Blomqvist et al. 
2013).
Cluster 5 exhibits high correlation coefficient across the entire region especially towards the N 
terminal end and is potentially immunogenic over larger areas than other clusters. In contrast, 
cluster 6 shows relatively lower correlation coefficients across the whole length and may be 
poorly immunogenic. This difference in the immunogenicity among variants of the surface 
antigens has been observed in field studies using whole parasites (Bull et al. 1999).
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Fig 6.10 Correlation (y-axis) between genetic and the antigenic distances among an antigenic cluster (black line) by 
sliding window analysis for each antigenic cluster. Also shown is the correlation obtained between pair-wise 
distances between all the antigens and all the alignments of the complete DBLa tag sequence (blue plot). The red 
plot indicates the amino acid identity score at each point of the alignment. The location of Positions of Limited 
Variability (PoIVs) are in the alignment are indicated by the shaded blue bars.
0 50 100 150
Window
E
Antigen Cluster 3 (n=8)
0 50 100 150
Window
c
Antigen Cluster 5 (n=5)
Antigen Cluster 4 (n=6)
Antigen Cluster 6 (n=8)
50 100
Window
Window
153 | P a g e
; g p gi f l O O
;—i j j 
P-* >+ P?- - ■ ■ :< -
j---—- R £  R Rczza o a o a
> = "  £  £  £  £
£ £ £ £ £ £ 
o  o  o  q  a  a  fc d R ri fc d
a>
CuO
lo*—i
U  ' 'lp i:p
i i a  
i l l I w  lI  A, e
3
i  : i g i•^— « s S w
f W H  H  M P
~ 3 r  «i *■!
> —  2  p  >  P  
«c ■ -asn-4
^ .. t~ te «--<. S! 53 & Si
• - »-.« • -c- •>
2 £ ; 5 ;
■* h'  r )  »J ^
3 I SijV
b f c
SGwfit;
--  E R E 13
i  1
7.
o a a q q
QAQQQ
i m O I"- O CT) I - 
f o  CO IT) CT) 00
l o  ro cm I -  ro
I'-1--- I -- I -  '-O
f  ..»•* \
^ r ta
fM
X  js|ia§g;§-2 S o w w ci 
t I I I i I I I I I I i
i i
X i~ X SJ
3*-bfcil2
fx-« U-* I*-* t*-*
B 2 g £ gi-EEC "3S CBoSE-SiSSta
,J3 jJJ ,J  ^  J-4
6  x
W W W W I
W Q W
tc- k-i ja-,
«  P  «  P  «  H
ft  f l  A  f l  f l  Cl
m
i_
f t  f t  f t  f t  Pa pH
* I f~l (ft h”J •“! f~3 t~l^  Jh ^  t ,  J;h K
c ^ ’ O  O  O  p O D
£ £ £ £ £ £ 
r  1 o  o  0  0  «  «£ir js £ £ £ £ 0
w»-" !> >  i> £>
a -  o  1 o  o  o—.- H I h r  K ' J
# ! fc !
•( I I A
-  I I I (=1
I I I O r.2> I w  f t  o  sE 2 ft
ci2c-.; K  f t  p  f t  O
3 5  g  " ! - n c  
-  S w f l b
:  EC w  EC
1 !
-  I W I I I I
1 1 M  J_
i  4 ;: I o«V ° g §
•MB
’*• {7* &i g  U) I
•—<
U f t  ^  W W W W  ^•■■h !x Jh [x [w |h
^  ^  I f t  W  -« 
Di<. ^  E  O  p  ^  Q  
w : . > g W O  - 1 ft ' ■ w 11 1 1 1 1 1
Ja* 1 1 1 '■'- M "f fJJrL I H
"8 3 A 3 a 81
r-:—— P  P  P  P  f ;  P
—SCf^  3  -S* raj r3*! -< U U m ^
- i  § & s 11- fe s — & S *-
"V  * 8* * 39§ £ SsSSlsCZX~ ft B ft ft ft B
L_x__| W W W W W Wft ft ft ft ft ft
  -1 ; • g  J  g  w
O x
h
T T T t i ;  
S G p
f t  f t  |I ft I
W « ~ S B din  P  P  ^  
B  ;  B  Pi n  ^  
r t  d  n  H  ^£ :': 5 3 £ ts- &  j  ^  w &  5
> g I I ! Ii L; ■ •
. . . . .  . wJ? jg ■
.1  ” ^ . :L iZ S « g
?Z 0 & £ 0 0 ~
• ■ 2  v  W ?  5  ?T  I 1 T  T  1• ■ 1 1 ■
fc£j
075
'£ 
t nt^ r. V
I
ill
4  i  !
H-l : :!:.feH j
W &H:W:
200EEEri ri t? Cia-!W W W
00g
W f t  ^
^ P 1 S S W|  
w  w
300
£  b
H H  '
f i f i wS ww  E  .rrj 
S O W  P ft ft
Q  O  Pi 
1-1 JW P"* K-*
J  J  J
0 Q 0
q
A
4- 4-
agS
a 0 07  : a
!~  Cl c i  
W W r* ft PI
0 0 0
Q  p  H  O  f l  f t
O COCDOPOOO  
• r o c o o  CO CO o
. JJ (JD T- hs. ^  ^  *3*
C/) N . OO CO CO CD
0 i  i  91
□  O  D  O  D
^  j£ ^  &
Q  Q  2  Q  Qddcfed
a i i x p p p ; ^ p & i
!:-« ::-h h-< k ,  t .  [1, :>■«
w S ^ r in M
i l i i  
'I* t  « !
-3? Sis-aj -=<! ^  5j dW  w  a  p  w
S 3 ^ «■ S ;c t“ tc te
Ig s a 1*
: I« _ h , 
03"!
i« tc |«:H  M  ^  .
H  b  rH !W W W  W W W I
E-i — a I
W W W )
l lH f
Cl Q Q O Cl
I'- >7) -?>• ro CC'
CO CD <D CO I ' -  I -
in
UJ
^  ^
Ci  ci  a
^  ^  £
£ £ £ £ >£ 
Q  Q  Q  Q  Q
^  ^  ^  £  0
Q 1 a  1I f*i
i i  d 4,1
i 0 a si cE  J p p  J  
U  ra* I
‘ W W W Pi I
1 1 :  1 1 
. i l l  1 1 I w  i P o p
i i i §  3
•fr Q  I ‘ J ■
-  ■ f t  <
* g s 5 ;
... . ! 
St t ! s
Q a 0 2 0  
I d o  I
“  e d *
I ^  u
B  ww w g  ^ 
O W P & S  w E  w < 
1 1 1 
1 1 1
E G ?
!m :— W W W  w ^
ri H h
W W WW ft
^ . r M
ft G ftft l ft
S I G 
R H  H
C W f t
T- H w ft w w
ft ft ft
0 0 °3 o  o
ft o B
ft ft ft
ftftftftftftftft
o s iL n c O '^ ^ ’— -=tco 
. • -5T 0 0  T - CO *T) 0C« O  00
®  CO -«- ’r -  CO CM CO
‘-ft OO fD  N . I ' -  W-1 -OO 00
S O
L ia;
+ j
V)
3
u
&o
c
o
-C
C T
aj
c
(U
"D
O
_Q
c  00  
do a.
Q . j zro ao
E  Z
<V  c
DO <u 
+-> a
fD aj 
CD ^ 
J= <->
T3
(D
<U
C
QJ
DO
■a
c
<u
DO
’■c
C
ro
QJ
0)
x :
DO
uo x :
DO ±4
iZ  $
QJ
DO
LT)
in
6.4 Loss/gain in response versus antigenic/genetic differences
In order to determine whether the boost/loss in response was related to either the antigenic or 
genetic distances obtained from Fig 6.1 and Fig 6.4, a linear regression model was used. The 
boost in responses was defined as an increase in response between the acute time point and 
the 4 week convalescent time point. Individuals with high responses at both these time points 
may have little or no boosting which may be misinterpreted as a poor or no response. 
Therefore, the regression was done separately for individuals with high responses at the acute 
time point. The high responders were defined as those with responses above the median at the 
acute time point. There was a negative and significant relationship between boost in 
heterologous antibody response 4 weeks after infection and the antigenic distance between 
variants for both the high and low responders (Fig 6.12 A and B). This suggests that more 
closely related variants generate more cross-reactive responses. I observed no significant 
relationship between loss in response and antigenic distance (Fig 6.12 C and D). There was also 
no relationship observed between genetic distance and the boost (Fig. 6.13 A and B) for both 
the high and low responders respectively. However, there was a significant relationship 
between loss in response (Fig 6.13 C and D) and the genetic distance for both the high and low 
responders. The highest loss in heterologous responses was observed in individuals infected by 
genetically distant variants. However, for both the genetic and antigenic distances, the R values 
describing their relationship with the changes in response after 4 weeks were low. This 
indicates that the changes in response after infection are largely explained by other factors.
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6.12 Boost/loss in IgG responses to other circulating variants of DBLa-tag the children had not been exposed to 
was measured 4 weeks after infection and regressed against the antigenic distance between the DBLa-tags as 
determined from antigenic cartography. The linear regression line was obtained for pair-wise antigenic distances 
excluding homologous data (black points). The red points on the graphs represent the heterologous data.
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Fig 6.13 Boost/loss in IgG responses to other circulating variants of DBLa-tag the children had not been exposed to 
was measured 4 weeks after infection and regressed against the antigenic distance between the DBLa-tags as 
determined from antigenic cartography. The linear regression line was obtained for pair-wise genetic distances 
excluding homologous data (black points). The red points on the graphs represent the heterologous data.
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6.4 Discussion
The adaptive arm of the immune system has, in theory, the capacity to recognize and mount a 
specific response to every antigen it encounters. B lymphocytes in particular, bind to their 
cognate antigen and undergo several rounds of somatic hyper-mutations at the antigen binding 
site of their receptor to create diverse receptors with different binding affinity to the antigen in 
the initial phase of an antibody response. These receptors are then selected for their ability to 
strongly bind the antigen resulting in highly specific receptors and thus secreted antibodies. 
This theoretical specificity is not always realized as antibodies that bind more than one antigen 
occur in nature. Using antigenic cartography, it was possible to quantitatively measure the 
antigenic distance between DBL-a tag variants to identify antigens that would cross-react with 
each other.
To gain perspective of how PfEMPl proteins are organised in immunological space, I exploited 
antigenic cartography using recombinant DBL-a tag as a model antigen. It was possible to 
quantitatively measure the antigenic distance between DBL-a tag variants to identify antigens 
that would cross-react with each other. Immunity to PfEMPl is thought to be largely variant 
specific. Based on this, it is expected that the immunological space describing PfEMPl variants 
to be large and in which points are scattered and distant from each other. However, I observed 
both antigenically distinct and similar variants. The choice of variants could partly explain the 
different results obtained in earlier studies on agglutination that showed either a variant 
specific accumulation of antibodies or a strain-transcending pattern. It is conceivable that the
global immunological PfEMPl shape space is organised into distinct serological clusters that
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show little or no cross reactivity between clusters. The members within specific clusters could 
be constrained by a common functional role e.g. binding to a particular receptor. The need to 
maintain functional/structural properties on one hand and the need to be polymorphic to 
evade humoral responses on the other could result in a balance where there are functional 
clusters that are immunologically distinct. Acquisition of effective cluster specific rather than 
variant specific responses would explain the rapid acquisition immune responses to PfEMPl. 
Such antigenic clusters are evident in other antigenically variable pathogens like Influenza, 
where viruses are organised into antigenic clusters in immunological space and vaccines are 
developed from a single strain that generates responses that protect people in a cluster specific 
rather than variant specific way (Smith et al. 2004; Smith 2003; Fouchier & Smith 2010).
To study this effectively in malaria, there is need for a more extensive study that will map out 
the global PfEMPl immunological antigenic space and establish the number of clusters within 
it. More importantly, it is imperative to establish whether a cross-reactive response that is 
effective across a particular cluster can be identified. Using a prospective longitudinal study, it 
could be demonstrated whether there is decreased probability of infection with parasites 
expressing antigens mapping to areas covered by pre-existing antibodies in the immunological 
shape space. The circle of reactivity of such responses compared to the size and number of 
antigenic clusters can then be used to inform vaccine development. Wider circles of reactivity 
increase the antibody repertoire with fewer infections. I anticipate that the circle of reactivity 
of parasites that cause non-celebral severe malaria and placental malaria to be wide whereas
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the corresponding parasites will form tight antigenic clusters in immunological shape space. 
This is because immunity to these syndromes is acquired rapidly after relatively few infections.
The boost in heterologous responses after infection was greatest among the antigenic similar 
variants indicating that the radius of effectiveness of this immunity is restricted to a certain 
area within immunological shape space. This makes biological sense because a wider circle of 
effectiveness would render the PfEMPl repertoire immunologically redundant and the parasite 
would have no benefit in having multiple copies of this gene within its genome and at the 
population level. Joergensen and colleagues pointed this out in their work where they observed 
limited cross reactivity within members in a single genome (Joergensen et al. 2006).
Due to the transient nature of the cross reactive responses observed and their limited radius of 
recognition, it is plausible to argue that for them to effectively provide protection individuals 
must be infected by multiple parasites expressing different variants that elicit responses that 
completely cover the immunological space such that no new infections can be established. This 
is supported by epidemiological studies that show an increase in multiplicity of infection 
increases with age in areas with high exposure and this is associated with protection from 
disease (Beck et al., 1997; Farnert, Rooth, Svensson, Snounou, & Bjorkman, 1999; Henning et 
al., 2004; Smith, Felger, Tanner, & Beck, 1999; al-Yaman et al.). The product of multiplicity of 
infection and the antigenic diversity of the parasites allows older children and adults resident in 
endemic area to cover large areas of the immunological space while the chronic nature of this 
infection prolongs the transient nature of this protection. The inability of young children to 
maintain chronic asymptomatic parasitemia combined with the low levels of multiplicity in
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infection could explain the susceptibility of children to malaria. Asymptomatic adults and older 
children in endemic areas may be protected partly by repeated exposure to low levels of a wide 
range of different P. falciparum strains.
Antigens are perceived by the immune system as similar possibly from sharing common 
epitopes or similar structural features. Regions within the DBL-a tags that best explain 
orientation of the antigens in the antigenic map were identified by comparing the genetic data 
to the antigenic map. Such regions form potential targets of antibody responses and, once 
verified by wet lab experiments, would be potential components of a multi epitope vaccine that 
would mimic naturally acquired immunity to malaria. The potential epitope regions identified 
were varied between antigen clusters and as pointed out earlier, more extensive work is 
required to define the number of such antigen clusters. The amino acid polymorphism 
identified at these potential antigenic sites suggests these polymorphisms are driven by 
immune selection pressures and could be part of conformational epitopes that are structurally 
similar within each antigen cluster. The antigenic sites identified in this study were located in 
regions that were different from those that define the Cys/PoLV grouping. This explains why 
there was little correspondence between the Cys/PoLV grouping and the antigenic clustering. 
Extending this analysis to other regions of the P/EMP1 molecule will identify other antigenic 
regions.
The three-dimensional structures of DBL domains from the EBA-175 antigen from P. falciparum 
and the DBP in P. Knowlesi have been solved (Tolia et al. 2005; Singh et al. 2006). Despite
limited sequence similarity, the two domains retain a remarkable similarity in their structure.
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Using the solved EBA-175 as a template, Howell and colleagues exploited semi-conserved 
blocks defined by multiple alignments to develop a three-dimensional structure for the DBL-a 
domain from PfEMPl (Howell et al. 2006). They observed that the DBL-a tag falls within the 
minimal region required for receptor binding for the DBL domain family (Ranjan & Chitnis 1999; 
Mayor et al. 2005). In a recent study, Juillerat and colleagues solved the crystal structure of the 
NTS-DBLa domain cassette from VarO, a rosette forming PfEMPl isoform, and report that the 
secondary structure of the DBLa domain is similar to other known DBL structures (Juillerat et al. 
2011). The region with the strongest affinity to the cognate ligand was traced by mutagenesis 
to two segments within the NTS region and a third region within the DBLa domain region. This 
third region occurred within the DBL-a tag region between PoLVl and PoLV2. Lysine residues 
within the NTS-DBLa domain cassette have been shown to be important for the interaction 
between VarO and its ligand. It was interesting to note that, for antigen clusters 2, 3, 4 and 6, 
the potential epitope regions identified occurred between PolVl and PoLV2 and that for 
clusters 2, 3, and 4 specifically, the predicted epitope region had a conspicuous Lysine residue. 
Taken together, this implies that epitopes identified within this region, whether linear or 
conformational, may be important for function. The use of antigenic cartography is not limited 
to antigen-antibody binding interactions but can be used to study any receptor-ligand binding 
interactions (Lapedes & Farber 2001). When applied to receptor-ligand binding interactions 
between P/EMP1 and host receptor molecules, it may be possible to easily profile variants 
associated with binding to certain receptors. This, if combined with antigenic and genetic data
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will allow us to identify potential immunogenic and functional regions within the proteins and 
determine whether these regions overlap.
In summary, the data presented here suggests that the immunity to malaria is made up of long- 
lasting, variant specific responses and short lived cross reactive responses generated against 
multiple parasites that share similar coordinates within immunological space. The effectiveness 
of such responses and their focus of reactivity remain to be determined. Such data will be 
instrumental in the selection of components to be included in a multi-component vaccine. In 
addition; it will assist in the temporal and spatial surveillance of the PfEMPl repertoire at the 
population level for changes that move the parasites to unoccupied areas of the immunological 
space in a post vaccination era. If effective, there will be need to developed strategies of 
extending the half life of such responses before they can be considered for vaccine 
development.
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Chapter 7 
Summary of main points 
Introduction
The immune system is tasked with defending the host from foreign agents that include 
infections. It must distinguish self molecules from non-self as well as one parasite from the 
next. This presents tremendous challenge when you take into account the immense diversity of 
pathogens to which the immune system could be exposed. Failure of the immune system to 
recognize pathogens usually results in infection and which may lead to disease. The underlying 
motivation for this thesis was to understand how the human host develops antibody responses 
against the variant antigen P/EMP1 expresses by P. falciparum. As discussed in chapter 1, 
opinion is divided as to whether antibody responses to these antigens are acquired in a variant 
specific manner or whether the strain specific response is accompanied by variant specific 
responses. To explore this, I expressed the DBLa-tag region of P/EMP1 from parasite isolated 
from children and used this region as a model antigen to study how the children developed 
antibody responses to their infecting parasite and to other parasites circulating in the 
community after the infection.
7.1 Main findings
1. The DBL-a tag region forms part of the epitopes targeted by the protective antibodies or 
has epitopes associated with the protective sites within the P/EMP1 molecules. Children 
were infected by parasites that correspond to gaps in their antibody repertoire and this 
gap was sealed after recovery (Chapter 4). In a recent publication, Ravira-Vallbona and
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colleagues found a negative association between IgG responses to the DBLa domain and 
parasite densities. In their work, they also report that severe malaria is associated with 
low IgG responses to DBLa (Rovira-Vallbona et al. 2012). Of practical importance is the 
work done in animal models indicating that immunization with DBLa constructs elicits 
humoral responses that protect from P. falciparum infection (Moll et al. 2007; Ahuja et 
al. 2006; Chen et al. 2004). Taken together, these data show that the DBLo is potentially 
an important target of natural immunity and should be given consideration for possible 
inclusion in a multi-component or multi-stage antigen sub-unit vaccine.
2. Children develop both variant and cross-reactive antibody responses to the DBL-a tag 
region of P/EMP1 after infection. The influence of such cross reactive responses on the 
subsequent risk of infection, parasite density and clinical outcome remains unresolved. I 
postulate that this would be dependent of the antigenic relatedness between variants. 
Parasites bearing similar antigenicity to those present in a host's antibody repertoire 
would be excluded or controlled to a degree corresponding their antigenic relatedness. 
If cross-reactive responses play a dominant role then this might pave the way for 
vaccine development. This has been well studied for Influenza. The generation of cross 
reactive responses that recognize influenza variants is key to the success of influenza 
vaccination. By generating cross-reactive responses, a host is able to cover large 
antigenic space with relatively few exposures. Whether this is a deliberate strategy of 
the host to variant pathogens or an early phase transient state in the path to the
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generation of antigen specific responses after affinity maturation remains to be 
determined.
3. The potential epitope regions identified from the DBL-a tag peptides are not conserved 
and are likely to be part of conformational epitopes that fold to form similar secondary 
structures between variants in an antigenic cluster. The conserved secondary structure 
could be due to functional constraints imposed of the PfEMPl molecule. Support for 
such a theory comes from recent work that traces the functional regions to the 
predicted potential epitope regions identified in this thesis (Juillerat et al. 2011). The 
polymorphisms observed at these sites could be due to a need to evade immune 
responses.
7.2 General Discussion
The description of the antigenic structure of variant antigens will be key deciding which variants 
to consider when designing vaccines that target polymorphic proteins such as P/EMP1. From 
this work, I hypothesize that the P/EMP1 antigenic repertoire is organized into discrete clusters 
that are serologically distinct. The acquisition of cluster-specific rather than variant-specific 
responses may present a plausible explanation to the relatively rapid acquisition of clinical 
immunity to malaria by adults and in children after a limited number of infection compared to 
the vast number of PfEMPl variants in circulation in a given parasite population. Exploitation 
and manipulation of the cluster-specific properties of PfEMPl has the potential to assist in the 
development of an effective vaccine. The potential for such an approach may be particularly 
viable for parasites causing severe disease as such parasites appear to present and antigenically
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distinct and limited number of variant surface antigens (Bull et al. 1999; Nielsen et al. 2002). 
Methods that quantitatively analyze antigenic variation therefore become important.
I used antigenic cartography to construct metric space in which the DBL-a tags are organized 
into serological clusters that elicit potentially cross-reactive responses within a cluster. A critical 
question that remains unanswered however is what role the cross-reactive responses play in 
protecting an individual from future infections from parasites expressing antigens within the 
same or different cluster. The answer to this question will require a longitudinal prospective 
study in which children presenting to hospital or in the community with disease, will be actively 
followed up and the subsequent antigens or parasites mapped onto the antigenic space. I 
hypothesize that antigens/parasites from secondary infections will map to new regions within 
the antigenic map. The distance between the antigens/parasites in the primary and secondary 
infections in the map will partly be determined by the time since infection because the 
heterologous response in this study declined over time. Therefore, the ability to maintain 
chronic parasitemia will be key in maintaining the heterologous responses which is consistent 
with increased antibody responses to a variety of malarial antigens in parasite-positive children 
(al-Yaman et al. 1995; Bull et al. 2002; Kinyanjui et al. 2004; Kinyanjui et al. 2009). In order to 
maintain antibody levels across the multiple serological cluster and hence broad protection, the 
host will have to asymptomatically maintain multiple parasite genotypes circulating in the 
bloodstream at any given point. The ability to maintain both chronic and multi-clonal infection 
will be key to reducing the risk of disease in this model.
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In this work, I describe predicted epitope region within the DBL-a tags that exhibit considerable 
polymorphism within a defined serological cluster. Similar findings were observed in a study 
carried out by Gamain and colleagues (Gamain et al. 2001). In this study, the authors developed 
cross-reactive monoclonal antibodies against the CIDR region of P/EMP1 in mice and used these 
to screen for epitopes within this region. The authors hypothesised that the cross-reactive 
monoclonal antibodies would be directed to the conserved regions within the CIDR domain. 
Contrary to their expectations, the monoclonal antibodies identified a genetically diverse region 
of CIDR as the epitopic region. In addition, the monoclonal antibodies identified in this study 
showed minimal reactivity to the conserved region. My favored interpretation of these 
observations and those presented in this study is that the parasite, under natural settings, 
diverts cross-reactive responses away from conserved regions in order not to make the 
antigenic repertoire redundant. As such immunogenic regions of PfEMPl would mostly 
observed in polymorphic regions. However, some of these regions even though polymorphic, 
occur in functional areas and form tertiary structures that may be similar in structure and hence 
have comparable ligand-receptor interactions. It is conceivable that immune responses to such 
regions would be cross-reactive but limited within PfEMPl proteins mediating a particular 
function. In this way, the parasite attains a balance in which the entire PfEMPl repertoire is not 
exhausted.
Importantly, this also cautions against drawing conclusions about the serological diversity of 
antigens from in silico predictions of genetic data. The sequence diversity in this case appears 
to be exaggerating the serological diversity. A similar case has been observed for influenza
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viruses (Smith et al. 2004). These viruses accumulate several silent mutations that do not 
change the serological properties of important immune targets. When projected in antigenic 
space, the authors observed viruses that had polymorphisms at the genotypic level falling 
within a single cluster. However, after accumulation of several mutations, the viruses are 
moved to a new antigenic space by one final mutation. It is therefore conceivable to have 
parasites with a diverse genotype but a relatively conserved phenotype. The conserved 
phenotype could be driven by the need to maintain a common function. The analysis of 
serological data together with functional binding data using multi-dimensional scaling 
techniques described here has the potential to elucidate serological clusters that are driven by 
common functional roles. A similar approach can be applied for the analysis of binding data to 
identify functional clusters.
7.3 Limitations of the study
Use of broad spectrum antibody serum
Antigenic cartography assumes that each antibody represents a single binding affinity to an
antigen. In previous studies, serum raised in an appropriate animal model against one strain
was used to measure antigen-antibody distances against other strains. Such sera will typically
contain a mixed population of antibodies binding to different antigenic determinants of the
strain with varying affinities. Despite this, the use of polyclonal sera against one variant has
allowed for the construction high resolution maps with accurate antigenic relationships. The
multiple antibody affinities are represented as a single point of action. However, this fails when
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the sera contains antibodies against more than one variant. Representing several sera with 
binding affinities to multiple antigens as a single point will inaccurately project the relationships 
between antigens. The sera used in this study were obtained from children who may have been 
exposed to other variants of PfEMPl prior to the current infection. I tried to correct for this by 
excluding responses recorded by ELISA to previous infections. I however acknowledge the 
possibility that even within the period of a single infection, the parasite may have expressed 
more than one variant. This is compounded by a recent report showing the surface co­
expression of two different P/EMP1 antigens on a single plasmodium falciparum-infected red 
blood cell (Joergensen et al. 2010). The precision of the antigenic relationships between 
PfEMPl antigens will be greatly improved using variant specific sera obtained from naive 
animals or first infection on individuals infected with parasites that have only expressed a single 
P/EMP1 isogenic variant.
The surface of a red cell infected with mature stages of P. falciparum has PfEMPl as one of 
several variant antigen families. In order to study specific immune responses to PfEMPl it will 
be necessary to either express the antigens as recombinant antigens or carry out agglutination 
assays using variant specific sera raised in animals. Previous agglutination studies have 
measured an aggregate response to all the antigens families on the red blood cell.
Small antigenic region
The choice of the DBL-a tag as the region to study in this thesis was primarily driven by the 
previous observation that it is the only region of the PfEMPl ectodomain that is accessible to
amplification by PCR in most parasites isolated from sick children. While the tag region is an
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important target for the acquisition of both natural and vaccine-induced protection as out lined 
in section 4.1, it only represents a small region of the entire PfEMPl molecule. The PfEMPl 
molecules are large multi domain molecules with molecular weights of 200-300KDa. This is 
large compared to the DBL-a tag region which has molecular weights approximately ranging 
from 10-20KDa. In addition, several studies have demonstrated important functional and 
immunological properties of other non-DBLa domain regions of PfEMPl. The functional and 
immunological findings described for the DBL-a tag region or domain can only form part of and 
cannot be taken to be representative of the whole PfEMPl molecule. A comprehensive 
description of immune responses to P/EMPl molecules will require the ability to easily clone all 
domains of a given P/EMPl molecule and express them as recombinant antigens. The recent 
development of cloning vectors that allow for the rapid and efficient selection whole var genes 
repertoires from different P. falciparum strains (Louis et al. 2011) and the ability to 
recombinantly express full length P/EMPl molecules (Srivastava et al. 2013; Srivastava et al. 
2010; Khunrae et al. 2010; Kraemer et al. 2003) make this possibility in the near future.
Sample size for cluster analysis
The work presented in this thesis describes an initial attempt at describing antigenic
relationships in a small important region of the variant Plasmodium falciparum antigen P/EMP1.
I describe 6 serological clusters obtained by hierarchical cluster analysis analysis of the
distances between 36 DBL-a tag antigens. This represents a small number. The repertoire of
PfEMPl variants in the population is much broader and there are potentially more serological
clusters. There are no rules-of-thumb about the sample size necessary for cluster analysis. It is
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anticipated however that the sample size required will be a factor of the extent of variability 
within the dataset. Variables with extensive variation are likely to form more clusters as 
compared to variables with limited variation and as a result, more data points may be required 
in order to adequately capture the number of clusters inherent in a variable with extensive 
variation. This makes the determination of sample size a priori difficult. This, however, can be 
inferred at the point where adding new data points to a variable do not yield new clusters. For 
PfEMPl to be considered a viable vaccine candidate, extensive work should be carried out in 
order to include more variants in order to have a global understanding of the complex antigenic 
relationships of P/EMPl antigen family at the DBL-a tag region and other domains. If the 
antigenic space is finite, a point of saturation in the antigenic space will be attained beyond 
which addition of more samples will not yield new antigenic cluster. This will enable scientist to 
determine whether there are associations between particular clusters with certain clinical or 
phenotypic parasite features. In addition, there is a higher likelihood of forming random 
clusters with smaller sample sizes as compared to larger ones.
7.4 Concluding remarks
The methods described in this thesis, provide a powerful tool that can be used to inform 
whether vaccine development to variant surface antigens is a viable option. For this to occur, 
there is need to develop standardized methods and appropriate reference sera as discussed in 
section 7.2.1. The description of the antigenic clusters at the population level and comparisons 
of overlap between populations will be a key criterion in deciding whether a P/EMPl based
vaccine is viable. In addition, antigenic cartography provides a powerful tool with which to
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monitor the serological evolution of antigenically dynamic P/EMPl family of antigens for 
vaccine escape in a post-vaccine era.
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CM o CN LO CD rH CD o CD rH CD LO CM CN CD CD LO 00 cn CM LO CD LO CM CD CD CM
LO q fN <3- rH rH CM q rH rH q cq rH rH cn q q LO CM rH CM rH rH q on rH cn CM CD cn q CN
o o d d o o d O o o o o o O o o o o o o o o o o o o o o o o d o o o o O
CD
00
LO cn
CD
LO LO LO LO LO LO LO LO LO LO LO LO LO LO LO LO LO LO LO
ro CN CD o 00 is 3 CM CM rH 00 LO o LO 00 cn rH CD o 00 3 rH CM 3 rs CD 00 5 rs CN
q o cq 00 °q 00 00 q q rs q CD is q q q q q q q CD CM 00 q on o CD cn CD CD q r^ 00. q cn q
CM CN rH CN rH o o o r—i o r-i o o rH cn d O rH cn cn o o o rH r—i rH o rH o o CM o CM rH o CM
LO LO LO LO rs LO LO LO LO LO LO LO LO LO LO LO LO LO LO LO LO LO LO LO LOo CN CN CD cn 00 is CD CD CN rH o CD CD is o CD r^ rH e-s CM cn cn LO 00 CD 00 CD CD o LO
00 00 rH rs rH CD CD CD CD O rs CM 00 LO cn cn CD is cn CD CD LO CM CD o CD CD cn O o cn
rH q q q q q CD r—1 q q 00 CD CD q rH q q rH cn CD CM CD o rH 00 00 q q q q q q cn q
cm fN rH CN rH o o o r—i o o d o r-i cn o o rH cri cri o o o rH r-i o o o o O cri o rH rH d CM
LO LO LO LO LO LO LO LO LO LO LO LO LO LO LO LO LO LO
00 CD is o o is cn cn CD CD 00 CM CD cn LO LO rH cn CM cn LO CD CD CD o CM CM rH cn
CD rs CN o CD LO CD LO CM CD CN CD rs rH cn CD cn cn 00 CD CM LO LO LO CM CM cn 00 LO CM cn CM o
rH q CN o q cq q q CM q LO q CD q rH q q q rH q 00 q q q q CD o rH q q q q q CM rH
cri CM r—i cri r—i o o O rH O o d o rH cn o o r-i on cri o o o o tH o o rH r-i o rH d CM rH o CM
CD
CD
LO LO LO LO LO LO LO LO LO LO LO LO LO
3 CN 3 o CN CO rs 3 3 CN 00 CD LO LO LO o CD CM rH 3 O rH s CD 3 <3- LO 00 CD 3 CD 3
(N rH q q °9 q q q q q o o CM q q q q q q q q M; rH o q o q 00 o rH o q qcri fN CN CN rH rH rH d rH rH rH r—i rH CM cri o o rH cn cri r—i d rH rH CM CM rH CM r—i o cri CM cri CM d CM
LO LO LO LO LO LO LO LO LO LO LO LO LO LO LO LO LO LO
CD 00 cn CN rH cn CN rs is CD CD CD CD CD is rH CD 1^ h- r- rs 00 CM 00 O rH CDco 00 rH CD fN fS cn rs CD 00 rH cn CD CM 00 CD CN LO O is cn O cn CM LO rH CD CD CD LO rH rs CD CD 00 CMq q cq q fN rH q q o q CM CD o q q q q q r—1 o CD q q q q q q q q cn q q q q qcri fN CN cri cri rH rH r—i CN r-i rH o rH CM* CM* rH rH CM CM cri o o r-i rH CM rH rH rH rH rH cri rH cri CM o cm
LO LO LO LO LO LO LO LO LO LO LO LO LO LO LO LO LO LO LO LO
rH cn CD CM rs rs 00 T^ rH cn CD 00 rH fN rH cn cn CD CD CD 00 CD 00 LO CD 00cn LO CD LO O 00 CN CM 00 LO rH o O rH is en O rH cn r^ - LO 00 CD e- 00 CM cn rH rs CD cn CD cn
LO q CN q cn rH rH CM q CN rH CM q q rH CM q r—1 CM CM 00 rH q q q q q q cn CM
o o o o o o o o o o o o o o o o o o o o o o o o O o o o o o o o rH o d o
LO LO LO LO LO LO LO LO LO LO LO LO LO LO LO LO LO LO LO LO LO
00 is LO r—1 cn is o CM CD rs cn LO 00 LO CD CM CM CD cn 00 cn 00 CD CM CD cn cn 00 00 CD
q rH o q cq o q q q q q CD CD q q rH r—( q cn q 00 cn rH q q q q q q q cq q o q qcri cri CM cri CN CN d rH CM CM rH o o r—i CM rH r-i rH CM CM o o rH r—i rH CM rH CM CM r—1 CM CM cri CM d rH
LO LO LO LO LO LO LO LO LO LO LO LO LO LO LO
LO rs rH cn rH rH rH 00 CD rs CD CM cn CM rH 00 rH LO 00 rH CD CD CM 00 00 00 o CD
00 LO o CD LO cn <3- cn CM O cn CM CD rH o CD cn CD r^ LO CD CD cn rH rH CM cn 00 00 00 o 00
o CN q q cn q r—1 'sT q q q q cq q q o rH cn q o q cn q q cn o q o q q q q q cq CD q
CM cri CN cri cri rH rH o rH rH CM rH r—i r—i r-i r-i rH CM r—1 r—1 rH o rH d rH CM rH rH CM rH cri rH cri rH o rH
LO LO LO LO LO LO LO LO LO LO LO LO LO LO LO LO LO
rs rH rs is O e'­ is cn LO CD CM rH cn CM 00 LO CD LO LO 00 00 CD T^ CD cn r^ m 00 CM cn rH CN rH
rs CD 00 rs cn en rH CD LO CD CD CM CD 00 00 |S 00 o CO cn rH o O 00 rH 00 cn cn CM O CD cn LO cn
<N q q q q q q CD q 00 q o CD o q q rH q cn q q ■q rH q q o q q q q rH q CD cq
cri fN cm cri fN CN r—i o CM rH rH rH O CM CM rH CM CM CM m CM d rH r—1 CM CM r-i CM CM rH CM CM cri cri d rH
LO LO LO LO LO LO LO LO LO LO LO LO LO LO LO LO LO LO LO
LO is LO T—1 rH fN cn 00 rH CD CD cn o rs |S LO LO CM 00 cn CD o o CD CD cn 00 cn rs
q o q q cq o o LO q q q rs rs q rH rH r—1 o q q q 00 q q q rH CD q q q q rH q q rH cq
CM cri csi cri cn r—i rH o CM rH CM o o rH CM rH rH rH r—1 CM O o o CM rH cri d r—i rH r—i rH rH CM CM rH rH
LO LO LO LO LO LO LO LO LO LO LO LO LO LO LO LO LO LO LO LO LO LO LO
rs CD o 3 cn cn rH LO 00 rH 3 3 CD LO CO CN rH rH LO 3 LO r-v 00 3 3 s LO rH CD 3 CD rH CD CD rs
cq rH cq q q q q q q q q q 00 rH rH q M; q q q CD q q q q rH q q °9 q q rH CD q
r-i rH CN o csi fN rH o d rH r—i rH r—i CN r—i r-i rH rH rH rH CM o rH r—i CM CM r-i o CM r—i cri rH r-i rH o CM
LO
LO
fN
LO cn
CD
LO LO LO LO LO LO LO LO LO LO LO LO LO LO LO LO LO LO LO LO LO LO
LO rH CD 3 cn rH O 00 CD IS 3 CO cn is s LO CM 00 o 3 rH cn 3 CD r** 00 3 O LO CD LO
cq G) rH q o q q rH o rH rH rs 00 M; q q q q q q CD rH q q q CD q rH q q q q rH q cn
fN CN cri cri cri rH rH o CM r—i rH o o CM rH r-i rH cn r-i cri o o rH r—i r—1 r—i o r—i CM CM cri r-i cri CM o CM
LO LO LO LO LO LO LO LO LO LO LO LO LO LO LO LO LO LO LOCO LO CD CD CD 00 is rs cn |S cn CM 00 CD 00 CM fN CD 00 CD CM rH cn 00 CD CD CD CD LO CD 00 00 00
rH q q CD q 00 q rH q q rH q q q q q q q q 00. q q q q q q q q 00 00 q cn q 00. r—1 q
CN d CN O rH o r—i rH rH rH CM r—i rH cn rH rH r-i r-i rH rH o d r-i rH CM CM r-i r—i o r—1 cri cri CM r—1 o CM
LO LO LO LO LO LO LO LO LO LO LO LO LO LO LO LO LO LO LO LO
CO 00 00 CD rs rH CN rs LO CN o CD 00 fN cn cn rs cn CM cn CD 00 CD r". LO CM CD CD cn rH
CO
CD rH
cq cq q LO cn q q q O cq q o o CM q q q q o q CD o rH o o q q q q q q rH q q q q
r-i o CN o rH o rH o r-i o CN rH rH o rH rH rH rH r—i rH o r—i r-i rH cri r-i r-i o O rH cri rH rH rH d CM
LO
CD
LO LO LO LO LO LO LO LO LO LO LO LO LO LO
rH S fN rH 00 cn CD 3 3 O LO § ro rH 3 rH rs 3 3 CM LO 3 3 3 3 CM o r^ o r^ 3
rH q q q cq q q q q o q q CN q q rH q q q rH cn cn q q rH rH q q o q q q q cn q
fN o csi o rH rH r—1 o rH rH CM r—i r—i CM rH r-i r—i rH r—i CM r-i o r—i rH cri r—i rH o o cri cri rH CM rH d cri
LO LO LO LO LO LO LO LO LO LO LO LO LO LO LO
O rs LO cn cn rH ^r CD 00 CD LO r—i CD 00 r^ CM 00 CM 00 CN CM 00 rs cn CM CM CD rH CD
o q rH cn cn q q 00 q q cq q cn q 00 q q q q q q cn q o q cn q cq q q q cn q q rH
fN o CN o r-i o rH o rH rH rH rH r-i CM rH o rH r—i rH rH rH o rH r—i CM O r—i d CM rH cri CM CM rH o CM
LO LO LO LO LO LO LO LO LO LO LO LO LO LO
00 rH 00 CM T^ LO rH CD CN CD 00 CD 00 rH 00 CM CD LO cn CD rH 00 00 00 00 cn cn cn rH rs
cn rs CD cn fN cn cn o C- 00 cn tH CN rH rH rH O rH rH rH r^. CD r^ o o LO CD rH CM cn o CD CD
rH cq o q cq q q 00 q q q q rH cq o q q q q q cn o o q o q q o o q q q q q qcri CN cn cri fN r—i rH o rH O o o r-i CM CM r—i rH CM rH CM rH o rH CM rH CM rH rH CM CM cri rH CM CM o CM
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I LD LD LO LD LT) LD U )OOLnfNCOinCOHOI^fNlDOOlDinH^^hCO • ^ 0) 000000^0  
i d r i o O H r i f N i f N
| LD 00 _
O  O  00 CN 
r o  r o  fN r o
LO LO LO LO 
O  00 CO LO LO
H  LO LD (Tl
CN CO LO T-j rH
fN H  O  H  CN
LO LO LO LO
H  (M LD IN fN 
^  LO O  00 r l  LO
co co ' t  ^  o  o  i d
t—I rH t—I rH CN CN CO
LO LO LO
co co Di  co i d  cn __
LT) Lf) LO LO LO LO LO LO LOHooco^^cnfNinoi^oocniDooooLD^D^ LO LO LON u i  uu w  vaj m_a vu CN CO CO fN
C O ^ D C T ) C O ( J l ( N k D O O L O O O ^ C n O ^ C J  
-  ~ ’ ^ L O L O ^ ^ L D O l O O r H C O
CN co rH CO CN
I CN LO 
I cn l o  
i CN rH (N
CN LO 00 LD rH H  H  O CO
CN O rH O  CO LO CN 00 LD
r l L D I N C N I N r ' C f l O i n O I C N L O ' T L D O lHoj H^qmwoocj ocx j i Nf NoncoH
rH rH rH rH rH rH CO CN rH
LO LO LO LO LO LO LO LO lO LO LO
H C O C O O ^ L D f M C O C O C O H ^ H ^ C O O L D O l ^
LO LO LO LO
- . _  - . I  . . . . . . . . .  . ^  rH 00 CN <N LD
O O L D r H H r ^ C O r H O ' > L D L O C O r H O C O r ^ O O O l O ( T > L O O C N ( N O O L D L D < 3 ’ O r ^ O C N ' d - ( N l D
L D L D L O L D O O L D L O C O O ^ r N . p C N C O r ^ C O O C s j p o q O O C O C N r ^ L O L D O q c O O q r ^ q L D L D
C N O r v j c N C N r H ( N r H r H r H r H C O f N r H r H C v i c N C O C > 4 0 ( N C O C N C N r H r H ( N r H ( N r H C N C N O C N
LD 0"* LD CN CO CD LO rH CN P’- rH O  OU Ul  rH CO LO CO LO CN Ol  CN rs»
L O C ^ l O O ' t O O l N N O ^ C O L D O C N ^ O H l O C O C O ^ O ^ H O O H  
r + » —t r H « —i r t - i —i * — i m r r N m r H  m  ^  n  i n  h  i n  h  m  m  t n  n. . p r H ^  r H r H p r H p p p ^ %. , , .  
T - i r H r H C O C N f N C N C N C N C N O ^ H r H C N
LO LO LO LO LO LO LO
L O C N j r H f N L D t J l C n r N f N f N J r l L D C O  ^ c o o o c o c o r N r ^ L o o o o o o L O L D c o  r ^ o c N p p ^ - j p p p p p p p p p
C N C N r H C N r H C N C N O O r H C N r H C N r H r H
OS p  LO O  
CN CO O  CN CN
LO LO LO LO
fNs CD CJl St  LO fN
CD O  CN CN 
rH LO LO O) LO CO LO
CN CO CN CN CN O  CN
LO LO LO LO LO LO LO LO LO LO LO LO LO LO lO LO LO LO LO
o r ^ t H r ^ c N L o r ^ L O  o i ^ c D c o ^ r N ^ o o c N i o i o c o o ^  i o o o o o l o l o d o o h  oo cd i n
O L D r ^ C T i C N L D O C T > O O O C N O C O L D L O L O L D r H c O O O r H r ^ C O C N O O L O L O ^ C T » C r > L D O O C O C D C OinH-MMrnN00(t|(Y)00c0^inpff)i4pH0000in(Ni40](Nf0^rjC)000rNOrjc0fNJlD 
r H O C N r H r H r - i r H C O r H r H C N o j r H C N O O ^ H C N C N r H r H r H O r H C O C N C N r H O C N
LO LO LO
H i D L O ^ ^ C M ^ L O O ^ C O ^ h l D C N C O C O C D O C D t O
^  -    ‘ ^ L D ^ O O N L O L O H i O C D H
o o r H r ^ c o L O p r ^ q p i O L O  
C N C N r H r H O r H C O C N C N r H O
LO LO LO LO LO LO LO LOc N Oi c o o o L o r ^ r H r ^ r ^ r ^
O ^ t O C N C N O O r ^ L D O c O
r - j c q p r ^ c n q q c q r ^ o q
r H C N C N r H r H r H O C N C O O
LO LO LO LO LO LO LO LO
O H L O H ^ C O ^ c n C D f N H C N O c n O O     _  - . _. _.
I D O h l D l O H O ^ O H H O ^ f r i H ^ c n i O l O H ^ O O l O l O(Noooocopinpi/]ino)0)^cof^{Nj(Ni/)(Niqiscoro
C N H H O C N H  C O H H C N H H  H H C N C O H O H r i f O r i
U) U) U) LI) U) LO LO LO LO
O O H O O f O C D C N C T l C n i N l D l O C N l O L D O O C O C T i a i
^ p r H p O r ^ r - H C N p  
r H O C O C O C N C N C N O C O
CO CN CO CO CN
LO LO cn ct» cn o  cn cn
LD LO 00
LD LD 00CD LO
LO LO LO LO
fN CO H  o  CD LD
(D LO CO O  CO 00 CN LD LO
( N l D H - O O O O l O f N C D f N
LO LO
^  LO CO (D CO
Sf CO CO CO CO 
00 00 CD 00 CO ^
00 00 
LD 00
LO lO
LD CN _
LO 00 CO LO CO CD
00 CD LO CD
00 CO 00 LO 
LO LO CD LD
CN CD CD 
LD LO
LO LO LO LO LO
__ . CD CO L O r H C D C O L O C N r H L D N t
LO LO LO CO LO 00 LD LO rH CN O  00 LO CD LO
^ ■ C N C D C O O O m c N  
CN (N
O LO LO CD
CO CO CN LO
CN LO CO Nt LO LO
C N C O L O C D L D L D L O L OLD LD LO 
CD 00 
LD LO LO CN CN LO
CN CN
LO LO LO
CD LO CN LD CO CD tH
LO CO CN CO CO lo CN
CD LO f N  ^  LH ( N
LO LO LO LO LO
C N L O r H L D ^ t C N C D C D  
CO CN CD CO LO
CO 00 LO CD LD CO LO
LD 00 
LD CO LD
LO LO LO L0 
LO CN 00 CN rH LO 00
C O c O O ^ C O C O C O f N
CO CO LO O  H  r o  CD 
CO CO CN
LO CN CD CO LO 
LD 00 
CN LO LO fN ro LO
CD 00 LD 
00 CO 00
CN LD LO
00 cq
CN CNCO CN CN CN CO
LO LO
C D C N r H C O L O O O O L D L O C O  
C D O O L O O O I N L O O O C N L O f N  
CO LD N  00 CO ~
LO LO 
CO CN
00 CN LO 
LO CO CO CO LO
LO LO 
LO CO 
CN CN CD CO 
CO CO CD ^  CD 00
LD 00 CD 00
fN CD IN LD O 
L D L D L O O C O C O L D C O  
CO CN CN CO
LO LO LO LO 
00 LO fN LO O  CO LD
LO LO LO LO
CO CN LO 00 CN LD
00 CD CO 00 00
00 LD ^  CD LO 00 LD
00 CD CO CO CO ^ t  
O O O O f N C N J O O f N O O C N L D  
CO CN
00 LO CN 
LO CD O  CO CN
LO LO LO LO LO 
CO CN CN O  ^  00 CN
C N C O C D H c O ^ - ^ C D C n
q  ro ld cn l o  co ^
CN CN
LO LOLO LO 
00 LO CO 00
CN 00 CN
CO CO 00 LO CN
o
LO CD 
LO LO
CO CN
LO LO LO LO LO LO LO
CO LD Q  lO H  00 ^  CD CO CD 
. . h d C O O O C O f S f N L O O O l O C D  
r H L O O O L O O O L O L O L D C O C N C N C N
LO LO
CD LD 
CO CN
LO CD CD N  CO CO
L D C O C O L D ^ L D C N C N ^ 00 CN
CO 00 CO O  O  CN 00 
C O C N C N r H r H C N C N r H r H C N C O C O r H O r H C O C O C O
CN CO LO LD
CO CN
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LO LO LO 
N  H  CN LO 
N  LO CO 00
LO LO LO LO
CN LO CD LO (N CN 00
CO O  s r  N  00 CO CD
rH o  LO CO o
LO LO LO LO LO
CD 00 N  CD O
LO CD LD CO LO LD N
) ^  CN LD
rH CO LD 
^  00 CN 
00 LO LO
LO LO LO
rH m  <3- CN CO LD
) 00 00 N  00
I H  f s  CO LO
LO (D ^  CD r-.
CD 00 LD LD CO CO rH
CN 00 rH 1^ CN CO 00
CN CO CN CN CN O  CN
LO LO LO LO LO LO LO LO
lo  o  l o  lo  l o c d c d c o c o c o c n o i ^ h o o ^  <3-fnfOCDLD^C^CD^COCNfNNncNOlOHCOOtNp O r H p p C N O r H p C N r H O O p O p p p C N c q ^ r
O C N r H C N O O r H C N C N r H r H O O C N C O O r - i r H O C N
LO LO LO LO LO L O L O l O L O L O
L O C D r H O O r H r H ^ t C O L D C O O L D L D L D L O O O O C D C N L O O O  OCN^CNOO^CNOOCNOO^rHCO^fr^^^l -CDCD 
r H L D L O C N C D L D L O L O C O O ^ L D r ^ C O r ^ L O O ^ L O O O C N L O C N
LO LO LO LO LO LO LO LO LO LO
L O L D ^ L O C D C N O I ^ i O L D O O L D C O c n r ^ O O C N C O O O  LO “ “ C O C D N ^ t ^ H N C O O O f N  
O p r H r H p p p l ^ p p  
C N C N C O r H O r - i c N C O C N C N r H C N C N C O r H C O C N O C N
LO LO LO LO LO LO LO LO CN LO LO LO
i N C N r H L O c D L D L O C D i o c D r ^ r ^ r ^ c n L O c o  cd
)  ^  f f )  CJ O  (N (N LO
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LO LO LO 00 LO LO LO LO LO LO LO LO LO LO LO LO
LO LO 00 LD CD rH <3- LD CD 00 LD rH rH r-s rH LO 00 rs  oo 00 fN 00 rs ro  oo LO ^  H  CDrs o ro ro 00 CD o  r-. 00 LD LO r-s r-s CN LD rH CN LD ro o  ^ ld  r-s LO LD 00 o LD LO ld  ro CD fN  ro
LO LO fN lo ^ "T rH rH CN q q rH rH cn cq CN rH q  q O CN rH rH rH q r-J o CN LD ro  q  q
d o o o  o o o o  o o o o o o o O  O o  o o o o  o o  o o  o o o o  o o  o o d d
LO LO LO LO LO LO LO LO LO LO LO LO LO LO LO LO LO
rH rs rH r-s ro l-s 00 ro ro LO 00 r-s rH LD CD fN 00 LO 00 rH CN CD I-S fN rH LD CD CN 00 LD rHrs ro ro o rs O  LD r-s 00 LO LO rH o CD l-s LD 'T fN CD O oo r-s ro  r s rs O LD O ro  O rs  oo <3-
LO CN LO rH rH q q o rH rH cn q rH rH q ^ cn cn CN rH rH rH rH CN rH cn cn q ro  h  q
d o O o  o o o o  o o rH o o o O o  o o  o o o o  d o  o o  d o d o  o o  o o d d
LO LO r-s LO LO LO LO LO LO LO LO LO LO LO LO LO
LD LO CD rH LD r-s CD CN LD fN r-s LO rs LO rH rH CN LD rH LO CN rH CO cd r s rH rH rs CD cn ro  CD
ro rs CD LD CD LD CN CN 00 CD rs. LD rH f-s rH 00 00 LD CN rH O  LD 00 rH LD 'T O  LD ro  oo i s  00 O
G) cn fN o  r-. rH o cn  q rs LD 00 G] cn q 00 rH CN LO o q CN fN q  rH q  q fN rs rH LO q  q fO H  r j
CN fN ro ro  r- i rH rH o  r- i o o o o cn O O  r- i rH o CN rH o  r - i r i  rsi rH rH o o rH ro o  o O  d  ro
LO LO LO LO lo rs LO LO LO LO LO LO LO LO LO LO LO LO LO LO LO LO LO
LD CN o CN LO CD o oo ro 00 CN r-s 00 LD LO l-s cn ro LO ro LD rH CN LD oo ro o LD 00 O is  oo 00 ^  oo
rH rH CN ro  lo 00 00 O  00 o fN o LD r-s LD r-s lo rH CN r-s O ^  r s CD rH 00 i s LD LO rH ro  CD rs  cd rs
LO LO 00 o  q CD r-s q  q o o 00 rs q q lo r s rs q q q  q LD rH CN CD CN q q  rH q  q q  r- j o
rsi CN rH ro  r- i o o o  o rH r-i o o fN o o  o rH O CN o o  d rH rH rH O o rH O  ro o  o r - i d  cn
LO lo ro LO LO LO LO LO LO LO LO LO LO LO LO LO LO LO LO LOrs LO ro  lo ro CD fN  fN O r-s LO rs CD O  ro ro rH cd r-s CN CO r s  oo 00 CD rH ro ro  i s  ro
LO 00 ro O  rH LD rH rH ro CD ro CN ro CD cn ro 00 CD r-s rH rH rH CD fN r s  oo LD ro i s  <3- ld  ro rs  oo rs
q o r-s q LO q fN  00 q q q q cq r s ld q  q q q q  q q  q q  ld fN LO q ^ q ro  rH q
r- i CN rH CN r - i o o o  o o O o d rH o o  o d  o rH o o  d o  o o  d o d O  ro d  co o  o  r- i
LO LO LO l-s LO LO LO LO LO LO LO LO LO LO LO
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LO rH LO "T rs o cn ro rH LO rH r-s LO CD LO rH ro  cd LO fN rH CD LD LO CN LD o LO IS  o O  IS CD ro  LD
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